Endoscopy

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed device that temporarily excludes the proximal small intestine, aiming to improve glucose metabolism through both weight-dependent and weight-independent mechanisms. Why was this study needed?: . Many patients with obesity and uncontrolled T2DM do not achieve adequate control with medications and lifestyle modification. . Bariatric surgery is highly effective but is not suitable or acceptable for all patients. . Evidence from large randomized sham-controlled trials evaluating the EndoBarrier device has been limited. . The balance between metabolic benefits and device-related safety required confirmation before wider adoption. Results: In this multicenter double-blind randomized sham-controlled trial, the EndoBarrier significantly improved glycemic control compared with sham treatment, with greater reductions in HbA1c and significantly higher rates of achieving target glycemic control. Patients receiving the device also experienced substantially greater weight loss and were more likely to achieve clinically meaningful weight reduction. Although device-related serious adverse events occurred, including gastrointestinal bleeding, intolerance, and hepatic abscess, the overall safety profile met the predefined study criteria and was considered acceptable with appropriate monitoring. Clinical Impact: The EndoBarrier offers an effective minimally invasive metabolic intervention for patients with obesity and poorly controlled T2DM who are not candidates for or decline bariatric surgery. While its metabolic benefits are clinically meaningful, careful patient selection and close surveillance are essential because of device-related complications, particularly hepatic abscess. The device may serve as an important bridge between pharmacotherapy and surgery in specialized centers. Bottom Line: The EndoBarrier significantly improved glycemic control and weight loss compared with sham treatment, supporting its role as an effective endoscopic metabolic therapy for selected patients with obesity and poorly controlled type 2 diabetes, provided appropriate safety monitoring is ensured.

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves DEN for patients with inadequate clinical response, immediate DEN may accelerate recovery by achieving earlier clearance of necrotic material. Why was this study needed?: The ideal timing of DEN after EUS-guided drainage has not been established. The drainage-oriented step-up approach delays necrosectomy until clinically indicated. Earlier necrotic tissue removal may shorten recovery without increasing complications. Randomized evidence comparing immediate versus on-demand DEN has been lacking. Results: In the multicenter WONDER-01 randomized trial, immediate DEN significantly shortened the time to clinical success compared with the conventional drainage-oriented step-up strategy. Technical success was similarly high in both groups, and rates of procedure-related adverse events and mortality were comparable. However, all patients assigned to immediate DEN underwent necrosectomy, whereas fewer than half of those managed with the step-up approach ultimately required the procedure, highlighting that many patients can recover with drainage alone. Clinical Impact: Immediate DEN offers faster clinical resolution without compromising safety, making it an attractive option for patients in whom rapid recovery is desirable. However, because the step-up approach avoids unnecessary necrosectomy in a substantial proportion of patients, it remains an efficient and less invasive strategy. Treatment decisions should therefore be individualized based on disease severity, clinical response, and local expertise. Bottom Line: Immediate endoscopic necrosectomy after EUS-guided drainage accelerates recovery without increasing adverse events but results in more necrosectomy procedures, supporting individualized selection between immediate and step-up treatment strategies.

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures after bevacizumab therapy, despite limited evidence supporting this practice. Why was this study needed?: The optimal timing of endoscopy after recent bevacizumab exposure remains uncertain. Clinicians are concerned about increased risks of gastrointestinal perforation and postprocedural bleeding. Existing evidence is limited and largely based on small observational studies. Better data are needed to guide the safety of diagnostic and therapeutic endoscopic procedures in patients receiving bevacizumab. Results: In this large propensity score–matched analysis, recent bevacizumab use was not associated with an increased risk of gastrointestinal perforation within 30 days after either diagnostic or therapeutic endoscopy compared with other active chemotherapy. However, patients receiving bevacizumab had a significantly higher risk of postprocedural bleeding, particularly after therapeutic endoscopic interventions, with the excess risk largely driven by upper gastrointestinal procedures. Diagnostic endoscopy alone did not demonstrate an increased bleeding risk. Clinical Impact: These findings suggest that recent bevacizumab therapy should not automatically delay necessary endoscopic evaluation because the feared increase in perforation risk was not observed. However, therapeutic endoscopic procedures, especially upper GI interventions, should be undertaken with greater caution, balancing procedural benefits against the elevated bleeding risk. Careful procedural planning and post-procedure monitoring remain essential. Bottom Line: Recent bevacizumab exposure does not increase post-endoscopy perforation risk but is associated with higher bleeding risk after therapeutic endoscopic procedures, supporting individualized procedural planning rather than routine postponement of endoscopy.

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk factors, and clinical outcomes of colorectal ESD-related perforations. Why was this study needed? Perforation is the most feared complication of colorectal ESD. Real-world Western data on perforation outcomes are limited. Predictors of perforation and need for surgery remain poorly defined. Better risk stratification can improve patient counseling and procedural planning. Understanding delayed perforation is essential for post-ESD surveillance. Results: More than 90% of ESD-related perforations were successfully managed conservatively, particularly intraprocedural perforations, avoiding surgery in most patients. Delayed perforation was uncommon but carried a high likelihood of emergency surgery, making early recognition and close post-procedure monitoring critical. Large lesions, severe fibrosis, previous resection, poor endoscope maneuverability, and proximal colonic location significantly increased the risk of perforation. Clinical Impact: These findings reassure endoscopists that most intraprocedural perforations can be safely managed endoscopically without surgery. However, delayed perforation remains a serious complication requiring prompt diagnosis and surgical evaluation. Careful patient selection and recognition of high-risk lesions are essential to optimize ESD outcomes. Bottom Line: Colorectal ESD perforation is usually manageable without surgery, but delayed perforation remains the major clinical challenge. Patients with large, fibrotic, previously treated, or proximal colonic lesions require heightened procedural caution and close post-procedure surveillance.

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue these therapies within 1–2 years because of cost, adverse effects, or limited access, often leading to rapid weight regain. Why was this study needed? Weight regain commonly occurs after GLP-1 receptor agonist discontinuation. Long-term maintenance strategies after stopping GLP-1 therapy are lacking. A non-pharmacological approach may help sustain metabolic benefits. The duodenum plays a central role in glucose metabolism and insulin resistance. Endoscopic metabolic therapies are emerging as less invasive alternatives to surgery. Results: A single session of Duodenal Mucosal Resurfacing (DMR) helped maintain weight loss and metabolic improvements after GLP-1 discontinuation. DMR appears to function as an "off-ramp" therapy, reducing early rebound weight gain after stopping GLP-1 treatment. These findings support the concept that combining pharmacological and endoscopic metabolic therapies may provide more durable long-term outcomes than either approach alone. Clinical Impact: DMR is a minimally invasive endoscopic procedure that uses hydrothermal ablation to regenerate the duodenal mucosa, targeting abnormal metabolic signaling rather than simply reducing caloric intake. If confirmed in larger studies, DMR may become an attractive strategy for maintaining weight loss after GLP-1 withdrawal and reducing lifelong dependence on medication. Bottom Line: The future of obesity treatment may not be lifelong medication alone. Combining GLP-1 therapy for weight loss induction with Duodenal Mucosal Resurfacing for long-term maintenance could represent a new paradigm in metabolic disease management.

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing FNB tissue in formalin for histopathology could provide comparable diagnostic performance. Why was this study needed? Many centers lack rapid on-site cytopathology (ROSE) or dedicated cytopathologists. Histopathology may better preserve tissue architecture for diagnosis and ancillary testing. The optimal processing method for EUS-FNB specimens remains uncertain. Simplifying specimen handling could improve workflow and reduce procedure time. Prospective data comparing histopathology with conventional cytology are limited. Results: Histopathologic evaluation of EUS-FNB specimens achieved diagnostic accuracy comparable to conventional cytology for solid pancreatic lesions. Histopathology required fewer needle passes, potentially reducing procedure time and improving efficiency. With macroscopic on-site evaluation (MOSE), all histopathology specimens were adequate for analysis, supporting its reliability even without on-site cytopathologists. Clinical Impact: This study supports direct formalin submission of EUS-FNB specimens for histopathology as a practical alternative to cytology, particularly in centers without ROSE or cytopathology services. It may simplify specimen processing while maintaining excellent diagnostic performance. Bottom Line: Histopathology with MOSE is a reliable alternative to cytology for EUS-FNB of solid pancreatic lesions. It provides comparable diagnostic accuracy with fewer needle passes, making it an attractive approach for routine clinical practice, especially in resource-limited settings.

Durable Endoscopic Partial Reversal of Roux-en-Y Gastric Bypass Using Parallel LAMS Septotomy: GIE | July 2026

Introduction: Although Roux-en-Y gastric bypass (RYGB) is an effective bariatric procedure, a small proportion of patients develop severe nutritional complications, refractory dumping syndrome, or other debilitating adverse events requiring reversal. This study describes a novel endoscopic technique that offers a minimally invasive alternative to surgical reversal. Why was this technique needed? Surgical reversal of RYGB carries substantial morbidity, particularly in malnourished or medically complex patients. Conventional EUS-guided gastrogastric fistulas created with lumen-apposing metal stents (LAMS) often close after stent removal, limiting long-term success. What did the study show? Six patients underwent endoscopic partial RYGB reversal using the parallel LAMS septotomy technique. Technical and clinical success was achieved in 100% of patients. Durable gastrogastric anastomosis was maintained after stent removal in all patients during follow-up. No major procedure-related adverse events were reported. The technique eliminates the need for permanent indwelling LAMS while maintaining long-term luminal patency. Patients experienced sustained restoration of gastric continuity without requiring surgical reversal. Clinical Impact: Parallel LAMS septotomy represents an important advance in third-space endoscopy, providing a minimally invasive option for selected patients requiring RYGB reversal. The technique may reduce surgical morbidity while offering durable anatomical restoration. Take-Home Message: Parallel LAMS septotomy enables durable endoscopic partial reversal of Roux-en-Y gastric bypass without permanent stent dependence. Although early results are highly encouraging, larger studies with longer follow-up are needed before widespread adoption.

EUS Double Drainage for Malignant Dual Obstruction : Gut | Jul 2026

Introduction: Simultaneous malignant distal biliary obstruction (MDBO) and gastric outlet obstruction (GOO), commonly caused by advanced pancreatic, biliary, or duodenal cancers, presents a major palliative challenge. Conventional endoscopic approaches often require repeated interventions and may be technically difficult when both obstructions coexist. Endoscopic ultrasound (EUS)-guided double drainage has emerged as an innovative minimally invasive strategy to address both obstructions in a single therapeutic approach. Problem Statement: Traditional management with ERCP and enteral stenting is frequently limited by anatomical distortion, stent dysfunction, and the need for repeat procedures. Surgical bypass remains effective but is associated with greater morbidity, particularly in frail patients with advanced malignancy. A durable, less invasive alternative is needed to improve symptom control and quality of life. Summary: This review highlights the growing role of EUS-guided double drainage (EUS-DD), combining EUS-guided gastroenterostomy (EUS-GE) and EUS-guided biliary drainage (EUS-BD), for patients with synchronous malignant gastric outlet and distal biliary obstruction. EUS-GE restores enteral passage by creating a bypass to the small bowel, while EUS-BD provides internal biliary drainage when ERCP is unsuccessful or not feasible. Together, these procedures offer effective relief of obstructive symptoms without the need for surgery. Compared with conventional endoscopic techniques, EUS-DD is associated with improved long-term patency, fewer reinterventions, and durable palliation, while achieving outcomes comparable to surgical bypass in selected patients. The approach is particularly valuable for patients with advanced malignancy who are poor surgical candidates. However, EUS-DD is technically demanding and should currently be performed only in experienced, high-volume centers with multidisciplinary interventional and surgical support. Successful implementation requires advanced EUS expertise, dedicated training, and careful patient selection. As procedural experience, training pathways, and supporting evidence continue to expand, EUS-guided double drainage is expected to become the preferred endoscopic palliative strategy for malignant dual obstruction in appropriately equipped centers.

Endoscopic Mucosal and Submucosal Cutting in benign esophageal stricture: Gut | July 2026

Introduction: Long benign esophageal strictures remain one of the most difficult benign conditions to manage. Although endoscopic dilation and incision techniques provide temporary relief, recurrence is common, often requiring repeated interventions. This study introduces a novel endoscopic approach designed to achieve more durable stricture release. Why was this technique needed? Conventional balloon dilation and radial incision frequently result in restenosis, especially in long, complex strictures. There is a need for a technique that provides more complete scar release while minimizing repeated procedures. What did the study show? The technique combines methylene blue-guided visualization of scar tissue with longitudinal mucosal and submucosal cutting down to the muscularis propria, followed by triamcinolone injection. Eleven patients with long benign esophageal strictures underwent the procedure, with eight receiving it as primary treatment. Short-term clinical success was achieved in nearly all patients. Only one patient required repeat treatment during follow-up. The technique appeared feasible and safe, with encouraging outcomes over a mean follow-up of approximately 11 months. Clinical Impact: This novel endoscopic approach offers a promising alternative for patients with long or refractory benign esophageal strictures, particularly when conventional dilation or incision techniques have failed. Larger prospective studies are needed to confirm long-term efficacy and safety. Take-Home Message: Endoscopic mucosal and submucosal cutting represents an innovative third-space endoscopic technique that may provide more durable relief for long benign esophageal strictures, potentially reducing recurrence and the need for repeated endoscopic interventions.

Economic Impact of POEM and ESD: GIE | June 2026

Introduction: Peroral endoscopic myotomy (POEM) and endoscopic submucosal dissection (ESD) have revolutionized the management of esophageal motility disorders and early gastrointestinal neoplasia. Despite their proven clinical benefits, widespread adoption has been limited by concerns regarding procedure costs and relatively low reimbursement. Why was this study needed? Hospital administrators often view POEM and ESD as financially unattractive because of their complexity and low procedural reimbursement. This study evaluated whether these advanced endoscopic procedures generate broader economic value through downstream healthcare utilization. What did the study show? The study analyzed 825 patients undergoing POEM or ESD at a high-volume tertiary center between 2018 and 2024. Although direct procedural reimbursement was relatively low (15.5%–22.4%), the program generated $73.5 million in total physician and hospital charges. Downstream care accounted for $39.9 million in additional healthcare charges. Overall reimbursement reached $15.7 million during the study period. The program attracted 349 new referral patients, generating an additional $28.5 million in healthcare charges and $5.8 million in reimbursements. The financial benefits extended well beyond the endoscopic procedures themselves through referrals, follow-up care, imaging, surgery, and multidisciplinary services. Clinical Impact: The value of POEM and ESD should be assessed across the entire healthcare system rather than by procedural reimbursement alone. Investment in third-space endoscopy programs can strengthen referral networks, improve patient access to advanced therapies, and generate substantial long-term institutional revenue. Take-Home Message: POEM and ESD are not only clinically transformative but also economically valuable. While direct procedural reimbursement remains modest, the substantial downstream revenue and referral growth make advanced endoscopy programs a worthwhile investment for healthcare systems.

Remimazolam Improves Sedation Safety During ERCP : GIE | Jun 2026

Introduction: Deep sedation is essential for successful endoscopic retrograde cholangiopancreatography (ERCP), a technically complex procedure frequently performed in elderly patients and those with significant comorbidities. Propofol remains the most commonly used sedative agent because of its rapid onset and effectiveness; however, cardiopulmonary adverse events such as hypotension and respiratory instability remain important limitations. Problem Statement: As the complexity and volume of therapeutic endoscopic procedures continue to increase, safer sedation strategies are needed. Remimazolam, an ultra-short-acting benzodiazepine with rapid recovery, predictable metabolism, and the availability of reversal with flumazenil, has emerged as a promising alternative. However, prospective randomized evidence supporting its use specifically during ERCP has been limited. Summary: This multicenter randomized controlled trial compared remimazolam with propofol for deep sedation during ERCP. The study demonstrated that remimazolam provided effective procedural sedation while maintaining procedural success and high operator satisfaction. Importantly, remimazolam was associated with a lower incidence of cardiopulmonary adverse events compared with propofol, highlighting a potential safety advantage in a population often characterized by advanced age and multiple medical comorbidities. Despite its improved safety profile, remimazolam maintained adequate sedation quality and did not compromise procedural performance. These findings are particularly relevant for advanced therapeutic endoscopy, where prolonged and stable sedation is required while minimizing hemodynamic and respiratory complications. The pharmacologic characteristics of remimazolam, including rapid onset, short duration of action, organ-independent metabolism, and reversibility with flumazenil, further support its suitability for use outside the operating room environment. As one of the largest prospective randomized studies evaluating remimazolam specifically in the ERCP setting, this trial provides important real-world evidence supporting its clinical adoption. Overall, the results suggest that remimazolam may represent a safer alternative to propofol for deep sedation during ERCP, especially in patients at increased risk for sedation-related complications. Future studies should further define optimal dosing strategies, cost-effectiveness, and outcomes in higher-risk patient populations.

Sustainability Cuts Endoscopy Carbon Footprint and Costs : GIE | Jun 2026

Introduction: Endoscopy services generate substantial amounts of healthcare waste due to high procedural volumes, extensive use of disposable accessories, and stringent infection-control requirements. As healthcare systems increasingly focus on environmental sustainability, reducing the ecological impact of endoscopy has become an important priority. However, evidence demonstrating the effectiveness of practical sustainability interventions in routine endoscopy practice remains limited. Problem Statement: Endoscopy is among the largest contributors to hospital hazardous waste, resulting in significant environmental and financial burdens. Whether simple interventions such as staff education, improved waste segregation, and recycling initiatives can meaningfully reduce carbon emissions and waste-processing costs has not been well established. Summary: This prospective study evaluated the impact of a structured sustainability intervention within an endoscopy unit, focusing on waste segregation, recycling promotion, and staff education. Following implementation of the intervention, the investigators observed a significant reduction in the unit’s carbon footprint, accompanied by a meaningful decrease in waste-processing expenses. These improvements were achieved despite only a modest reduction in the overall volume of waste generated, suggesting that appropriate waste classification and diversion from regulated medical waste streams were the primary drivers of benefit. The findings highlight the importance of behavioural and organizational changes rather than solely reducing procedural waste production. By improving staff awareness and encouraging correct disposal practices, the intervention successfully reduced both environmental impact and operational costs without requiring major infrastructure changes or compromising clinical care. Given the increasing emphasis on environmentally responsible healthcare delivery, these results demonstrate that relatively simple and low-cost sustainability measures can produce measurable benefits in endoscopy practice. The study provides a practical framework for endoscopy units seeking to improve environmental performance while simultaneously reducing expenditure. Overall, the findings support broader adoption of structured waste-management programs as an achievable strategy to advance sustainable endoscopy and reduce the environmental footprint of gastrointestinal healthcare services.

Modern Endoscopic Management of Flat Colonic Neoplasia : Endoscopy | June 2026

Introduction: Non-pedunculated colonic neoplasia (NPCN), including flat and sessile colorectal lesions, is being detected with increasing frequency due to widespread colorectal cancer screening and advances in high-definition endoscopy. Compared with pedunculated polyps, these lesions present greater challenges because of their higher risk of submucosal invasion, incomplete resection, and recurrence. Consequently, accurate lesion characterization and appropriate selection of resection technique are essential for optimal patient outcomes. Problem Statement: The expanding range of endoscopic imaging technologies and resection techniques has created increasing complexity in the management of NPCN. Clinicians must determine which lesions can be safely treated with cold resection techniques, which require advanced endoscopic interventions, and which should be referred for surgery. Clear guidance is needed to integrate evolving evidence into routine clinical practice. Summary: This review provides a contemporary overview of the diagnosis and management of NPCN, highlighting major advances that have reshaped endoscopic practice over the past decade. Modern optical diagnosis systems, including NICE, JNET, and Kudo pit pattern classifications, now enable more accurate real-time assessment of lesion histology and invasion depth, facilitating informed therapeutic decision-making. Cold snare polypectomy and cold EMR have emerged as preferred approaches for small and intermediate-sized lesions because of their excellent safety profile and high rates of complete resection. For lesions measuring 20 mm or larger, piecemeal EMR combined with systematic margin ablation using snare-tip soft coagulation has become the standard approach, substantially reducing recurrence rates. The review also discusses the growing role of underwater EMR, cap-assisted EMR, and endoscopic full-thickness resection for challenging fibrotic or non-lifting lesions. ESD remains an important technique when en bloc resection is required, particularly in lesions with suspected superficial submucosal invasion, although its adoption varies according to local expertise and service infrastructure. Looking ahead, artificial intelligence-assisted optical diagnosis, standardized training pathways, and robust quality metrics are expected to further improve outcomes. Overall, the review reinforces a lesion-specific, evidence-based approach to NPCN, emphasizing accurate optical diagnosis and tailored resection strategies as the foundation of high-quality colorectal endoscopic care.

EUS-GJ Preferred for Malignant Gastric Outlet Obstruction : GIE | Feb 2026

Introduction: Malignant gastric outlet obstruction (GOO) is a debilitating complication of advanced gastrointestinal and pancreatobiliary cancers, leading to nausea, vomiting, poor oral intake, malnutrition, and impaired quality of life. Palliation aims to restore enteral intake rapidly while minimizing complications, hospital stay, and need for repeat procedures. Available options include enteral stenting, surgical gastrojejunostomy, stomach-partitioning gastrojejunostomy, and EUS-guided gastrojejunostomy (EUS-GJ). Problem Statement: Despite multiple available approaches, the optimal palliative strategy for malignant GOO remains uncertain. Enteral stenting is widely available and less invasive but may be limited by recurrent obstruction and need for reintervention. Surgical bypass offers durability but is associated with longer hospitalization and perioperative burden. Comparative evidence across all modalities has remained fragmented. Summary: This systematic review and network meta-analysis compared major treatment options for malignant GOO using randomized trial data. EUS-GJ emerged as the most favorable strategy, demonstrating superior clinical success compared with surgical gastrojejunostomy, stomach-partitioning gastrojejunostomy, and enteral stenting. Importantly, technical success and severe adverse events were broadly comparable across approaches, suggesting that the advantage of EUS-GJ lies mainly in more durable symptom relief rather than increased procedural risk. Enteral stenting remained an important alternative because it is less invasive, widely available, and generally less expensive; however, it carried a substantially higher need for reintervention, reflecting the risk of stent dysfunction or recurrent obstruction. Surgical approaches were associated with longer hospital stay, which may be particularly relevant in patients with limited life expectancy or poor performance status. Overall, the findings support EUS-GJ as the preferred palliative treatment for malignant GOO when local expertise is available. Treatment selection should still be individualized based on expected survival, tumor anatomy, procedural expertise, patient fitness, and resource availability.

Structured Closure Improves Safety of Duodenal ESD and EFTR : GIE | April 2026

Introduction: Endoscopic submucosal dissection (ESD) and endoscopic full-thickness resection (EFTR) have expanded the therapeutic options for duodenal epithelial and sub epithelial lesions, allowing organ-preserving treatment of lesions that previously required surgery. However, the duodenum remains one of the most technically challenging locations for advanced endoscopic resection because of its thin wall, narrow lumen, rich vascularity, and exposure to bile and pancreatic secretions. These anatomical factors increase the risk of bleeding, perforation, and delayed adverse events. Problem Statement: Although ESD and EFTR are increasingly performed in expert centers, data regarding real-world outcomes, predictors of complications, and strategies to reduce delayed adverse events remain limited. Identifying high-risk lesions and optimizing defect closure techniques are critical to improving procedural safety. Summary: This real-world study demonstrates that both ESD and free-hand EFTR can be performed with high technical success and excellent oncologic outcomes for carefully selected duodenal lesions. The investigators achieved high rates of complete resection while maintaining low recurrence rates during follow-up. Importantly, all intraprocedural bleeding and perforation events were successfully managed endoscopically, highlighting the feasibility of advanced endoscopic therapy in experienced hands. A key finding of the study was the identification of severe fibrosis as the strongest predictor of procedural adverse events in sub epithelial lesions, particularly when associated with ulceration. These features may therefore serve as valuable markers for procedural complexity and risk stratification before intervention. The study also underscores the importance of meticulous defect management. By implementing a structured closure protocol that incorporated stepwise closure techniques, intraoperative assessment, and selective postprocedural imaging, the investigators achieved near-complete defect closure and remarkably low rates of delayed complications. This finding is particularly relevant because delayed perforation and bleeding remain major concerns after duodenal resection. Overall, the study supports ESD and EFTR as effective minimally invasive alternatives to surgery for selected duodenal lesions and suggests that a systematic closure strategy may be a critical factor in enhancing procedural safety. These results provide a practical framework for optimizing outcomes in advanced duodenal endoscopic resection.

Bariatric Endoscopy in the GLP-1 Era : Frontline Gastroenterol | June 2026

Introduction: Introduction: Obesity affects more than one billion individuals globally and is a major driver of type 2 diabetes, cardiovascular disease, metabolic dysfunction–associated steatotic liver disease (MASLD), and multiple obesity-related cancers. While incretin-based therapies such as GLP-1 and dual agonists have transformed medical obesity management, concerns remain regarding long-term adherence, treatment costs, access, and weight regain following discontinuation. These limitations have renewed interest in metabolic and bariatric endoscopy (MBE) as a minimally invasive treatment modality positioned between pharmacotherapy and bariatric surgery. Problem Statement: Problem Statement: The rapid success of highly effective anti-obesity medications has raised questions about the future role of endoscopic bariatric therapies. Determining how endoscopic interventions can complement pharmacotherapy, provide durable weight loss, and address metabolic disease remains a critical challenge for obesity care pathways. Summary: Summary: This review examines the evolving role of bariatric metabolic endoscopy and its future position within modern obesity management. Current endoscopic therapies target multiple components of the gut–metabolic axis and can be broadly classified into gastric-directed, small bowel-directed, and pancreatic-directed interventions. Among gastric therapies, endoscopic sleeve gastroplasty (ESG) remains the most established procedure. By reducing gastric volume through endoscopic suturing, ESG promotes early satiety, delays gastric emptying, and induces clinically meaningful weight loss with a favorable safety profile. Long-term studies continue to demonstrate sustained metabolic benefits, particularly when combined with multidisciplinary lifestyle interventions. Intragastric balloons remain an option for selected patients requiring temporary weight reduction, although durability and tolerability limitations have restricted their long-term role. Newer generation devices and swallowable balloon technologies aim to improve patient acceptance and safety. Small bowel-directed therapies focus on modifying nutrient exposure and enteroendocrine signaling. Techniques such as duodenal mucosal resurfacing and other endoscopic duodenal interventions seek to improve insulin sensitivity and glycemic control by altering proximal intestinal nutrient sensing. These approaches are particularly attractive for patients with obesity-associated type 2 diabetes. Emerging pancreatic-directed endoscopic therapies are based on the concept of modifying neurohormonal pathways involved in appetite regulation, glucose homeostasis, and energy metabolism. Although still largely investigational, these technologies may represent future therapeutic targets within the gut–brain–pancreas axis. A major theme of the review is the integration of endoscopic therapies with incretin-based pharmacotherapy rather than viewing them as competing strategies. Combination approaches may offer synergistic benefits by enhancing weight loss magnitude, improving durability, reducing medication requirements, and minimizing weight regain after drug discontinuation. The future of obesity treatment is increasingly moving toward personalized therapy selection. Patients with moderate obesity, inadequate response to pharmacotherapy, medication intolerance, or reluctance to undergo surgery may represent ideal candidates for bariatric endoscopy. The review also highlights the expanding relevance of metabolic endoscopy beyond weight reduction alone. Improvements in diabetes control, MASLD, cardiovascular risk factors, and obesity-related quality of life are becoming important therapeutic targets and may ultimately drive patient selection. As obesity is increasingly recognized as a chronic relapsing disease, bariatric endoscopy is expected to become an integral component of comprehensive obesity care pathways, functioning alongside lifestyle modification, pharmacotherapy, and surgery within a multidisciplinary precision medicine framework. Overall, bariatric metabolic endoscopy is evolving from a niche intervention into a key pillar of obesity management, with future success likely to depend on strategic integration with incretin therapies, individualized patient selection, and continued innovation across the gut–metabolic axis.

Advanced Endoscopy Enhances Celiac Atrophy Detection : GIE | May 2026

Introduction Celiac Disease remains dependent on histological confirmation of villous atrophy for diagnosis. However, endoscopic recognition of subtle mucosal abnormalities has become increasingly important for improving biopsy targeting and reducing missed disease. Problem Statement Conventional White-Light Endoscopy often underdetects patchy or mild villous atrophy, particularly in patients with early or atypical celiac disease. Multiple advanced imaging techniques have emerged, but comparative diagnostic performance across modalities has remained uncertain. Summary This systematic review and meta-analysis evaluated the diagnostic accuracy of multiple endoscopic techniques for detecting duodenal villous atrophy in celiac disease. More than 22,000 studies were screened, with 52 eligible studies included, making this one of the largest comparative analyses of endoscopic imaging modalities in celiac disease. Standard white-light endoscopy demonstrated excellent specificity but only moderate sensitivity, confirming its limitation as a standalone tool for excluding villous atrophy. While classic findings such as scalloping, mosaic patterning and reduced folds remain highly suggestive, subtle disease continues to be frequently overlooked. Among all evaluated modalities, the water-immersion technique showed the best overall diagnostic performance, achieving both very high sensitivity and specificity. This approach likely improves visualization of villous architecture by reducing luminal collapse and enhancing mucosal detail. Narrow-Band Imaging also demonstrated excellent performance, supporting its increasing role in high-definition upper GI assessment. Enhanced mucosal contrast likely facilitates identification of subtle villous abnormalities and patchy disease distribution. Dye-based chromoendoscopy similarly achieved high sensitivity and specificity, reinforcing the value of enhanced mucosal surface characterization in suspected celiac disease. White-light magnification endoscopy improved sensitivity but suffered from lower specificity, potentially increasing false-positive interpretation of nonspecific mucosal irregularities. Other advanced techniques including Confocal Laser Endomicroscopy also showed promising diagnostic performance, although their availability and procedural complexity may currently limit routine use. Importantly, heterogeneity across studies remained low, strengthening the reliability of the pooled diagnostic estimates. Clinically, the findings support a shift from purely random duodenal biopsy strategies toward image-enhanced targeted sampling. Advanced endoscopic imaging may improve detection of patchy atrophy, reduce sampling error and potentially lower the number of biopsies required. The study is especially relevant in contemporary practice, where increasing recognition of non-classical and serology-positive celiac disease requires more sensitive endoscopic assessment strategies. These techniques may also become particularly valuable in patients with mild histologic abnormalities, seronegative celiac disease, partial gluten restriction or equivocal mucosal changes. From a practical perspective, water immersion and NBI appear especially attractive because they can be integrated into routine upper GI endoscopy without substantial procedural burden. The review additionally highlights an important educational point for endoscopists: high-quality duodenal inspection should extend beyond rapid biopsy acquisition and include careful mucosal pattern analysis. Limitations include variability in operator expertise, differences in endoscopic platforms and inconsistent histologic reference standards across studies. Future directions will likely involve integration of high-definition imaging with artificial intelligence-assisted mucosal recognition to improve real-time identification of villous abnormalities during routine gastroscopy. Overall, this meta-analysis demonstrates that advanced endoscopic imaging techniques, particularly water immersion, narrow-band imaging and dye-based chromoendoscopy, substantially improve the detection of villous atrophy compared with standard white-light endoscopy and may enhance diagnostic precision in celiac disease.

Water-Assisted Colonoscopy: Endoscopy| May 2026

Water-assisted colonoscopy (WAC), also known as hydrocolonoscopy, is an evolving insertion technique in which water is used instead of, or alongside, gas insufflation during colonoscope advancement. Over recent years, growing evidence has shown that WAC not only improves patient comfort but may also enhance adenoma detection and procedural quality. Conventional air or CO₂ insufflation can elongate the colon, promote loop formation, increase angulations, and contribute to procedural discomfort. In addition, inadequate mucosal cleansing may impair adenoma detection. The challenge is to achieve: Less painful colonoscopy Better loop control Improved mucosal visualization Higher adenoma detection rates (ADR) without compromising procedural efficiency. The principle behind WAC is maintaining the lumen minimally distended using water during insertion. Water exerts a gravitational effect that helps straighten the colon, reduces angulations, and minimizes loop formation. This translates into reduced patient discomfort and lower sedation requirements. Two major forms are commonly used: 1. Water immersion 2. Water exchange Among these, water exchange appears superior for reducing pain and improving ADR because residual stool and debris are aggressively washed away during insertion. An additional benefit is improved mucosal visualization. Continuous irrigation cleans the mucosal surface, enhancing detection of subtle lesions and adenomas. Water also has therapeutic advantages during endoscopic resection. During underwater polypectomy or EMR, water dissipates thermal energy and may reduce deep electrosurgical injury to the muscularis propria. Many experienced endoscopists now use a hybrid dynamic approach, combining water and CO₂ selectively during insertion and withdrawal. Water helps traverse difficult angulations and clean the mucosa, while CO₂ is used strategically to expand folds during detailed inspection. Overall, WAC represents a practical, low-cost technique that improves colonoscopy ergonomics, patient tolerance, mucosal visualization, and potentially adenoma detection without prolonging procedure time.

Optimizing Barrett’s Endoscopy Quality to Reduce Missed Neoplasia : FG | May 2026

Introduction Barrett's Esophagus is the principal precursor lesion for Esophageal Adenocarcinoma. Surveillance endoscopy aims to detect dysplasia and early neoplasia at a curable stage; however, post-endoscopy upper gastrointestinal cancers remain a significant problem. Contemporary UK data suggest particularly high rates of missed neoplasia in Barrett’s surveillance compared with upper gastrointestinal endoscopy overall, emphasizing the urgent need for improved examination quality. Problem Statement Despite widespread Barrett’s surveillance programs, substantial rates of missed dysplasia and early cancer persist, largely due to variability in endoscopic examination quality, lesion recognition and adherence to optimal imaging and biopsy protocols. Summary This video review provides a practical and clinically focused framework for improving the quality of Barrett’s endoscopy, emphasizing meticulous mucosal inspection, advanced imaging utilization and standardized biopsy techniques to enhance neoplasia detection. The review begins by reinforcing the importance of accurate endoscopic landmark recognition and Barrett’s segment characterization. Proper identification of the gastroesophageal junction, diaphragmatic pinch and squamocolumnar junction is essential for reliable Prague classification and longitudinal surveillance consistency. A major emphasis is placed on careful mucosal inspection using high-definition white light endoscopy combined with image-enhanced technologies. Modalities such as Narrow Band Imaging, blue light imaging and i-scan are highlighted as critical adjuncts for identifying subtle vascular and mucosal abnormalities associated with dysplasia. The review additionally emphasizes the growing role of acetic acid chromoendoscopy, which can accentuate dysplastic mucosal patterns and improve targeted lesion recognition. This reflects the broader evolution of Barrett’s surveillance from random biopsy-driven protocols toward increasingly targeted optical diagnosis approaches. Importantly, the article highlights that many dysplastic lesions in Barrett’s esophagus are extremely subtle and easily overlooked during rapid or low-quality examinations. Careful slow inspection, adequate mucosal cleansing and optimized insufflation are therefore fundamental components of high-quality surveillance. The authors also stress adherence to systematic biopsy protocols following targeted lesion assessment. Although advanced imaging improves lesion detection, systematic four-quadrant biopsies remain important because flat dysplasia may still be endoscopically occult. Clinically, the work reinforces that Barrett’s surveillance quality is operator dependent. Variability in withdrawal time, familiarity with dysplastic morphology and use of enhanced imaging likely contribute substantially to the persistently elevated post-endoscopy cancer rates observed in Barrett’s patients. The review also aligns with increasing evidence supporting dedicated Barrett’s surveillance expertise and centralization of complex neoplasia management. High-quality surveillance requires not only technical proficiency but also advanced lesion recognition skills and familiarity with endoscopic resection strategies. An important practical implication is the need for structured training in Barrett’s neoplasia recognition. As endoscopic eradication therapies increasingly replace surgery for early neoplasia, accurate detection and delineation of visible lesions become even more critical. The article further reflects the broader movement within gastrointestinal endoscopy toward quality metric-driven practice. Similar to adenoma detection rates in colonoscopy, Barrett’s surveillance may increasingly adopt formal quality indicators including inspection time, adherence to biopsy protocols and use of advanced imaging. From a therapeutic perspective, improved detection directly influences patient outcomes because early Barrett’s neoplasia can often be managed endoscopically using Endoscopic Mucosal Resection and ablative therapies, avoiding esophagectomy. Overall, this review emphasizes that high-quality Barrett’s endoscopy requires a structured, meticulous and technology-enhanced approach. Careful landmark identification, prolonged mucosal inspection, advanced imaging utilization and systematic biopsy acquisition are central to reducing missed dysplasia and improving early esophageal cancer detection in Barrett’s surveillance programs.

Recurrent Colorectal Polyps Require Advanced, Structured Endoscopic Management : Frontline Gastroenterology | May 2026

Introduction Colorectal Polyps are identified in up to half of screening colonoscopies and represent key precursor lesions for Colorectal Cancer. Advances in endoscopic resection techniques have dramatically reduced the need for surgery; however, recurrence or residual neoplasia after initial polypectomy remains an important clinical challenge. Recurrence rates may approach 20%, particularly after piecemeal resection of large lesions. Problem Statement Optimal management strategies for recurrent or residual colorectal polyps remain incompletely standardized. Limited evidence exists regarding selection among repeat endoscopic therapy, advanced resection techniques and surgery, particularly in technically difficult or fibrotic lesions. Summary This review comprehensively evaluates current evidence regarding management of recurrent or residual colorectal polyps after initial polypectomy, with particular emphasis on advanced endoscopic approaches and strategies to minimize repeated interventions. The review highlights that recurrence is strongly influenced by the initial resection technique. Piecemeal endoscopic mucosal resection (EMR) carries substantially higher recurrence risk compared with en bloc resection because microscopic residual neoplastic tissue may remain at resection margins. Larger lesion size, difficult location, multiplicity and lesion morphology additionally contribute to recurrence risk. Several patient-related factors were also associated with recurrent neoplasia, including male sex, older age, obesity and smoking history. These observations reinforce the multifactorial biology underlying colorectal neoplasia persistence and recurrence. A key theme throughout the review is the importance of expert initial resection. Incomplete primary therapy frequently converts otherwise manageable lesions into technically complex recurrent polyps characterized by fibrosis, scar formation and distorted tissue planes. These recurrent lesions are often substantially more difficult to eradicate than treatment-naïve lesions. The review discusses a spectrum of advanced therapeutic options for recurrent lesions. Repeat EMR may remain feasible for smaller residual adenomas, whereas more advanced approaches such as Endoscopic Submucosal Dissection can facilitate en bloc excision of scarred or recurrent lesions. Avulsion techniques combined with thermal margin ablation have also emerged as valuable tools for fibrotic residual disease not amenable to standard snare capture. The role of full-thickness endoscopic resection is additionally emphasized for selected nonlifting or heavily scarred lesions. These techniques may help avoid surgery in carefully selected patients while still achieving definitive resection. Importantly, the review underscores that surgery remains necessary in selected circumstances, particularly when invasive malignancy is suspected, complete endoscopic excision is not feasible or repeated endoscopic attempts have failed. However, the authors strongly advocate referral to advanced endoscopy centers before surgical referral whenever possible, given the morbidity associated with colorectal resection. A major practical message is that recurrent polyp management should ideally occur in highly experienced, well-resourced tertiary centers. Advanced imaging, expert lesion characterization and availability of multiple resection platforms are critical for maximizing endoscopic cure rates and minimizing repeated procedures. The burden of recurrent procedures is also appropriately highlighted. Beyond technical complexity, repeated interventions increase patient anxiety, healthcare utilization, procedural risk and surveillance burden. Consequently, achieving high-quality definitive initial resection is likely the most effective recurrence-prevention strategy. The review also reflects the broader evolution of therapeutic colonoscopy toward organ-preserving minimally invasive management. Increasingly sophisticated endoscopic techniques are now allowing successful treatment of lesions previously referred directly for surgery. Overall, this review emphasizes that recurrent colorectal polyps represent a technically demanding but increasingly manageable clinical problem. Optimal outcomes depend on expert lesion assessment, advanced endoscopic resection capability and early referral to specialized centers, with the overarching goal of achieving definitive organ-preserving therapy while minimizing repeated interventions and unnecessary surgery.

Recurrent Colorectal Polyps Require Advanced, Structured Endoscopic Management : Frontline Gastroenterology | May 2026

Introduction Colorectal Polyps are identified in up to half of screening colonoscopies and represent key precursor lesions for Colorectal Cancer. Advances in endoscopic resection techniques have dramatically reduced the need for surgery; however, recurrence or residual neoplasia after initial polypectomy remains an important clinical challenge. Recurrence rates may approach 20%, particularly after piecemeal resection of large lesions. Problem Statement Optimal management strategies for recurrent or residual colorectal polyps remain incompletely standardized. Limited evidence exists regarding selection among repeat endoscopic therapy, advanced resection techniques and surgery, particularly in technically difficult or fibrotic lesions. Summary This review comprehensively evaluates current evidence regarding management of recurrent or residual colorectal polyps after initial polypectomy, with particular emphasis on advanced endoscopic approaches and strategies to minimize repeated interventions. The review highlights that recurrence is strongly influenced by the initial resection technique. Piecemeal endoscopic mucosal resection (EMR) carries substantially higher recurrence risk compared with en bloc resection because microscopic residual neoplastic tissue may remain at resection margins. Larger lesion size, difficult location, multiplicity and lesion morphology additionally contribute to recurrence risk. Several patient-related factors were also associated with recurrent neoplasia, including male sex, older age, obesity and smoking history. These observations reinforce the multifactorial biology underlying colorectal neoplasia persistence and recurrence. A key theme throughout the review is the importance of expert initial resection. Incomplete primary therapy frequently converts otherwise manageable lesions into technically complex recurrent polyps characterized by fibrosis, scar formation and distorted tissue planes. These recurrent lesions are often substantially more difficult to eradicate than treatment-naïve lesions. The review discusses a spectrum of advanced therapeutic options for recurrent lesions. Repeat EMR may remain feasible for smaller residual adenomas, whereas more advanced approaches such as Endoscopic Submucosal Dissection can facilitate en bloc excision of scarred or recurrent lesions. Avulsion techniques combined with thermal margin ablation have also emerged as valuable tools for fibrotic residual disease not amenable to standard snare capture. The role of full-thickness endoscopic resection is additionally emphasized for selected nonlifting or heavily scarred lesions. These techniques may help avoid surgery in carefully selected patients while still achieving definitive resection. Importantly, the review underscores that surgery remains necessary in selected circumstances, particularly when invasive malignancy is suspected, complete endoscopic excision is not feasible or repeated endoscopic attempts have failed. However, the authors strongly advocate referral to advanced endoscopy centers before surgical referral whenever possible, given the morbidity associated with colorectal resection. A major practical message is that recurrent polyp management should ideally occur in highly experienced, well-resourced tertiary centers. Advanced imaging, expert lesion characterization and availability of multiple resection platforms are critical for maximizing endoscopic cure rates and minimizing repeated procedures. The burden of recurrent procedures is also appropriately highlighted. Beyond technical complexity, repeated interventions increase patient anxiety, healthcare utilization, procedural risk and surveillance burden. Consequently, achieving high-quality definitive initial resection is likely the most effective recurrence-prevention strategy. The review also reflects the broader evolution of therapeutic colonoscopy toward organ-preserving minimally invasive management. Increasingly sophisticated endoscopic techniques are now allowing successful treatment of lesions previously referred directly for surgery. Overall, this review emphasizes that recurrent colorectal polyps represent a technically demanding but increasingly manageable clinical problem. Optimal outcomes depend on expert lesion assessment, advanced endoscopic resection capability and early referral to specialized centers, with the overarching goal of achieving definitive organ-preserving therapy while minimizing repeated interventions and unnecessary surgery.

STER Demonstrates Strong Real-World Outcomes for Upper GI Subepithelial Tumors : Gastrointest Endosc | May 2026

Introduction Submucosal Tunneling Endoscopic Resection has emerged as an important minimally invasive approach for management of upper gastrointestinal Subepithelial Tumors arising from or closely associated with the muscularis propria layer. Although extensive Asian experience has established the efficacy of STER, Western outcome data have remained limited, particularly regarding technical feasibility, fibrosis-related complexity and transmural resection requirements. Problem Statement Real-world U.S. data evaluating procedural success, adverse events and predictors of technical difficulty during STER for upper gastrointestinal subepithelial lesions are sparse. In particular, factors influencing transmural resection and incomplete resection remain poorly characterized. Summary This multicenter U.S. retrospective study evaluated outcomes of STER across eight tertiary centers for upper gastrointestinal subepithelial lesions originating from or inseparable from the muscularis propria layer. Most lesions had undergone prior diagnostic sampling before referral, and suspected gastrointestinal stromal tumors represented a major indication for intervention. STER achieved excellent technical outcomes, with en bloc resection and successful specimen retrieval in more than 94% of lesions. Importantly, no recurrences were observed during follow-up, supporting the oncologic adequacy and durability of endoscopic resection in appropriately selected lesions. A major finding was the impact of submucosal fibrosis on procedural complexity. Fibrosis was identified in nearly one-fifth of lesions and was universally associated with prior tissue sampling. Fibrotic lesions were substantially more likely to require transmural resection, highlighting how repeated biopsy or EUS-guided sampling may alter tissue planes and compromise technical ease of definitive endoscopic therapy. Gastrointestinal Stromal Tumor histology and extraluminal extension were also strongly associated with transmural resection requirements. These lesions likely reflect deeper muscular involvement and distorted anatomic planes, increasing procedural complexity and the need for full-thickness dissection. Importantly, although transmural resection prolonged procedure duration and increased R1 resection rates, it did not significantly increase adverse events. Most complications were managed conservatively, supporting the relative safety of advanced third-space endoscopic techniques in experienced centers. The study has several important practical implications for therapeutic endoscopy. First, it reinforces STER as an effective organ-preserving alternative to surgery for selected upper GI subepithelial tumors, particularly in lesions arising from the muscularis propria layer. Preservation of mucosal integrity through the tunneling approach likely contributes to reduced leak risk and faster recovery compared with exposed full-thickness techniques. Second, the findings challenge the routine use of extensive pre-resection tissue acquisition in lesions already strongly suspected to represent resectable GISTs or symptomatic muscularis propria tumors. Excessive prior sampling may induce fibrosis that complicates subsequent definitive resection without necessarily improving management decisions. The work also highlights the increasing sophistication of third-space endoscopy within Western practice. Historically concentrated in high-volume Asian centers, advanced submucosal tunneling techniques are now demonstrating reproducible safety and efficacy across U.S. tertiary institutions. Clinically, optimal patient selection remains critical. Lesions with extraluminal growth, deep muscular attachment or prior fibrosis may require advanced expertise and longer procedural planning. Nevertheless, even these technically challenging cases remained manageable endoscopically in experienced hands. Overall, this multicenter U.S. experience demonstrates that STER is a safe, effective and durable minimally invasive approach for selected upper gastrointestinal subepithelial tumors. The study additionally identifies prior sampling-induced fibrosis, GIST histology and extraluminal extension as key predictors of transmural resection complexity, emphasizing the importance of procedural planning and careful diagnostic sequencing.

Diathermy Principles Every Endoscopist Should Understand ; Frontline Gastroenterol | May 2026

Introduction Electrosurgery forms the foundation of modern therapeutic gastrointestinal endoscopy. Procedures including polypectomy, Endoscopic Mucosal Resection, Endoscopic Submucosal Dissection, endoscopic sphincterotomy and third-space endoscopy all rely on controlled delivery of electrical energy to tissue. Despite routine use, many endoscopists select generator settings empirically without fully understanding the electrophysical principles that determine tissue effects, procedural efficiency and adverse event risk. Problem Statement Electrosurgical outcomes during endoscopy vary substantially even when identical generator settings are used. Inadequate understanding of factors such as voltage, current density, impedance, waveform modulation and tissue environment may contribute to unpredictable cutting, excessive thermal injury, delayed bleeding or perforation. Summary This clinically oriented review translates the fundamental physics of electrosurgery into practical endoscopic guidance. The authors emphasize that tissue effects are not determined solely by generator settings, but instead result from complex interactions among current density, tissue impedance, electrode geometry, application time and procedural technique. A key principle highlighted is that cutting and coagulation are fundamentally governed by current density and voltage behavior. High current density concentrated over a small tissue area generates rapid intracellular heating and vaporization, producing cutting effects. In contrast, lower-density current with prolonged application promotes protein denaturation, desiccation and coagulation. Thus, identical generator settings may produce very different outcomes depending on snare tension, electrode contact, tissue compression and duration of activation. The review carefully explains waveform modulation, one of the most misunderstood aspects of diathermy. Continuous low-voltage waveforms primarily facilitate cutting, whereas intermittent or pulsed higher-voltage waveforms generate coagulative effects. Modern blended currents dynamically alternate between these properties to balance effective tissue transection with hemostasis. Understanding waveform behavior is particularly important during advanced resections where excessive coagulation may impair dissection planes or increase delayed thermal injury. Another major focus is the influence of tissue environment, particularly the increasingly important distinction between procedures performed in air versus saline immersion. In underwater EMR and saline-assisted procedures, electrical current disperses differently because saline conducts current far more efficiently than air. This alters current density and tissue heating characteristics, meaning electrosurgical effects observed in conventional luminal procedures cannot simply be extrapolated to underwater techniques. The review additionally contrasts monopolar and bipolar electrosurgical systems. Monopolar devices remain dominant in GI endoscopy because of their versatility and cutting efficiency, but bipolar systems may provide more localized current flow and potentially reduced collateral injury in selected settings. Understanding current return pathways is also important for minimizing unintended thermal damage and ensuring safe device application. Importantly, the authors emphasize that electrosurgical safety depends heavily on technique rather than generator selection alone. Factors such as excessive tissue tenting, prolonged activation, inadequate submucosal lift and inappropriate immersion environments can markedly alter thermal spread and complication risk despite apparently correct settings. The review is especially valuable for trainees and general gastroenterologists because it reframes diathermy from a “preset-based” practice into a mechanistically predictable process. Developing conceptual understanding of electrosurgical physics may improve procedural precision, optimize resection quality and reduce complications across the expanding spectrum of therapeutic GI endoscopy. Overall, this review provides a highly practical electrophysical framework for understanding diathermy in gastrointestinal endoscopy and highlights how procedural context, tissue interaction and current behavior collectively determine clinical outcomes beyond generator settings alone.

Sedation Strategy Influences Aspiration Risk After PEG : Frontline Gastroenterol | May 2026

Introduction Percutaneous Endoscopic Gastrostomy is widely performed for long-term enteral nutritional support in patients with neurological disease, dysphagia and chronic debilitating illness. Aspiration pneumonia remains one of the most important early complications following PEG insertion and contributes substantially to post-procedural morbidity and mortality. However, the influence of sedation and local anaesthesia practices on aspiration risk has remained poorly defined at a population level. Problem Statement Considerable variation exists in endoscopic sedation and throat anaesthesia practices during PEG insertion across institutions. Whether specific sedation approaches independently increase post-PEG aspiration pneumonia risk has not previously been evaluated in a large real-world multicentre cohort. Summary This large retrospective population-based study analyzed more than 33,000 adult patients undergoing PEG insertion across England between 2016 and 2021. Investigators integrated Hospital Episode Statistics with National Endoscopy Database provider-level sedation practices to evaluate associations between procedural anaesthesia strategies and aspiration pneumonia occurring within seven days of PEG placement. Substantial variation in sedation practice was observed across providers. Nearly half predominantly used combined midazolam-opioid sedation, while others favored midazolam alone, local anaesthetic throat spray or propofol/general anaesthesia approaches. Stroke represented the most common indication for PEG insertion and was associated with the highest baseline aspiration risk compared with other clinical indications. The strongest associations with post-PEG aspiration pneumonia were observed among providers predominantly using propofol/general anaesthesia and those combining midazolam with local anaesthetic throat spray. In contrast, aspiration risk was substantially lower among providers using midazolam alone or combined with opioids without routine throat spray. These findings suggest that suppression of protective airway reflexes may play a central role in aspiration pathogenesis during PEG procedures. The association with local anaesthetic throat spray is particularly notable because topical pharyngeal anaesthesia may impair laryngeal sensation and cough reflexes in already vulnerable dysphagic patients. Similarly, deeper sedation with propofol or general anaesthesia likely further compromises airway protection and swallowing coordination during and immediately after PEG insertion. Additional procedural and patient-level risk factors included low provider procedural volume, advanced age and emergency hospital admission. Providers performing fewer than 23 PEG procedures annually demonstrated higher aspiration rates, suggesting an important volume-outcome relationship and potential benefit of procedural centralization or enhanced training pathways. Clinically, the findings challenge routine use of aggressive sedation strategies during PEG insertion, particularly in frail neurological populations already predisposed to aspiration. The data support more individualized sedation approaches balancing patient comfort with preservation of airway protective reflexes. Overall, this large national study demonstrates that sedation and local anaesthesia practices substantially influence aspiration pneumonia risk following PEG insertion. The findings have important implications for endoscopy sedation protocols and suggest that minimizing deep sedation and cautious use of local anaesthetic throat spray may improve procedural safety in high-risk PEG populations.

3D-Printed Distal Caps for ESD: Clinical and Translational Gastroenterology | May 2026

Conventional Method Commercial distal attachment caps are routinely used during Endoscopic Submucosal Dissection to improve visualization, tissue traction, and procedural stability. Although effective, these caps are commercially manufactured, relatively costly, and offer limited customization for operator preference or lesion characteristics. Why a New Method Was Required As ESD expands globally, especially into resource-limited settings and training programs, there is growing interest in affordable and customizable accessories. The challenge has been whether low-cost 3D-printed devices can match the safety, efficiency, and ergonomics of standard commercial caps without compromising procedural outcomes. New Method The ENDOPRINT trial evaluated a custom 3D-printed distal cap made from flexible medical-grade resin against a standard commercial Olympus cap in an ex vivo multicenter porcine ESD model. Ninety-nine ESD procedures across centers in Prague, Olomouc, and Boston were randomized between the two devices. The study demonstrated identical median procedure times between both caps, with 100% en bloc resection and technical success rates in both groups. Importantly, operators consistently rated the 3D-printed cap superior for visibility, scope manipulation, and tissue retraction. Adverse events were uncommon and similar between groups. Clinical Utility This study suggests that 3D-printed caps may provide a safe, effective, and substantially lower-cost alternative to commercial ESD caps. The ability to customize cap design could improve ergonomics and procedural flexibility, particularly for training environments and advanced therapeutic endoscopy units. Although the study was ex vivo, the results support future in vivo evaluation and cost-effectiveness studies. If validated clinically, customizable 3D-printed accessories may represent an important step toward more accessible and personalized ESD practice worldwide

Post-ERCP Bleeding Risks Clarified in Large Meta-analysis : Gastrointest Endosc | May 2026

Introduction Endoscopic retrograde cholangiopancreatography (ERCP) is a cornerstone therapeutic procedure in pancreatobiliary disease but carries a risk of clinically significant bleeding, particularly following therapeutic interventions such as sphincterotomy. Accurate identification of bleeding predictors is essential for procedural planning, risk stratification and optimization of preventive strategies. Problem Statement Existing studies evaluating post-ERCP bleeding risk factors have shown inconsistent findings, particularly regarding antithrombotic therapy, procedural techniques and patient-related comorbidities. A comprehensive evidence-based analysis was needed to better define independent predictors of bleeding after ERCP. Summary This systematic review and meta-analysis evaluated nearly 150,000 ERCP procedures and identified several major independent predictors of post-ERCP bleeding. Coagulopathy emerged as the strongest risk factor, followed by hemodialysis, anticoagulation therapy and cirrhosis, highlighting the critical role of impaired hemostatic reserve and advanced systemic disease in postprocedural hemorrhage. Procedural interventions also substantially influenced bleeding risk, with endoscopic sphincterotomy and precut sphincterotomy significantly increasing the likelihood of bleeding events. Intraoperative bleeding itself was an important predictor of subsequent clinically significant hemorrhage, emphasizing the importance of meticulous intraprocedural hemostasis. Male sex was associated with a modest increase in bleeding risk, although the biologic explanation remains uncertain. Importantly, several commonly presumed risk factors—including older age, obesity, cholangitis, choledocholithiasis, pancreatic duct stones, NSAID use and antiplatelet therapy—were not independently associated with increased bleeding risk after adjusted analysis. Notably, antiplatelet therapy did not significantly elevate bleeding risk, an observation that may influence future peri-ERCP medication management strategies. Similarly, endoscopic papillary balloon dilation and covered metal stent placement were not associated with excess bleeding risk. Overall, the findings provide a refined evidence-based framework for predicting post-ERCP bleeding and support the development of individualized risk assessment models to improve informed consent, procedural planning and prophylactic management in therapeutic ERCP.

Predictors of Post-ERCP Bleeding Identified in Large Meta-analysis : Gastrointest Endosc | May 2026

Introduction Endoscopic retrograde cholangiopancreatography (ERCP) is an essential therapeutic procedure in pancreatobiliary disease but remains associated with important adverse events, including postprocedural bleeding. Although bleeding occurs relatively infrequently, it can result in significant morbidity, need for intervention and prolonged hospitalization. Problem Statement Previous studies evaluating predictors of post-ERCP bleeding have produced inconsistent results, particularly regarding patient comorbidities, antithrombotic therapy and procedural techniques. A comprehensive risk stratification framework is needed to better identify high-risk patients and optimize preventive strategies before ERCP. Summary This large systematic review and meta-analysis identified several clinically important predictors independently associated with post-ERCP bleeding. The strongest risk factors included coagulopathy, hemodialysis, anticoagulation therapy and cirrhosis, emphasizing the major contribution of impaired hemostatic reserve and advanced systemic disease to bleeding risk. Procedural factors also played a significant role, with endoscopic sphincterotomy, precut sphincterotomy and intraprocedural bleeding emerging as important predictors of subsequent hemorrhage. Male sex was additionally associated with modestly increased bleeding risk. In contrast, several traditionally presumed risk factors—including older age, elevated body mass index, cholangitis, choledocholithiasis, NSAID use and antiplatelet therapy—were not significantly associated with higher bleeding risk after adjusted analysis. Notably, antiplatelet therapy did not independently increase bleeding risk, an observation that may influence future periprocedural management decisions in selected patients. The study also demonstrated that not all technically advanced interventions confer equal bleeding liability, as endoscopic papillary balloon dilation and covered metal stent placement were not associated with significantly increased bleeding rates. Overall, the findings provide a more refined evidence-based understanding of post-ERCP bleeding risk and support development of predictive models integrating patient-related and procedure-related variables to guide individualized procedural planning, informed consent and preventive strategies in therapeutic ERCP.

International Consensus Defines Best Practices for EUS-Guided Gastroenterostomy : Gastrointestinal Endoscopy | May 2026

Introduction Endoscopic ultrasound–guided gastroenterostomy (EUS-GE) has rapidly emerged as an important minimally invasive option for the management of gastric outlet obstruction, offering an alternative to surgical bypass and enteral stenting. As adoption increases globally, EUS-GE is being applied across increasingly diverse benign and malignant indications. Problem Statement Despite growing utilization, EUS-GE techniques remain highly variable among centers and operators, including differences in access methods, stent deployment strategies, procedural setup and adjunctive imaging techniques. This lack of standardization may contribute to heterogeneous clinical outcomes and creates challenges for training, quality assurance and procedural safety. Summary This international modified Delphi consensus provides the first structured expert-driven technical recommendations for standardizing EUS-guided gastroenterostomy. Through a multiround consensus process involving leading interventional endosonographers, the study identified broad agreement on several core procedural principles considered essential for safe and effective EUS-GE. Strong consensus supported routine fluoroscopic guidance, free-hand deployment of electrocautery-enhanced lumen-apposing metal stents and the requirement for operator expertise in managing major complications such as perforation, bleeding, stent dysfunction and misdeployment. Consensus was also achieved regarding procedural sedation, patient positioning and the use of saline for bowel distension. More nuanced topics—including dye use, optimal bowel distension techniques and preferred catheter-assisted approaches—generated moderate agreement, reflecting evolving operator preference and ongoing technical refinement. Importantly, several unresolved areas failed to achieve consensus, particularly regarding contrast utilization and superiority of specific technical approaches, highlighting persistent procedural heterogeneity and important future research priorities. Overall, this consensus document represents a major step toward procedural standardization in therapeutic EUS and provides a practical framework for training, quality improvement and safer adoption of EUS-GE in advanced endoscopy practice.

EUS-Directed Transenteric ERCP Expands Options in Surgically Altered Anatomy : Gastrointestinal Endoscopy | May 2026

Introduction Biliary intervention in patients with surgically altered anatomy remains one of the most technically challenging areas in therapeutic endoscopy. Conventional enteroscopy-assisted ERCP is often limited by difficult limb access, prolonged procedure time and reduced cannulation success, particularly in Roux-en-Y reconstructions and hepaticojejunostomy anatomies. Therapeutic endoscopic ultrasound (EUS) has increasingly emerged as an alternative platform for creating transluminal access pathways in these complex settings. Problem Statement Although EUS-guided anastomosis using lumen-apposing metal stents (LAMS) has transformed access strategies in gastric bypass anatomy, evidence supporting EUS-directed transenteric ERCP (EDEE) in other surgically altered anatomies remains limited. Key concerns include procedural feasibility, adverse events, fistula persistence and the practical role of this technique compared with percutaneous or enteroscopy-assisted approaches. Summary This multicenter study demonstrates that EDEE using EUS-guided anastomosis with LAMS is a highly effective approach for biliary intervention in patients with complex surgically altered anatomy. The technique achieved excellent rates of EUS-guided anastomosis creation and high technical and clinical success for subsequent ERCP, even in anatomies traditionally considered extremely difficult for standard endoscopic access. Most procedures were performed for benign indications, particularly hepaticojejunostomy strictures requiring repeated interventions, highlighting one of the major advantages of EDEE: the ability to establish durable and repeatable endoscopic access to the biliary limb. The study also emphasizes the technical versatility of EDEE, with multiple strategies successfully used to identify the biliary limb depending on surgical configuration. Adverse events occurred in approximately one-fifth of patients, although severe complications were relatively uncommon and most LAMS-related events were managed endoscopically or conservatively. Persistent fistula formation after LAMS removal remained a notable issue, although its long-term clinical significance outside bariatric anatomy remains uncertain. Overall, the findings position EDEE as a major advancement in interventional endoscopy for surgically altered anatomy and support its role as a minimally invasive alternative to percutaneous drainage or surgery, particularly in benign disease requiring repeated biliary access.

Same-Day Discharge After G-POEM Appears Safe in Selected Patients | Gastrointestinal Endoscopy

Introduction Gastric per oral endoscopic myotomy (G-POEM) has emerged as an effective minimally invasive therapy for refractory gastroparesis. However, post-procedural care remains variable across centers, with no clear consensus on whether patients require routine overnight observation or can be safely discharged on the same day. Problem Statement Despite growing adoption of G-POEM, the optimal post-procedure disposition remains undefined. Routine overnight admission increases resource utilization and costs, yet concerns persist regarding delayed adverse events, unplanned readmissions and emergency visits after same-day discharge. Defining the safety of same-day discharge is essential to standardize post-G-POEM care and improve procedural efficiency. Summary This systematic review and meta-analysis suggests that same-day discharge after G-POEM is a safe and feasible strategy in appropriately selected patients with refractory gastroparesis. Across pooled studies, same-day discharge was not associated with higher rates of readmission, emergency department visits or procedure-related adverse events compared with routine overnight observation. These findings support the clinical safety of same-day discharge when applied in carefully selected patients following uncomplicated procedures. Notably, same-day discharge was also associated with shorter procedure times, suggesting that procedural efficiency and case selection may contribute to successful early discharge pathways. Although patient selection and institutional protocols remain important, these data support a shift toward more streamlined post-G-POEM care and suggest that routine overnight admission may not be necessary for all patients. This analysis provides an important step toward standardizing post-procedural pathways and supports same-day discharge as a practical, resource-conscious approach in experienced centers.

Digital Family History Assessment Improves CRC Risk Stratification in Endoscopy | Endoscopy

Introduction Family history remains a critical but underused tool in colorectal cancer (CRC) risk assessment. Despite its importance in identifying individuals at increased hereditary risk, family history is often incompletely captured in routine endoscopy practice, leading to missed opportunities for genetic referral, inappropriate surveillance and inefficient colonoscopy use. Problem Statement Conventional family history assessment in endoscopy services is inconsistent, time-intensive and frequently insufficient for accurate CRC risk stratification. This creates two major clinical problems: overuse of colonoscopic surveillance in low-risk individuals and under-recognition of patients who may warrant enhanced surveillance or genetic evaluation. A practical, scalable approach is needed to integrate standardized hereditary risk assessment into routine endoscopy workflows. Summary This service improvement project demonstrates that integrating a digital family history questionnaire with a dedicated endoscopy genetic counsellor can substantially improve CRC risk stratification and surveillance efficiency within a modern endoscopy unit. In patients already undergoing family history–based surveillance, standardized reassessment led to clinically meaningful changes in surveillance recommendations for most patients, predominantly by downgrading unnecessary colonoscopy intensity, resulting in major reductions in avoidable procedures and substantial cost savings. In symptomatic patients, the same digital pathway identified previously unrecognized familial CRC risk, including individuals warranting moderate- or high-risk surveillance and potential genetic evaluation. These findings show that embedding structured family history assessment into routine endoscopy is both feasible and clinically impactful, improving risk stratification while optimizing resource utilization. The model is particularly valuable because it simultaneously reduces over-surveillance in low-risk patients and improves detection of individuals with clinically relevant inherited CRC risk. This scalable approach offers a practical framework for integrating precision prevention and genetic triage into everyday endoscopy practice.

Single-Dose NSAIDs in ERCP: Gastroenterology | May 2026

Introduction Post-ERCP pancreatitis (PEP) remains one of the most common and serious complications of Endoscopic Retrograde Cholangiopancreatography. Rectal NSAIDs such as Indomethacin and Diclofenac are strongly recommended for PEP prevention. However, concerns about renal safety—especially in elderly patients and those with chronic kidney disease—have limited their widespread use in clinical practice. This large multicenter prospective study evaluates whether a single peri-procedural dose of NSAIDs truly increases the risk of kidney injury, addressing an important clinical hesitation. Problem Statement Despite strong evidence supporting NSAIDs in reducing PEP, many clinicians avoid their use due to fear of acute kidney injury (AKI) or acute kidney disease (AKD). Current guidelines often recommend caution or avoidance in patients perceived to be at higher renal risk. This creates a clinical dilemma: 👉 Should we compromise effective PEP prevention due to theoretical renal risks, or is this concern overstated? Summary In a large cohort of over 11,000 patients undergoing ERCP, approximately half received a single dose of rectal NSAIDs. The study found: No significant association between NSAID use and AKI or AKD Low absolute rates of kidney injury (0.5%–0.8%), even in high-risk groups Consistent findings across: Elderly patients Patients with pre-existing chronic kidney disease Propensity-matched analysis Importantly, NSAIDs were also not associated with increased bleeding or other major adverse events. These findings suggest that single-dose NSAIDs are safe from a renal standpoint in the ERCP setting, challenging the routine avoidance of these drugs.

OTSC vs Band Ligation in Diverticular Bleeding: GIE | April 2026

Introduction Colonic diverticular bleeding is an increasingly common cause of lower gastrointestinal bleeding, particularly with aging populations. Although many cases resolve spontaneously, recurrent or severe bleeding often requires endoscopic intervention. Techniques such as endoscopic band ligation and over-the-scope clip have emerged as effective hemostatic options. While EBL is widely used and known for reducing rebleeding, OTSC is a newer modality with strong mechanical closure capabilities. However, direct comparative data between these techniques remain limited. Problem Statement There is insufficient evidence to determine whether OTSC or EBL provides superior outcomes in preventing rebleeding in colonic diverticular bleeding. Summary This propensity score–matched cohort study provides important comparative insights between OTSC and EBL in the management of CDB. Both techniques demonstrated similar effectiveness in achieving initial hemostasis, with no significant differences in need for transfusion, additional interventions, or adverse events. However, OTSC showed a clear advantage in reducing early (30-day) rebleeding rates and was associated with a shorter hospital stay. This suggests that while both methods are equally effective for immediate bleeding control, OTSC may offer more durable hemostasis. Clinically, these findings support considering OTSC as a preferred option in patients at high risk of rebleeding, particularly where long-term hemostatic durability is critical. Nevertheless, factors such as availability, expertise, and cost may influence real-world decision-making.

GLP-1 Therapy vs Bariatric Endoscopy: Obesity Surgery | April 2026

Introduction The management of obesity and type 2 diabetes has rapidly evolved, with GLP-1 receptor agonists emerging as highly effective pharmacological options, while bariatric endoscopic therapies provide minimally invasive procedural alternatives. Traditionally, metabolic bariatric surgery has been the gold standard, but newer less invasive options are reshaping treatment paradigms. Direct comparative evidence between GLP-1 therapies and endoscopic bariatric techniques remains limited, making clinical decision-making challenging. Problem Statement It is unclear whether GLP-1 receptor agonists or bariatric endoscopic therapies provide superior outcomes in weight loss and metabolic control in patients with obesity and type 2 diabetes. Summary This meta-analysis including eight studies with over 600 patients demonstrates that, in the short term (4–12 months), there is no significant difference between GLP-1–based therapies and bariatric endoscopic interventions in key outcomes such as weight loss, BMI reduction, glycemic control, or diabetes remission. These findings suggest that both approaches may offer comparable efficacy in early treatment phases. However, important distinctions exist in safety profiles. GLP-1 therapies are associated predominantly with gastrointestinal side effects, whereas endoscopic bariatric therapies carry risks related to device intolerance and procedural complications. A key limitation of the evidence is the high heterogeneity and predominance of retrospective data, along with short follow-up duration, which prevents firm conclusions regarding long-term durability and comparative effectiveness. Clinically, this study supports a personalized approach—where treatment selection should be guided by patient preference, comorbidities, risk tolerance, and resource availability—while emphasizing the need for robust long-term randomized trials to define optimal strategies.

Should We Continue Colonoscopy surveillance After 75?: JAMA | April 2026

Introduction Colorectal cancer (CRC) screening and surveillance have significantly reduced cancer-related mortality. However, in adults aged ≥75 years, clinical decision-making becomes complex. While cancer risk increases with age, competing risks—particularly non-cancer mortality and frailty—also rise substantially. Current guidelines provide limited clarity on when to stop surveillance colonoscopy, especially in patients with prior adenomas, where the perceived cancer risk often drives continued procedures despite uncertain benefit. Problem Statement In older adults ≥75 years, it is unclear whether the risk of colorectal cancer justifies continued surveillance colonoscopy, particularly when competing risks of mortality are high. Summary This large Veterans Affairs cohort study of over 90,000 older adults provides important clarity. Over a 10-year follow-up, the risk of CRC remained low—even in those with prior adenomas (1.1% incidence, 0.5% CRC mortality)—and only marginally higher than those without adenomas. In stark contrast, non-CRC mortality approached nearly 50%, far exceeding cancer-related risks across all frailty levels. Even among high-risk groups (prior adenoma, increasing frailty), the likelihood of dying from non-cancer causes was substantially higher than developing or dying from CRC. These findings highlight that the benefit of continued surveillance colonoscopy diminishes significantly with age and comorbidity burden. Clinically, this study supports a paradigm shift—from routine surveillance to individualized decision-making. In many older adults, especially those with frailty, it may be more appropriate to deprioritize colonoscopy and focus on overall health, quality of life, and management of comorbid conditions.

BSG Interim Position on LAMS Use After AXIOS Recall: FG | April 2026

Introduction Lumen-apposing metal stents (LAMS) have become central to therapeutic endoscopic ultrasound (T-EUS), especially for pancreatic fluid collection drainage, EUS-guided gallbladder drainage, choledochoduodenostomy, gastrojejunostomy, and EDGE procedures. In December 2025, the urgent recall of selected Hot AXIOS stents created an immediate gap in the delivery of several urgent and complex interventions. Because AXIOS has been widely used in the UK, this recall has major practical implications for endoscopists, referral networks, and patient safety. Problem Statement The recall of commonly used AXIOS stent sizes has disrupted routine T-EUS practice, creating uncertainty about which alternative devices, rescue techniques, and governance pathways should be used to maintain safe and effective care. Summary This British Society of Gastroenterology interim technical review provides pragmatic guidance for clinicians navigating the post-recall period. The key message is that T-EUS can continue safely, but endoscopists must adapt device choice and technique according to the indication. For pancreatic fluid collections and EUS-guided gallbladder drainage, unaffected AXIOS sizes and alternative LAMS such as HOT SPAXUS and Z-EUS remain reasonable substitutes, while plastic stents or percutaneous drainage may be used when appropriate. The greatest technical challenge is in malignant distal biliary obstruction, because the recalled smaller AXIOS sizes were commonly used for EUS-guided biliary drainage. In these situations, clinicians may need to consider larger LAMS in selected patients, alternative LAMS platforms, tubular metal stents, rendezvous procedures, hepaticogastrostomy, or antegrade stenting depending on anatomy and expertise. For EUS-guided gastrojejunostomy and EDGE, the review advises greater caution, use of staged approaches, and careful case selection. An important contribution of this paper is its emphasis on salvage strategies for maldeployment or failure of expansion, reminding clinicians that recognition must be immediate and that rescue plans should be predefined. Just as important, the document stresses governance: regional collaboration, expert case discussion, careful documentation, and prospective data capture are essential while device availability remains unstable. Overall, this is a highly practical position statement. Its value lies not in introducing a new technique, but in helping clinicians preserve procedural safety, maintain access to urgent T-EUS interventions, and standardize decision-making during a period of device limitation.

AI in Colonoscopy Withdrawal Time Accuracy: Endoscopy | April 2026

Introduction Withdrawal time during colonoscopy is a key quality indicator directly linked to adenoma detection and colorectal cancer prevention. However, accurate measurement in routine practice is often inconsistent, especially during procedures involving interventions. This variability limits standardisation and quality benchmarking, prompting interest in artificial intelligence (AI)-based systems to objectively measure withdrawal time. Problem Statement Despite the importance of withdrawal time, current measurement relies on manual estimation by endoscopists, which is prone to error and inconsistency, particularly when procedures involve therapeutic interventions. There is a lack of prospective validation of AI systems to determine whether they can reliably and accurately standardise this critical quality metric. Summary In this prospective study of 126 patients, AI demonstrated superior accuracy in measuring withdrawal time compared to physicians, with significantly lower error, especially during interventional procedures. In non-interventional cases, AI and physicians performed similarly. Additionally, the AI system generated high-quality procedural image reports with strong endoscopist satisfaction. Overall, this study highlights the potential of AI to improve standardization, enhance quality metrics, and streamline workflow in colonoscopy practice.

GLP-1 Agonists Before Endoscopy (OCULUS Trial): JAMA | April 2026

Introduction Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists have rapidly become integral in the management of type 2 diabetes, obesity, and metabolic diseases due to their effects on glycemic control and weight loss. A key mechanism underlying their efficacy is delayed gastric emptying, which raises concerns in procedural settings such as upper endoscopy, where retained gastric contents may increase the risk of aspiration. Despite widespread adoption of precautionary guidelines recommending withholding these agents before procedures, robust prospective evidence has been lacking. Problem Statement Current clinical practice is largely guided by expert opinion and limited retrospective data, leading to variability in recommendations regarding whether GLP-1/GIP agonists should be withheld before endoscopy. This uncertainty has practical implications, including procedure delays, cancellations, and potential compromise of metabolic control, highlighting the need for high-quality randomized evidence. Summary The OCULUS randomised clinical trial demonstrated that continuing GLP-1/GIP agonists significantly increased clinically relevant residual gastric volume compared to holding one dose before endoscopy (25% vs 3.1%). However, importantly, this did not translate into an increased rate of aspiration-related adverse events. Notably, patients undergoing combined procedures with a prior clear liquid diet showed negligible risk, suggesting a potential mitigating strategy. Overall, the study provides the first high-quality evidence supporting a balanced, individualised approach, where holding medication reduces gastric residue, but continuation may still be safe in selected settings, particularly with appropriate dietary preparation.

NBI and Acetic Acid Chromoendoscopy in Barrett’s Oesophagus: BMJ Open Gastroenterology | March 2026

Introduction Barrett’s oesophagus represents a well-established precursor to oesophageal adenocarcinoma, with progression from intestinal metaplasia to dysplasia and invasive cancer. Given the poor prognosis of advanced disease, early detection through surveillance endoscopy remains critical. Conventional surveillance relies on high-definition white light endoscopy combined with the Seattle protocol of random biopsies, which is labour-intensive and prone to sampling error. Emerging advanced imaging modalities, particularly narrow band imaging (NBI) and acetic acid chromoendoscopy (AAC), aim to enhance dysplasia detection and enable more targeted biopsy strategies. Problem Statement Despite technological advances, current surveillance strategies remain inefficient, with random biopsies risking missed dysplasia and increasing procedural burden. The key challenge is whether advanced imaging techniques can reliably replace or reduce reliance on the Seattle protocol while maintaining diagnostic safety. Summary This systematic review of 44 studies demonstrates that NBI-guided biopsies improve overall dysplasia detection compared with white light endoscopy, while AAC offers higher sensitivity for neoplasia detection and reduces biopsy burden. However, neither technique alone is sufficient to replace the Seattle protocol due to the risk of missed lesions. The findings support a hybrid approach, integrating advanced imaging with systematic biopsies, while emphasising the need for high-quality randomised trials to define cost-effectiveness and optimise surveillance strategies in Barrett’s oesophagus.

Choosing the Right Snare in Gastrointestinal Endoscopy

Introduction Endoscopic resection has evolved rapidly, with increasing emphasis on precision, safety, and complete lesion removal. While advances in techniques such as EMR and ESD have transformed outcomes, one fundamental aspect—snare selection—remains underappreciated. The physical properties of the snare, including wire thickness, stiffness, and shape, play a crucial role in determining cutting efficiency, tissue capture, and procedural success. Problem Statement In daily practice, snare selection is often based on personal preference rather than a structured, lesion-specific approach. This can lead to suboptimal resection, incomplete removal, or increased complications, particularly in challenging lesions such as flat, large, or fibrotic polyps. The lack of a standardised strategy results in variability in outcomes despite the availability of a wide range of devices. Summary A lesion-tailored approach to snare selection can significantly improve outcomes. Thin-wire snares enhance cutting efficiency and are ideal for cold techniques in small lesions, whereas thick-wire snares provide better grip for larger or fibrotic lesions. Soft snares adapt well to mucosa, while stiff snares offer better control in flat or large lesions. Similarly, snare shape influences effective tissue capture in different anatomical scenarios. Matching snare characteristics to lesion type—from diminutive polyps to large laterally spreading tumours—can optimise resection quality and safety. Moving toward a structured, evidence-informed snare selection strategy represents an important step in improving everyday endoscopic practice.

Routine Esophagram After POEM: Clinical Insight | Inspired by Expert Commentary

Introduction Routine esophagram after POEM has long been considered a safety checkpoint to rule out leaks before resuming oral intake. However, with improved procedural techniques and safety, its real-world value is increasingly being questioned. Clinical Insight Recent evidence suggests that clinically significant leaks after POEM are rare and almost always symptomatic. This raises an important question: 👉 Are we performing routine imaging out of habit rather than necessity? Routine esophagram: Adds radiation exposure Increases cost May delay diet advancement and discharge Often detects findings that are clinically insignificant Importantly, most actionable complications would be identified clinically, not radiologically. Key Message Routine esophagram has a low diagnostic yield in asymptomatic patients Clinical symptoms remain the most reliable trigger for intervention A selective, symptom-driven approach is likely more rational Conclusion In the modern POEM era, postoperative care should evolve from protocol-driven to patient-driven decision-making. Routine esophagram may no longer be necessary in all patients, and selective use could improve efficiency without compromising safety.

Post-Banding Ulcer Bleeding: Alime Pharmaco & Therap | March 2026

Introduction Endoscopic band ligation (EBL) remains the standard of care for managing oesophagal varices, both in acute variceal bleeding and for prophylaxis. However, post-banding ulcer bleeding (PBUB) is an important and often under-recognised complication, associated with significant morbidity and mortality. Identifying patients at higher risk for PBUB is clinically relevant, particularly in acute settings where outcomes are already compromised. Problem Statement Despite increasing recognition of PBUB, risk stratification remains inconsistent in clinical practice. Recent data have suggested that urgent EBL and renal dysfunction may increase PBUB risk, but real-world validation across larger cohorts is limited, and standardised definitions are lacking. Summary In this large real-world analysis of 920 EBL procedures, PBUB occurred in 3.4% overall, with a significantly higher incidence following urgent EBL compared to elective procedures (7.5% vs 1.4%). Urgent EBL emerged as a strong independent predictor of PBUB, reinforcing the vulnerability of patients undergoing intervention during acute bleeding episodes. Additionally, renal dysfunction was identified as a key risk factor, with patients having serum creatinine ≥1.5 mg/dL demonstrating markedly higher bleeding rates and an independent risk. These findings are consistent with prior literature and highlight a simple, clinically applicable framework combining urgency of EBL and renal function to identify high-risk patients. This approach may help guide closer monitoring and preventive strategies in routine practice.

Endoscopic Palliation in Pancreatic Cancer: AMJ, March 2026

This article reviews the endoscopic approach to palliation in pancreatic cancer, emphasising that most patients present with unresectable or metastatic disease, so symptom control becomes central to care. Because of the pancreas’ location, tumour growth commonly leads to biliary obstruction, gastric outlet obstruction (GOO), and pain from neural invasion. A major focus is the management of malignant biliary obstruction, which occurs in a large proportion of patients and can cause jaundice, pruritus, nausea, malabsorption, cholangitis, and delay in chemotherapy. The article highlights that biliary decompression is now commonly achieved using endoscopic or percutaneous techniques rather than surgery. The main drainage strategies: ERCP with placement of a plastic stent or self-expandable metal stent (SEMS) directly across the obstructed common bile duct. EUS-guided rendezvous technique, where a guidewire is passed into the bile duct and through the papilla to facilitate ERCP. EUS-guided biliary drainage (EUS-BD), which creates a new tract for bile drainage above the obstruction. EUS-HGS (hepaticogastrostomy), where a biliary SEMS drains the left intrahepatic duct into the stomach. EUS-CDS (choledochoduodenostomy), where a biliary SEMS or lumen-apposing metal stent drains the common bile duct into the duodenum. EUS-GBD (gallbladder drainage), where a lumen-apposing metal stent drains the gallbladder into the stomach or duodenum. Percutaneous transhepatic biliary drainage (PTBD) as an external/internal catheter-based option. The article also notes increasing use of preemptive biliary drainage when EUS-guided tissue diagnosis shows impending obstruction. Overall, the message is that endoscopic palliation has largely replaced surgical palliation, offering effective, less invasive relief of major pancreatic cancer complications.

G-POEM in Severe Refractory Gastroparesis: Gut March 2026

Introduction Gastroparesis is a chronic disorder characterised by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and postprandial fullness. Treatment options for severe and refractory gastroparesis are limited and often ineffective. Gastric per-oral endoscopic pyloromyotomy (G-POEM) is a minimally invasive endoscopic technique that divides pyloric muscle fibres to improve gastric emptying. Although observational studies have shown promising results, high-quality randomised evidence has been limited. Summary This randomised sham-controlled pilot trial evaluated the efficacy of G-POEM in severe gastroparesis. A total of 41 patients with refractory gastroparesis (diabetic, postsurgical, or idiopathic) were randomised to G-POEM (n=21) or sham procedure (n=20). The primary endpoint was treatment success, defined as a ≥50% reduction in the Gastroparesis Cardinal Symptom Index (GCSI) at 6 months. Key findings: Treatment success: 71% with G-POEM vs 22% with sham (p = 0.005) By aetiology: Diabetic gastroparesis: 89% response Postsurgical gastroparesis: 50% response Idiopathic gastroparesis: 67% response Gastric emptying: Median 4-hour gastric retention improved from 22% to 12% after G-POEM, No significant change after sham. Crossover results: Among 12 sham patients crossing over to G-POEM, 75% achieved symptom improvement. Clinical Takeaway This sham-controlled randomised trial demonstrates that G-POEM significantly improves symptoms and gastric emptying in severe refractory gastroparesis, particularly in diabetic cases. However, results remain less conclusive in idiopathic and postsurgical gastroparesis, and larger trials are required to confirm long-term benefits.

Colon Capsule Endoscopy vs Conventional Colonoscopy After Diverticulitis- Endoscopy | March 2026. DOI: 10.1055/a-2695-6904

Introduction After CT-confirmed diverticulitis, follow-up colonoscopy is routinely performed to exclude malignancy. Colon capsule endoscopy (CCE) offers a non-invasive alternative, but its impact on patient experience remains unclear. Summary In this randomized controlled trial of 159 patients, CCE was compared with colonoscopy 4–6 weeks after diverticulitis. Patients expected colonoscopy to cause greater discomfort; however, experienced physical and mental discomfort did not differ significantly between groups. Examination completion was slightly higher with colonoscopy (92%) than CCE (84%). No malignancies were detected. Nearly half of patients preferred CCE for future evaluation. The study shows that CCE is safe and patient-preferred, though colonoscopy remains diagnostically more complete.

METARSI Trial: Endoscopy International Open, Feb.26

The METARSI trial is a prospective, multicenter randomised controlled study comparing partially covered self-expanding metal stents (PC-SEMS) versus uncovered SEMS (U-SEMS) in patients with malignant unresectable distal biliary obstruction (DBO) undergoing ERCP. A total of 261 patients were randomised (130 PC-SEMS, 131 U-SEMS) with a 12-month follow-up. Most strictures were secondary to pancreatic adenocarcinoma (75%), and nearly half had metastatic disease. Key findings: Stent dysfunction rates were similar between groups (11% PC-SEMS vs 14% U-SEMS; P = 0.70). Overall survival did not differ significantly (median ~108 vs 100 days). Kaplan–Meier analysis showed comparable stent patency. A non-significant trend toward more procedure-related complications was observed in the partially covered group (2% vs 7%). Clinical Interpretation: There was no clear superiority of partially covered stents over uncovered stents in terms of dysfunction, survival, or patency. Given similar outcomes and potential migration risks associated with covered designs, stent selection should remain individualised based on anatomy, tumour characteristics, and operator experience. Takeaway: In malignant distal biliary obstruction, both PC-SEMS and U-SEMS perform comparably—routine preference for partially covered stents is not supported by this randomised evidence.

EUS-Directed Transgastric ERCP (EDGE) in RYGB: GIE, Feb.26

Endoscopic ultrasound–directed transgastric ERCP (EDGE) has emerged as a transformative technique for managing biliary and pancreatic diseases in patients with Roux-en-Y gastric bypass (RYGB) anatomy. Traditional ERCP is technically challenging in RYGB due to altered anatomy, often requiring enteroscopy-assisted ERCP or laparoscopic-assisted ERCP—both limited by lower success rates or higher invasiveness. EDGE overcomes these barriers by creating a temporary gastrogastric or jejunogastric fistula using a lumen-apposing metal stent under EUS guidance, enabling access to the excluded stomach and standard duodenoscope-assisted ERCP. Reported technical and clinical success rates exceed 90%, with shorter procedure times and high therapeutic efficacy. Adverse events include stent migration, bleeding, and persistent fistula, though most are manageable. Compared to surgical or enteroscopy-based approaches, EDGE offers a minimally invasive, highly effective alternative and is increasingly considered first-line in expert centres for RYGB patients requiring ERCP.

Linaclotide Administration plus PEG for Colonoscopy Bowel Preparation- AJG Feb.26

High-volume polyethene glycol (PEG) solutions remain a major barrier to successful colonoscopy bowel preparation because of poor tolerability. Linaclotide, a guanylate cyclase-C agonist that increases intestinal secretion and transit, has been explored as an adjunct to bowel preparation, but the optimal dose and timing have been uncertain. This large, multicenter randomised trial evaluated whether short-term linaclotide pretreatment could safely allow a reduction in PEG volume without compromising bowel cleanliness. Adults undergoing screening or diagnostic colonoscopy were assigned to one of three strategies: standard high-volume PEG alone, linaclotide combined with high-volume PEG, or linaclotide combined with reduced-volume PEG. The key finding was that three days of linaclotide combined with a lower PEG volume achieved bowel preparation quality comparable to standard regimens. Importantly, this lower-volume strategy did not negatively affect clinically relevant colonoscopy outcomes, including polyp detection, adenoma detection, or completion of bowel preparation. From a tolerability standpoint, the reduced-volume PEG plus linaclotide regimen was associated with fewer adverse gastrointestinal symptoms compared with the higher-volume combination regimen. This suggests a potential patient-centred advantage, particularly for individuals who struggle with large-volume preparations. Overall, this study supports a practical and patient-friendly bowel preparation strategy in average-risk individuals: short-term linaclotide pretreatment allows PEG volume reduction while maintaining preparation effectiveness and safety. If confirmed in broader populations, this approach could improve patient adherence, comfort, and willingness to undergo colonoscopy without sacrificing diagnostic quality.

SOCCER Trial: Forceps Boost Cannulation Success in Difficult ERCP- AJG Feb.26

Introduction Difficult biliary cannulation remains one of the most common and consequential problems in ERCP. Failed cannulation drives repeat procedures, percutaneous or surgical rescue, higher costs, longer hospital stay—and it also increases post-ERCP pancreatitis (PEP) risk because repeated attempts and unintended pancreatic duct (PD) wire passes are key triggers. Forceps-assisted cannulation has been used as a “trick” in challenging papillae (periampullary diverticulum, redundant folds, awkward papilla orientation), but until now it lacked randomized controlled trial evidence. The SOCCER trial tests a simple question: Does forceps-assisted cannulation improve success when cannulation is difficult? Problem statement When cannulation becomes difficult, endoscopists typically escalate to: double-wire techniques, precut/needle-knife access, PD stenting strategies, etc. These can be effective but may increase complexity and sometimes risk. A low-cost mechanical approach—using forceps to expose and stabilize the papilla—could reduce failure and potentially reduce repeated traumatic attempts. But its true efficacy needed an RCT. What the trial did: Randomized adults with difficult cannulation scenarios during ERCP to: forceps-assisted cannulation, or standard cannulation without forceps “Difficult” included: papilla in/on a diverticulum, redundant tissue overlying the papilla, challenging papilla morphology (type 2–4), or difficult cannulation defined by attempts/time/unintended PD wire passages. Primary outcome: successful cannulation Secondary: difficult cannulation metrics after randomisation and PEP Key results clinicians should remember 1) Cannulation success improved substantially with forceps Forceps assistance achieved near-universal cannulation success in this difficult subset, while standard cannulation had a meaningful failure rate. 2) Crossover to forceps rescued failures All patients who failed initial standard cannulation and then crossed over to forceps were successfully cannulated—suggesting forceps is a reliable rescue option. 3) Forceps reduced the “trauma load” of cannulation Even when overall difficult-cannulation rates didn’t reach statistical significance, the forceps approach resulted in fewer cannulation attempts, which is clinically important because attempts correlate with PEP risk. 4) PEP rates were low and similar in both groups This suggests the technique improves access without adding measurable pancreatitis risk in this trial setting. Clinical interpretation: where this fits tomorrow This trial supports forceps-assisted cannulation as a practical, low-cost, low-complexity tool in ERCP—especially when the papilla is hard to expose or stabilize. Best-use scenarios periampullary diverticulum (papilla in/on rim) redundant folds/tissue obscuring papilla small/protruding/creased papilla configurations (type 2–4) early difficult cannulation where you want to avoid escalating to higher-risk access What it does not replace precut access when anatomy/duct orientation truly prevents standard entry prophylaxis strategies (rectal NSAID, PD stent when indicated) thoughtful escalation algorithms Bottom-line takeaway for GastroAGI In difficult ERCP cannulation, forceps assistance significantly improves cannulation success and reduces repeated attempts, without a signal for increased PEP. The SOCCER RCT moves forceps-assisted cannulation from “expert trick” to evidence-supported technique. One-line GastroAGI takeaway When cannulation gets difficult, forceps assistance can turn failures into successes.

Robot-Assisted Gastric ESD Is Feasible and Safe-Endoscopy Feb.26

Introduction Endoscopic submucosal dissection (ESD) is the preferred curative treatment for early gastric cancer, but it remains technically demanding, largely because of poor traction and limited visualization during submucosal dissection. Multiple traction techniques have been proposed, yet most are either unstable, operator-dependent, or interrupt workflow. Robotic assistance—particularly flexible traction robots—has shown promise in animal models by providing stable, adjustable, and continuous traction. Until now, however, clinical data in humans were lacking. This pilot randomized trial represents the first real-world clinical evaluation of a traction robot–assisted ESD system for early gastric cancer. Problem statement The main challenges in gastric ESD are: maintaining optimal traction throughout dissection, avoiding muscularis propria injury, and reducing technical difficulty without compromising oncologic outcomes. Whether robotic traction can improve safety or procedure efficiency in actual patients—beyond experimental models—has been unknown. What the study did: Prospective, single-blind, randomized pilot trial Patients with high-grade intraepithelial neoplasia or intramucosal gastric cancer Randomized to: Robot-assisted ESD (flexible single-arm traction robot), or Conventional ESD Performed in a tertiary referral center by experienced endoscopists Primary focus: procedure feasibility and safety, with procedure time as the main endpoint. Key findings clinicians should remember 1) Robot-assisted gastric ESD is feasible and safe All procedures were completed successfully, with no perforations in either group. This is the most important first signal for any new ESD technology. 2) Oncologic outcomes were equivalent En bloc resection and R0 resection rates were similar between robotic and conventional ESD. 👉 This confirms that robotic assistance does not compromise curative intent. 3) Fewer muscular injuries with robotic traction Robot-assisted ESD significantly reduced muscularis propria injuries, suggesting: better traction control, more stable dissection planes, and potentially lower risk of delayed complications. 4) No clear reduction in overall procedure time—yet Overall procedure time was not significantly shorter with robotic assistance. However, a learning-curve signal was evident: in later cases, robot-assisted ESD times trended shorter than conventional ESD. 👉 This suggests the true efficiency benefit may emerge after familiarization, not in early pilot experience. Clinical interpretation This study should be viewed as a proof-of-concept, not a practice-changing trial. Key messages for endoscopists: Robotic traction works in real patients. It appears to improve safety margins by reducing muscular injury. It does not slow down ESD once operators gain experience. Oncologic quality is preserved. The absence of clear time savings is expected in a pilot randomized trial and should not be overinterpreted. Bottom-line takeaway Traction robot–assisted gastric ESD is clinically feasible, safe, and oncologically sound, with early signals of improved procedural safety. Larger trials are now needed to determine whether robotic traction can meaningfully reduce complications, shorten learning curves, or expand access to high-quality ESD. One-line GastroAGI takeaway Robotic traction can safely assist gastric ESD and may reduce muscular injury without compromising resection quality.

Cold EMR Is Safer Than Hot EMR for Large Colorectal Polyps-Endoscopy Feb.26

Introduction Endoscopic mucosal resection (EMR) is the standard of care for large (≥20 mm), nonpedunculated colorectal polyps. Over the last few years, cold EMR and thermal ablation–assisted EMR have been increasingly adopted, aiming to reduce recurrence and adverse events. However, safety comparisons between these approaches—especially for serious adverse events—have remained limited. This large, multicenter analysis asks a simple but critical question: Which EMR technique is safer for large colorectal polyps—cold or hot? Problem statement Hot EMR has long been the default approach but carries inherent thermal injury risks—bleeding, perforation, and post-procedural pain. Cold EMR avoids cautery, but many endoscopists remain hesitant to use it for large lesions due to concerns about incomplete resection or bleeding. At the same time, adjunctive margin or base ablation has been added to hot EMR to reduce recurrence, raising questions about whether added thermal injury worsens safety. What the study did (plain language) Secondary analysis of four prospective, multicenter studies Included nearly 1900 large (≥20 mm) nonpedunculated polyps Compared: Cold EMR Hot EMR without ablation Hot EMR with margin ablation Hot EMR with margin + base ablation Focused specifically on serious adverse events (bleeding, perforation, mortality) Key findings clinicians should remember 1) Cold EMR had the lowest serious adverse event rates Across all outcomes—serious adverse events, bleeding, and perforation—cold EMR consistently showed a safer profile than hot EMR. 2) Perforation and mortality were almost exclusive to hot EMR This is clinically meaningful: the most feared complications clustered with thermal resection, not cold techniques. 3) Thermal ablation did not worsen safety—but didn’t beat cold EMR Hot EMR with margin or margin-plus-base ablation did not increase serious adverse events compared with hot EMR alone. However, even with these refinements, hot EMR remained less safe than cold EMR. 4) Clipping matters in hot EMR When hot EMR was used, prophylactic clipping reduced serious post-EMR bleeding, reinforcing its role in selected cases. Clinical interpretation This study reinforces a growing message in therapeutic colonoscopy: If a large nonpedunculated colorectal polyp can be removed cold, it should be. Cold EMR appears to meaningfully reduce: serious bleeding, perforation, and procedure-related mortality. Hot EMR still has a role—particularly for fibrotic lesions, non-lifting areas, or when en bloc resection is required—but it should no longer be the automatic default. Bottom-line takeaway for practice Cold EMR = safest option for large nonpedunculated colorectal polyps when technically feasible. Hot EMR should be reserved for selected cases, with careful use of clipping. Ablation improves recurrence control but does not eliminate thermal risk. One-line GastroAGI takeaway: Cold EMR significantly reduces serious complications compared with hot EMR for large colorectal polyps.

Even One Pancreatic Duct Cannulation Raises PEP Risk-Endoscopy Feb.25

Introduction Post-ERCP pancreatitis (PEP) remains the most frequent and feared complication of ERCP. We all recognize that repeated pancreatic duct (PD) cannulations increase risk—but in real life, many cases involve just one inadvertent guidewire entry into the PD. Until now, the clinical significance of a single PD cannulation has been debated, and practice varies: some teams escalate prophylaxis immediately, others don’t. This study addresses a practical question every ERCPist faces: Is a single inadvertent PD guidewire cannulation enough to meaningfully increase PEP risk? Problem statement Current thinking often focuses on “multiple cannulations” as the trigger for concern. But the true intraprocedural exposure—how often the PD is entered, how deep, and where the wire goes—has been poorly captured in routine datasets. Key uncertainties: Does one main PD cannulation matter? Does location (head vs body vs side branch) change the risk? Should a single PD cannulation trigger immediate prophylaxis escalation (e.g., PD stent)? What they did (plain language) Prospective, multicenter study across nine centers (biliary-indication ERCPs). Real-time, third-party intraprocedural recording of PD wire entries (not just operator recall). Standard 30-day follow-up for PEP outcomes. Adjusted analysis accounting for other patient/procedure risk factors and prophylactic measures used. Key findings clinicians should remember 1) A single main PD cannulation is independently linked to PEP The key message: one inadvertent main PD cannulation is not “trivial.” Risk increases with single cannulation and stays similarly elevated with multiple cannulations—meaning the “first hit” may account for much of the risk signal. 2) Where the wire goes matters Main duct cannulation into the head and body was associated with higher PEP risk. Side-branch only cannulations did not show a clear association. 3) Clinical implication: prophylaxis should be triggered earlier Because one main PD cannulation already confers meaningful risk, this study supports a proactive stance: If you inadvertently cannulate the main PD, treat it as a significant event—not a near-miss. Practical “what should I do tomorrow?” When to escalate prophylaxis (based on this study’s signal) Any inadvertent main PD wire cannulation (even once), especially if it tracks into the head/body → strongly consider PD stent + standard prophylaxis bundle per your protocol. When risk may be lower (but still use judgment) Side-branch-only cannulation without main duct entry → may not carry the same risk signal, but consider the full clinical context. Conclusion This real-time multicenter dataset suggests that PEP risk starts with the first inadvertent main PD cannulation, and that the classic “multiple cannulations” framework may underestimate risk from a single wire entry. These findings support early use of preventive interventions—particularly PD stenting—when the main pancreatic duct is inadvertently cannulated.

Reusable vs Single-Use Duodenoscopes: The Environmental Cost- Endoscopy Feb.26

Introduction Duodenoscope-related infection outbreaks—largely linked to reprocessing failures—drove the development of single-use duodenoscopes to eliminate cross-contamination risk. The safety argument is compelling. But ERCP already sits in a resource- and waste-heavy environment, and healthcare is increasingly being held accountable for its environmental impact. This study tackles a question many endoscopy leaders are now facing: If we move to disposable duodenoscopes, what is the environmental cost—and is universal single-use sustainable? Problem statement The clinical trade-off is no longer just infection control vs cost. It now includes a third axis: environmental responsibility. Single-use devices are incinerated as biomedical waste, and many are made predominantly from plastics and resins. Until now, we have lacked high-resolution data on: what these scopes are actually made of, and where the main carbon burden comes from (manufacturing vs transport vs disposal vs reprocessing). What the study did: A single-center team compared: one reusable duodenoscope, and two single-use duodenoscopes from different manufacturers (A and B). They did two things: 1. Material composition testing (what metals and plastics are inside). 2. Life-cycle assessment (LCA): a “cradle-to-grave” carbon footprint estimate covering production, transport, reprocessing (for reusable), and end-of-life disposal (incineration for single-use). They modeled three real-world strategies over the usable lifetime of one reusable scope: All reusable All single-use Reusable with selective single-use (e.g., MDRO colonization/urgent cases) Key findings clinicians should understand 1) Reusable scopes are mostly metal; single-use scopes are mostly plastic Reusable duodenoscopes are largely built from metal alloys (high recyclability). Single-use devices are largely made of plastic polymers/resins (high incineration burden), and composition varies by manufacturer. 2) The major environmental hit for single-use is not transport—it’s disposal Because single-use scopes are biomedical waste, they are typically incinerated, and this step becomes a dominant driver of emissions. 3) Universal single-use creates a very large environmental footprint Across the modeled lifetime of one reusable scope, switching to “all single-use” produced dramatically higher total carbon emissions than staying reusable. 4) “Selective single-use” is a compromise strategy Using single-use scopes only for higher-risk situations (e.g., MDRO colonized patients, urgent cases where reprocessing logistics are limiting) reduces the environmental burden substantially compared with universal single-use—while still targeting the safety benefit where it’s most relevant. 5) Not all single-use scopes are equal The two single-use devices differed in per-scope carbon footprint, driven by differences in materials used. This supports the authors’ call for carbon footprint labeling to enable greener procurement decisions. Clinical interpretation This is not an “anti single-use” paper. It is a systems-level warning: If we default to universal single-use duodenoscopes—especially in high-volume ERCP centers—the environmental cost becomes difficult to justify without strong patient-outcome benefits. A more balanced approach emerges: Keep reusable as the default, with optimal reprocessing and/or improved designs (e.g., disposable components/endcaps), and reserve single-use for carefully defined indications where the infection-control advantage is highest. Conclusion Single-use duodenoscopes reduce cross-contamination risk, but universal adoption carries a substantial environmental burden—largely driven by plastic-heavy composition and mandatory incineration. The most realistic path forward is selective use plus better reprocessing and device design, supported by transparent carbon footprint labeling so endoscopy units can make informed, sustainable choices. Optional GastroAGI “Clinician Takeaway” Single-use duodenoscopes improve infection control, but universal adoption is environmentally costly—selective use may be the most responsible compromise.

Polyps ≥10 mm Alone: Low PCCRC Risk at 5 Years- Endoscopy Feb.26

Introduction Post-polypectomy surveillance is one of the biggest drivers of colonoscopy workload worldwide. Current guidelines often label any polyp ≥10 mm as “high risk,” triggering a 3-year surveillance colonoscopy. But many endoscopists have questioned whether size alone—especially for 10–20 mm lesions that are completely resected and lack dysplasia—really carries enough cancer risk to justify early repeat colonoscopy. This study asks a very practical question: Do patients with a ≥10 mm polyp as their only “high-risk” feature actually have a higher post-colonoscopy colorectal cancer (PCCRC) risk than patients with no polyps? Problem statement The “≥10 mm = high risk” rule may be too blunt. It can create: unnecessary surveillance colonoscopies, increased cost and patient burden, and pressure on already stretched endoscopy capacity. Yet, relaxing surveillance must be safe—especially in screening programs. So the key gap is: What is the real PCCRC risk over 5 years when size is the only high-risk feature? What the study did: Using the Dutch FIT-based national screening program data (quality-assured colonoscopies), the authors compared two groups: People with polyps ≥10 mm but no other high-risk features (no high-grade dysplasia, no dysplastic serrated lesions, no multiple high-risk findings). People with no polyps at baseline colonoscopy. Because the Dutch guideline at that time recommended 5-year follow-up for a subgroup of these “size-only” patients, the authors could safely examine what happened over a 5-year window. Key results clinicians should remember 1) Cancer risk was low—and not higher than polyp-free patients Over 5 years, people with ≥10 mm polyps as the sole risk feature had a similarly low PCCRC risk compared with people who had no polyps. 2) This matters because it’s a large group Most “high-risk” patients in real life fall into this category where size is the only high-risk feature—especially the 10–20 mm range. 3) Quality of the baseline colonoscopy matters more than polyp size alone A major insight: PCCRC risk was strongly influenced by the endoscopist’s ADR. In other words, the safety of longer intervals depends heavily on performing a high-quality baseline colonoscopy. Clinical interpretation This paper challenges a common habit in surveillance: treating “≥10 mm” as automatically equivalent to “high cancer risk.” It suggests a more nuanced approach may be safe in the right setting—particularly when: the colonoscopy is high quality (good prep, complete exam), the lesion is completely resected (especially en bloc), there is no dysplasia/high-risk histology, and the endoscopist quality indicators (like ADR) are strong. Practical takeaway for clinicians and endoscopy units If confirmed in other settings, this evidence supports extending surveillance intervals for patients with a 10–20 mm polyp as the only high-risk feature, rather than automatically bringing everyone back in 3 years. This could: reduce unnecessary procedures, improve colonoscopy capacity for higher-risk patients, and align surveillance intensity with actual cancer risk. Conclusion; In a national, quality-assured screening program, patients with ≥10 mm polyps without other high-risk features had PCCRC risk comparable to those with no polyps over a 5-year period. The study strongly suggests that colonoscopy quality and endoscopist performance may be more important than size alone when deciding surveillance intervals—especially for completely resected 10–20 mm lesions.

AI in Endoscopy: ESGE Curriculum for Safe Use- Endoscopy Feb. 26

Introduction Artificial intelligence is rapidly entering routine GI endoscopy—particularly for polyp detection, lesion characterization, and quality assurance. While early studies show improved detection and efficiency, AI also introduces new risks: inappropriate trust, cognitive bias, deskilling, and uncertainty about how and when AI should be used in clinical decision-making. Recognizing this gap, European Society of Gastrointestinal Endoscopy (ESGE) has issued a formal Position Statement defining a structured curriculum for the safe, effective, and responsible use of AI in endoscopy. This document is not about which AI to buy—it is about how clinicians should be trained to use AI properly. ⸻ The core problem AI tools are being deployed faster than training standards can keep up. Key unanswered questions in daily practice include: Who should be allowed to use AI in endoscopy? What level of endoscopic skill is required before using AI? How do we prevent over-reliance on AI? How do we monitor whether AI improves—or harms—real-world performance? Until now, no formal competency framework existed. ⸻ What ESGE proposes: a 3-phase curriculum 1️⃣ Before adoption (Preadoption phase) AI is not a shortcut for poor endoscopy Endoscopists must first be competent in standard endoscopic skills (scope handling, lesion visualization, interpretation). AI literacy is mandatory Clinicians should understand: what AI can and cannot do, how algorithms are trained, where bias and errors may occur. 👉 Message: AI supports good endoscopists—it does not replace fundamentals. ⸻ 2️⃣ Training phase Hands-on training with approved AI systems is essential. Education must go beyond buttons and alerts to include: recognition of automation bias (blind trust in AI), algorithm aversion (rejecting AI after seeing errors), anchoring and conservatism bias. 👉 Message: Human–AI interaction is the new technical skill. ⸻ 3️⃣ Independent use & quality assurance AI must never be used in isolation for clinical decisions. Key quality indicators (e.g. ADR in colonoscopy) must be monitored: before AI adoption, during implementation, and after routine use. If performance worsens or unintended effects appear, AI de-implementation should be considered. 👉 Message: AI use must be auditable, reversible, and accountable. ⸻ What this means for clinicians AI is an assistant, not an authority. Final responsibility always remains with the endoscopist. Safe AI use requires: baseline endoscopic competence, structured education, awareness of cognitive traps, continuous performance monitoring. This position statement reframes AI from a device issue to a professional competency issue. ⸻ Bottom-line takeaway for GastroAGI ESGE makes it clear: the success of AI in endoscopy depends less on algorithms and more on how clinicians are trained to use them. AI can improve quality—but only when embedded within a structured curriculum that prioritizes skills, judgment, and accountability.

Regenerative Endoscopy for Refractory GI Wall Defects- Endoscopy Feb.26

Introduction Gastrointestinal wall defects—such as leaks, fistulas, and chronic perforations—remain among the most frustrating complications in GI practice. Even with modern tools (clips, suturing, stents, vacuum therapy), chronic defects with inflamed, fibrotic, retracted margins often refuse to close. Many patients end up in prolonged hospital courses, repeated procedures, or high-risk surgery. This pilot trial explores a different strategy: rather than forcing closure mechanically, can we biologically “reboot” healing by injecting a regenerative cell-rich product directly into the defect margins? Problem statement When a defect becomes chronic, the tissue is no longer “fresh wound biology.” The margins become stiff and fibrotic, blood supply is poor, and standard endoscopic closure often fails even if the edges are approximated. The unmet need is a therapy that: revitalizes scarred tissue, supports angiogenesis and mucosal regeneration, and can be delivered endoscopically, with low added risk and reasonable cost. This study evaluates tSVFem (stromal vascular fraction obtained from the patient’s own adipose tissue via mechanical processing) injected endoscopically into the defect border to promote regeneration. What they did (in plain language) Single-center pilot: 30 consecutive patients with difficult defects after conventional options failed or were not possible. 15 esophageal defects and 15 rectal defects. Under the same session, they harvested a small amount of patient’s hip fat, mechanically processed it (filters + centrifugation), and then injected 1–2 mL into the four quadrants of the defect margins using a standard injection needle. For larger defects (≥5 mm), they sometimes used endoscopic suturing to approximate margins, then injected the regenerative product. Primary endpoint: complete defect closure on endoscopic/radiologic follow-up. Also tracked: number of sessions, complications, recurrence. Key results clinicians will care about 1) Esophageal defects responded extremely well Most esophageal defects closed—often after a single session—and nearly all closed after a second session. Importantly, closure was described as being covered by new vascularized mucosa, suggesting true regenerative healing rather than a fragile seal. 2) Rectal defects improved, but closure was harder Rectal defects had a more modest overall closure rate, often requiring repeat sessions (sometimes 3–4 treatments). This is clinically intuitive: rectal fistulas/defects are exposed to contamination, pressure dynamics, and complex tract biology. 3) Defects communicating with urinary tract were tougher Rectal defects involving the urinary system closed less reliably than those communicating with other organs—likely reflecting ongoing inflammation from bacterial colonization, pH differences, and pressure gradients. 4) Safety signal was excellent in this pilot No intraprocedural or postprocedural adverse events were reported, and there was no recurrence within the short follow-up window. What this means in practice This is an early—but highly intriguing—proof-of-concept that regenerative endoscopy is feasible. The technique is attractive because it is: Autologous (no rejection risk) Minimally manipulated mechanically (important for real-world regulatory feasibility) Endoscopically simple (injection needle rather than complex devices) Potentially cost-aware compared with repeated advanced closure devices—though repeated sessions can add cost and logistics. Clinical takeaway For refractory esophageal defects, tSVFem injection looks particularly promising as a “tissue rescue” strategy. For rectal defects (especially urinary-tract communication), results are encouraging but incomplete—suggesting the need for: protocol refinement, better patient/defect selection, and possibly combination strategies (e.g., scaffolds, repeated biologic dosing, improved tract control). Conclusion Endoscopic injection of autologous, mechanically processed adipose-derived stromal vascular fraction represents a new regenerative tool for complex GI defects—especially in the esophagus—where conventional endoscopic closure is frequently ineffective once fibrosis dominates. Larger controlled studies are now needed to define who benefits most, how many sessions are optimal, and how this approach compares with established endoscopic closure pathways.

CADe in endoscopy - Endoscopy Feb. 26

Introduction Colonoscopy quality is often judged by the adenoma detection rate (ADR), because better detection is linked to lower risk of future colorectal cancer. AI-based computer-aided detection (CADe) systems reliably increase ADR in the short term. But many clinicians have a practical concern: if endoscopists start depending on AI, will their “native” detection skills worsen when AI is not used? In other words—does CADe cause deskilling over time? Problem statement Most CADe studies show an immediate ADR benefit, but they are usually short-duration trials and rarely address what happens months to years later in real-world practice. The unanswered question is: After CADe is implemented, do endoscopists maintain their performance in standard (non-CADe) colonoscopy, or does performance drift downward because AI is doing the “thinking”? This study specifically examined whether CADe leads to skill transfer (endoscopists learn and improve even without AI) or deskilling (performance drops without AI). What the study did: Single-center, prospective, real-world study over 3 years (2021–2023). CADe was installed in half of the colonoscopy rooms, and patients were distributed across CADe vs non-CADe rooms as part of routine workflow. Endoscopists were grouped based on their baseline detection performance: High detectors (already meeting quality benchmark) Low detectors (below benchmark) The key focus: How detection performance changed over time, both with CADe and without CADe, to see if skills improved or deteriorated. Key findings clinicians should know 1. CADe improved detection when it was used Across both strong and weaker detectors, AI support increased the ability to find adenomas and polyps—especially subtle lesions. 2. No evidence of deskilling in non-CADe colonoscopy The most clinically important finding: once CADe was introduced, performance in standard colonoscopy did not fall over time. In other words, using CADe did not make endoscopists worse when they scoped without AI. 3. High detectors showed meaningful skill transfer High-performing endoscopists not only benefited during CADe use, but also appeared to internalize improvements—their non-CADe performance stayed strong and in some analyses improved over time. 4. Low detectors improved with AI—but showed limited learning without AI Low detectors clearly benefited when CADe was on, but their unassisted learning curve did not show the same degree of sustained improvement. This suggests CADe helps them “in the moment,” but may not automatically translate into durable skill gains without additional training support. 5. CADe particularly helps with subtle lesions Detection gains were strongest for lesions that are easier to miss—such as flat lesions and sessile serrated lesions—supporting CADe as a quality-enhancing tool, not just a “polyp counter.” Practical conclusion for clinicians CADe can be implemented without fear of deskilling. Over 3 years of real-world use, endoscopists did not lose their baseline detection ability in standard colonoscopy. However, the study also suggests a key implementation lesson: High detectors may naturally translate AI support into lasting skill improvement. Low detectors may need structured feedback/training (beyond simply turning on AI) to convert CADe assistance into sustained independent performance. What this means for your practice / unit If your unit is considering CADe, this study is reassuring: AI support does not appear to erode core skills. CADe can be positioned not only as a detection aid but as a quality framework tool, especially for improving detection of subtle lesions. For training programs: CADe should ideally be paired with targeted coaching, particularly for low detectors, to ensure long-term uplift even without AI. One-line GastroAGI “Clinical Takeaway” CADe boosts detection and—importantly—does not cause long-term deskilling; performance in non-CADe colonoscopy is maintained over time.

Colonoscopy-Related Adverse Events in the 21st Century - AJG 2026

The global incidence of colonoscopy-related adverse events (AEs) was analysed through a comprehensive meta-analysis of 82 population-based studies involving 38.5 million colonoscopies across 24 countries. The study categorised AEs into gastrointestinal and nongastrointestinal events. Gastrointestinal AEs included perforation (5.15 per 10,000 procedures), bleeding (18.39 per 10,000), and splenic injury (0.61 per 10,000). Nongastrointestinal AEs included cardiovascular events (52.11 per 10,000), respiratory events (4.26 per 10,000), and deaths (0.18 per 10,000). Despite the low overall risk, the findings emphasise the need for ongoing efforts to improve the safety of colonoscopy procedures. Subgroup analyses revealed some variability based on factors such as study design, region, and sample size. Most studies included in the analysis demonstrated a low to moderate risk of bias.

ESD – does techniques matter?(Endoscopy, Jan-2026)

Yes, techniques for Endoscopic Submucosal Dissection (ESD) matter significantly, as different techniques demonstrate varying advantages and outcomes depending on the clinical scenario. Based on the synthesized evidence from 18 randomized controlled trials (RCTs) involving 2,677 patients, three major techniques for ESD were compared: 1. **Tunnel/Pocket Method (Tu-ESD)** 2. **Traction Method (Tr-ESD)** 3. **Conventional Method (C-ESD)** ### Key Findings: - **Tu-ESD** achieved the highest ranking for **curative resection** (score 92.1) and was best for minimizing adverse events. - **Tr-ESD** ranked highest for **reducing procedure time** (score 100) and demonstrated significant reductions in procedure time compared with C-ESD (mean difference: –18.74 minutes). - Subgroup analyses by colorectal, gastric, and esophageal locations showed that: - **Tr-ESD** was superior for en bloc resection and procedure time. - **Tu-ESD** was best for curative resection and minimizing adverse events. ### Conclusion: Both Tu-ESD and Tr-ESD were found to be effective and safe compared to the conventional method (C-ESD). Given that different techniques offer distinct advantages, the choice of ESD technique should be tailored to the specific clinical scenario, lesion location, and procedural goals. This highlights the importance of selecting the appropriate method to optimize outcomes in ESD procedures.

TOF and endoscopic Occluders(Endoscopy, Jan-2026)

Tracheoesophageal fistulas (TOF) or gastrointestinal (GI)–tracheobronchial fistulas are abnormal connections between the trachea and the esophagus or GI tract. These conditions are often challenging to manage, especially when refractory to conventional treatments. Endoscopic occluders represent a minimally invasive therapeutic option for such fistulas, and recent studies have compared the efficacy and safety of different occluder designs. For example, in a retrospective cohort study, two novel occluders were evaluated: the double umbrella-shaped (DU) occluder and the mushroom umbrella-shaped (MU) occluder. The MU occluder demonstrated superior outcomes in terms of sustained occlusion, with a 12-month cumulative sustained occlusion probability of 82.1% compared to 65.5% for the DU occluder. Additionally, the MU occluder had fewer complications, such as esophageal wall injuries, which were observed in the DU group. Both occluders achieved 100% technical success rates, and adverse events were mild in both groups. The results suggest that the MU occluder may be a more effective and safer option for managing refractory GI–tracheobronchial fistulas. However, further prospective studies are necessary to validate these findings and optimize treatment protocols.

Endoscopy and Gastric Varices(Endoscopy, Jan-2026)

**Role of Endoscopy in Gastric Varices:** Endoscopy is a critical tool in the diagnosis and management of gastric varices in patients with cirrhosis. Gastric varices are enlarged veins in the stomach that develop due to increased portal venous pressure, often associated with liver cirrhosis. When these varices bleed, they can lead to life-threatening hemorrhage, making endoscopic intervention essential. **Study Insights:** 1. **Treatment Approaches:** In the study, two endoscopic strategies were compared: - **Aggressive Endotherapy:** Obliteration of all visible gastric varices using cyanoacrylate glue, regardless of bleeding status or risk features. - **Conservative Endotherapy:** Treatment limited to varices with stigmata of recent hemorrhage or high-risk features. 2. **Outcomes:** - **Rebleeding Rates:** At one year, rebleeding rates were similar between the aggressive and conservative groups (18.2% vs. 15.0%). - **Mortality:** All-cause mortality was also comparable, with a nonsignificant trend toward lower mortality in the aggressive group. - **Efficiency:** Aggressive therapy achieved faster obliteration of varices and required fewer endoscopic sessions for GOV1 varices. 3. **Adverse Events:** The rates of complications were similar between the two groups, indicating that aggressive therapy did not increase the risk of adverse events. **Conclusion:** Endoscopy, specifically through the use of cyanoacrylate glue injection, is a highly effective method for managing gastric varices. The study suggests that while aggressive therapy may lead to faster variceal obliteration, it does not significantly improve rebleeding or mortality outcomes compared to a conservative approach. This highlights the importance of tailoring endoscopic treatment strategies to individual patient risk factors and clinical scenarios.

Photometric Capsule and Emergency Upper Endoscopy(Endoscopy, Jan-2026)

The **Photometric Capsule Examination (PCE)** is a novel diagnostic tool designed to evaluate suspected nonvariceal upper gastrointestinal hemorrhage (NVUGIH). It is a small, ingestible capsule equipped with sensors and imaging technology that can detect signs of active bleeding or abnormalities in the gastrointestinal (GI) tract. This method is emerging as an alternative to traditional diagnostic approaches, particularly in stratifying patients for emergency or elective endoscopy. ### How Photometric Capsule Works 1. **Ingestion**: The patient swallows the capsule, which travels through the upper GI tract (esophagus, stomach, and duodenum). 2. **Imaging and Detection**: The capsule uses photometric technology to capture images or detect blood in the GI tract. 3. **Result Classification**: - **Positive Result**: Indicates active bleeding or high-risk lesions, prompting emergency endoscopy (within 12 hours). - **Negative Result**: Suggests no active bleeding, allowing for a more delayed, elective endoscopy (within 48–96 hours). --- ### Benefits of Photometric Capsule in Nonvariceal Upper GI Bleeding The study summarized in the context demonstrates several advantages of using the photometric capsule for patients with suspected NVUGIH: 1. **Stratification of Patients**: - The capsule helps differentiate between patients who need immediate intervention (emergency endoscopy) and those who can safely delay the procedure. - In the study, patients with a positive capsule result underwent emergency endoscopy, while others were treated conservatively with proton pump inhibitors until elective endoscopy. 2. **Avoiding Unnecessary Emergency Endoscopies**: - Among the 41 patients with a negative capsule result (Group B), only two required emergency endoscopy, and neither had active bleeding. This means that 95.1% of emergency endoscopies were avoided in this group. - This reduces the burden on healthcare systems and minimizes risks associated with unnecessary invasive procedures. 3. **High Negative Predictive Value**: - The photometric capsule demonstrated a **100% sensitivity and negative predictive value** in excluding active bleeding. This means it is highly reliable in ruling out patients who do not need immediate intervention. 4. **Ease of Use and Safety**: - The capsule is non-invasive, quick, and easy to administer. - No technical, capsule-related, or bleeding-related complications were reported during the 30-day follow-up period in the study. 5. **Patient Outcomes**: - The capsule allows for a tailored approach to patient care, reducing the risks of unnecessary procedures while ensuring timely intervention for those who need it. --- ### Comparison with Elective Endoscopy Elective endoscopy has been the standard diagnostic and therapeutic tool for suspected NVUGIH, but it has limitations that the photometric capsule can address: - **Timing**: Elective endoscopy often requires scheduling within a specific timeframe (24–96 hours), which can delay diagnosis and treatment in some cases. - **Invasiveness**: Endoscopy is an invasive procedure with potential risks, such as sedation-related complications or perforation. - **Resource Intensive**: Emergency endoscopy requires significant hospital resources, including specialized staff and equipment, which can strain healthcare systems. The photometric capsule offers a complementary approach by identifying patients who truly need emergency endoscopy, thereby optimizing resource allocation and patient care. --- ### Can Photometric Capsule Replace Elective Endoscopy? While the photometric capsule shows great promise, it is unlikely to fully replace elective endoscopy in the near future. Instead, it serves as a valuable **triage tool** to improve patient management. Here's why: 1. **Diagnostic and Therapeutic Capabilities**: - Unlike the capsule, endoscopy is not only diagnostic but also therapeutic. It allows for interventions such as cauterization, clipping, or injection therapy to control bleeding. 2. **Limitations of the Capsule**: - The capsule only provides diagnostic information and cannot treat bleeding or other abnormalities. - It may not detect all types of lesions or bleeding sources, particularly in cases of slow or intermittent bleeding. 3. **Complementary Role**: - The capsule is best used as a **pre-endoscopy tool** to stratify patients and prioritize those who need emergency endoscopy. It can reduce the number of unnecessary procedures but cannot replace the therapeutic role of endoscopy. 4. **Future Potential**: - With further advancements, the capsule could evolve to include therapeutic capabilities or more advanced diagnostic features. However, as of now, it is primarily a triage tool. --- ### Conclusion The photometric capsule is a promising innovation in the management of suspected NVUGIH. It offers a quick, non-invasive, and highly accurate method to identify patients who require emergency endoscopy, thereby reducing unnecessary procedures and optimizing healthcare resources. However, it is not a replacement for elective endoscopy, which remains essential for both diagnosis and treatment. Instead, the capsule serves as a complementary tool that enhances patient care and improves the efficiency of GI bleeding management.

Esophageal ESD and stricture prevention(GIE, Jan-2026)

The study published in *Gastrointestinal Endoscopy (GIE), January 2026* focuses on esophageal endoscopic submucosal dissection (ESD) and strategies for preventing esophageal strictures, a common and serious complication following extensive resections. Below is a detailed summary of the key findings and advancements discussed in the study: --- ### **Background on Esophageal ESD and Stricture Formation** 1. **Preferred Therapy**: Esophageal ESD is now the standard treatment for large esophageal dysplastic and superficial neoplastic lesions due to its precision and efficacy. 2. **Stricture Risk**: The risk of esophageal strictures increases significantly when more than 75% of the esophageal circumference is resected. Strictures result in severe patient morbidity, frequently necessitating repeated endoscopic dilations, which negatively impact quality of life. 3. **Limitations of Current Prevention Strategies**: Existing methods to prevent strictures, such as steroid therapy, stents, tissue shielding, and dilations, have shown inconsistent results. No single approach has emerged as clearly superior. --- ### **Introduction of Submucosal Steroid Pre-Injection Strategy (SSPS)** 1. **Novel Technique**: SSPS involves injecting steroids into the submucosa before the ESD procedure. This is combined with two postoperative intralesional steroid injections, creating a multiphase steroid delivery system. 2. **Rationale for Pre-Injection**: Pre-resection steroid injection ensures uniform distribution and prolonged submucosal exposure, aligning with the critical healing period when strictures typically form. 3. **Comparator Therapy**: The control group received intralesional steroids post-ESD along with an extended course of oral steroids. --- ### **Key Findings** 1. **Lower Stricture Rates**: SSPS demonstrated significantly lower stricture rates compared to the control group. The benefit was consistent even after adjusting for lesion location, width, and length. 2. **Safety Profile**: No adverse events were reported in patients treated with SSPS, addressing concerns about potential risks such as delayed perforation. 3. **Encouraging Results for Full Circumferential ESD**: Achieving a low stricture rate in cases of full circumferential ESD is clinically notable and represents a significant advancement. 4. **Potential Mechanical Dilation Effect**: The repeated passage of the endoscope during follow-up steroid injections may have had a mechanical dilation effect, unintentionally contributing to stricture prevention. --- ### **Challenges and Considerations** 1. **Visualization and Equipment Limitations**: The opacity of steroids without contrast dye can impair visualization during dissection. Additionally, the increased viscosity of the steroid injectate may not be compatible with certain ESD knives. 2. **Complexity in Attribution**: The multiple interventions in the SSPS group make it difficult to attribute the benefit solely to pre-resection steroid injection. 3. **Theoretical Risks**: While no delayed perforations were observed in the study, the potential risk remains a theoretical concern. --- ### **Emerging Alternative Strategies** The study highlights other promising approaches for stricture prevention, including: 1. Endoscopic vacuum therapy. 2. Peptide gels. 3. Tissue shields. These strategies are in early stages of development and require further investigation. --- ### **Call for Further Research** 1. **Need for Prospective Trials**: The study emphasizes the importance of well-designed, prospective trials to validate the efficacy of SSPS and compare it with emerging modalities. 2. **Future Directions**: Further research is needed to refine SSPS, address its limitations, and determine its long-term outcomes in diverse patient populations. --- ### **Conclusion** The introduction of SSPS represents a promising advancement in the prevention of esophageal strictures following ESD, particularly for extensive or full circumferential resections. With its favorable safety profile and significant reduction in stricture rates, SSPS has the potential to improve patient outcomes. However, challenges such as equipment compatibility, visualization issues, and the complexity of attributing benefits to pre-resection steroids warrant further investigation. Prospective trials are essential to confirm these findings and to compare SSPS with other emerging strategies.

POEM and GERD – dose technique matter? (GIE, Jan-2026)

### POEM Techniques and GERD: Does Technique Matter? POEM is a minimally invasive endoscopic procedure used to treat achalasia, a motility disorder of the esophagus. There are two primary techniques for POEM: 1. **Full-Thickness (FT) POEM**: - This technique involves cutting through all layers of the esophageal muscle, including both circular and longitudinal fibers. - While FT POEM is effective in relieving achalasia symptoms, it has been associated with higher incidences of GERD, as the full-thickness myotomy disrupts the integrity of the lower esophageal sphincter (LES), increasing the likelihood of acid reflux. 2. **Modified Myotomy (MM) POEM**: - MM POEM includes techniques such as: - **Selective Circular Myotomy (CM)**: Only the circular muscle fibers are incised, sparing the longitudinal fibers. - **Oblique Fiber-Sparing Myotomy (OS)**: A more targeted approach that spares oblique fibers while addressing the circular fibers. - These techniques aim to preserve some of the LES functionality, potentially reducing the incidence of GERD while still effectively treating achalasia. ### GERD Incidences and Technique Differences: The meta-analysis described in the context highlights the following key findings regarding the impact of POEM techniques on GERD: - **FT POEM**: - Associated with a higher rate of symptomatic GERD (Odds Ratio [OR]: 1.58; 95% CI: 1.12-2.23, P = .009) compared to MM POEM. - This is likely due to the complete disruption of LES function caused by cutting through all muscle layers. - **MM POEM**: - Specifically, the Oblique Fiber-Sparing (OS) technique was found to have reduced symptomatic reflux compared to FT POEM. - Selective Circular Myotomy (CM) showed similar rates of symptomatic reflux as FT POEM but had the advantage of shorter procedure duration. ### Clinical Implications: - The choice of POEM technique matters significantly in terms of GERD outcomes. Patients undergoing FT POEM may experience higher rates of post-procedure GERD, necessitating close monitoring and potential use of acid-suppressive therapies (e.g., proton pump inhibitors). - MM POEM, particularly the OS technique, appears to be a promising alternative for reducing GERD risk while maintaining clinical efficacy in treating achalasia. - However, the meta-analysis emphasizes the limited number of studies available and the observational nature of most included research, suggesting that further randomized controlled trials are needed to confirm these findings. ### Conclusion: The technique used in POEM does indeed influence GERD outcomes, with MM POEM techniques (especially OS) showing a potential advantage in reducing symptomatic reflux compared to FT POEM. The choice of technique should be tailored to individual patient needs, balancing the risk of GERD with the effectiveness of achalasia symptom relief.

Green Endoscopy Unit (GIE, Jan-2026)

The Green Endoscopy Unit (GIE) concept, set to launch in January 2026, aims to minimize the environmental impact of endoscopic procedures while maintaining high-quality patient care. Its core strategy revolves around reducing unnecessary activities, emphasizing high-value care with the lowest environmental cost. Adherence to evidence-based guidelines and structured triage systems ensures only clinically appropriate and timely procedures are performed, avoiding low-value or repeat interventions. Key practices include provider education to improve referral quality, patient communication to explain deferred procedures, and the use of non-endoscopic alternatives when suitable. Efficient scheduling prevents cancellations and resource underutilization, while combining procedures into single visits reduces overall waste. Operational strategies involve minimizing instrument use, simplifying interventions, avoiding low-yield biopsies, and consolidating specimens to reduce material consumption. Inventory management prevents overstocking and expiration, supported by first-in, first-out storage practices. Sedation methods and IV fluid use are optimized to match patient needs, avoiding excess resource use. The unit also focuses on reducing paper dependency through digital documentation and encourages patient engagement by promoting reusable personal items. These measures collectively align with sustainability goals, ensuring environmentally conscious endoscopic care without compromising clinical outcomes. GIE represents a forward-thinking approach to healthcare delivery in the face of climate challenges.

Saline-Immersion Technique for Colorectal ESD: Outcomes From a Western Cohort - J of JGH - Jan,26

The referenced study, "Saline-Immersion Technique for Colorectal ESD: Outcomes From a Western Cohort," published in the *Journal of Gastroenterology and Hepatology* on January 26, evaluates the use of the saline-immersion/irrigation technique combined with the pocket-creation method (SITE-PCM) for endoscopic submucosal dissection (ESD) of complex colorectal lesions in a Western clinical setting. Below is a detailed summary of the study's outcomes: ### Background: - Endoscopic submucosal dissection (ESD) is a minimally invasive technique used for removing complex colorectal lesions en bloc, which is crucial for achieving curative outcomes with clear margins. - Adoption of ESD in Western countries has been limited due to the technical challenges posed by colonic anatomy, such as its narrow lumen, sharp angulations, and thin walls. - The SITE-PCM approach was developed to enhance visualization, stability, and control during ESD by using saline immersion and a pocket-creation technique. ### Study Design: - This was a retrospective analysis of all consecutive colorectal ESD procedures performed over several years in a Western tertiary referral center. - SITE-PCM was consistently applied across all cases. - Key parameters reviewed included lesion location, procedural success, histological outcomes, complications, and follow-up data. ### Key Findings: 1. **Effectiveness:** - SITE-PCM–assisted ESD achieved high rates of en bloc resections (complete removal of the lesion in one piece) across various colorectal locations, including challenging areas like the proximal colon and rectum. - Most lesions were successfully removed with clear histological margins, ensuring curative outcomes for the majority of cases. 2. **Safety:** - Adverse events were rare and generally manageable. Complications, such as perforation or bleeding, were infrequent, and escalation of care (e.g., surgical intervention) was required in very few cases. - The majority of procedures were performed safely under conscious sedation, which is less invasive and more cost-effective than general anesthesia. 3. **Procedure Time:** - While procedure times were longer compared to simpler endoscopic techniques, they were deemed acceptable given the complexity of the lesions treated. 4. **Clinical Implications:** - The use of SITE-PCM improved visualization and control during the dissection, addressing key technical challenges associated with colorectal ESD in Western populations. - These results support the feasibility of adopting ESD more widely in Western clinical practice. ### Conclusion: The study concludes that SITE-PCM–assisted ESD is a safe, effective, and minimally invasive approach for treating complex colorectal lesions in Western settings. It provides high-quality outcomes with manageable risks, supporting its broader adoption and further prospective evaluation. This study is significant as it demonstrates that advanced techniques like SITE-PCM can overcome the anatomical and technical barriers that have historically limited the use of colorectal ESD in Western countries. It also highlights the potential for this approach to improve patient outcomes by enabling curative treatment of complex lesions with minimal invasiveness.

Endoscopic Full-Thickness Resection for Extraluminal Gastric Submucosal Tumors - J of JGH - Jan,26

Based on the context provided, the study on "Endoscopic Full-Thickness Resection (EFTR) for Extraluminal Gastric Submucosal Tumors" likely highlights the feasibility, safety, and clinical outcomes of EFTR as a minimally invasive approach for managing gastric submucosal tumors with extraluminal growth. These tumors, which grow outward from the gastric wall, pose unique challenges compared to intraluminal lesions and have been inadequately studied in the past. ### Key Findings of the Study: 1. **Feasibility and Effectiveness:** - EFTR was shown to be a feasible technique for removing gastric submucosal tumors with extraluminal growth, including those with completely extraluminal patterns. - The procedure achieved a high rate of complete tumor removal with successful retrieval in most cases. 2. **Safety Profile:** - Adverse events related to the procedure were infrequent and manageable, indicating an acceptable safety profile. - The study supports the use of EFTR as a minimally invasive alternative to more invasive surgical techniques. 3. **Challenges and Complexity:** - Tumor-related factors such as larger size and irregular morphology were associated with increased technical challenges, including difficulties in tumor extraction and longer operative times. - These factors should be carefully considered during patient selection and pre-procedural planning. 4. **Oncologic Outcomes:** - Long-term follow-up data revealed no evidence of local recurrence or distant metastasis, suggesting that EFTR provides oncologically adequate treatment for these tumors. 5. **Clinical Implications:** - EFTR offers a promising treatment option for patients with gastric submucosal tumors that exhibit extraluminal growth, reducing the need for more invasive surgical procedures. - Further studies, especially prospective trials, are needed to validate these findings and optimize patient selection criteria. ### Conclusion: The study concludes that EFTR is a safe and effective minimally invasive method for treating gastric submucosal tumors with extraluminal growth. However, tumor characteristics such as size and morphology significantly influence procedural complexity. Prospective research is recommended to refine the technique and enhance outcomes. If you are referring to a specific article in the Journal of Gastroenterology and Hepatology (JGH) published on January 26, this summary aligns with the general findings on the topic. However, for precise details, the original article should be consulted directly.

Reflux-Related Esophageal Stricture After POEM - J of JGH - Jan,26

Based on the context provided, the study titled "Reflux-Related Esophageal Stricture After POEM" published in the *Journal of Gastroenterology and Hepatology (JGH)* on January 26 likely focuses on the clinical differentiation between reflux-related esophageal strictures and recurrent achalasia that may develop following peroral endoscopic myotomy (POEM). The study investigates the symptoms, underlying mechanisms, diagnostic approaches, and treatment strategies for reflux-related strictures after POEM. ### Key Findings: 1. **Clinical Differences**: - Reflux-related esophageal strictures and recurrent achalasia share overlapping symptoms like dysphagia and regurgitation but are distinct clinical entities. - Patients with reflux-related strictures exhibit more reflux-associated symptoms (e.g., heartburn) and inflammatory changes visible during endoscopy. - Functional testing showed differences in lower esophageal sphincter pressure patterns between reflux-related strictures and recurrent achalasia, suggesting distinct pathophysiological mechanisms. 2. **Diagnostic Tools**: - Symptom patterns, endoscopic findings (e.g., inflammatory changes), and functional assessments (e.g., sphincter pressure measurements) are critical in distinguishing reflux-related strictures from recurrent achalasia. 3. **Endoscopic Treatments**: - Endoscopic therapies, such as radial incision and balloon dilation, were effective for managing reflux-related strictures. - These treatments demonstrated good long-term outcomes and acceptable safety profiles, making them viable options for patients with this condition. 4. **Associated Factors**: - Tissue changes within the esophageal wall were identified as key contributors to the development of reflux-related strictures. ### Conclusion: Reflux-related esophageal stricture after POEM is a distinct condition that can be reliably differentiated from recurrent achalasia using clinical, functional, and endoscopic evaluations. Endoscopic management techniques are safe and effective for treating these strictures. If you are looking for more detailed insights or specific sections from the article, I recommend accessing the *Journal of Gastroenterology and Hepatology* directly, as the full text will provide comprehensive data and analysis.

ESD Vs TEM for Rectal Polyp

Endoscopic Submucosal Dissection (ESD) and Transanal Endoscopic Microsurgery (TEM) are both minimally invasive techniques used for the treatment of rectal polyps, particularly early-stage rectal cancer or large benign polyps. Comparing ESD and TEM for rectal polyps requires an evaluation of their respective outcomes, including efficacy, safety, and technical considerations. ### Key Comparisons Between ESD and TEM for Rectal Polyps: #### 1. **En-bloc Resection Rates:** - **ESD:** Achieves higher en-bloc resection rates compared to TEM. En-bloc resection involves removing the tumor or polyp in a single piece, which is critical for accurate pathological assessment and reducing the risk of recurrence. - **TEM:** While TEM is effective, it may not achieve as high en-bloc resection rates as ESD, especially for larger or more complex polyps. #### 2. **Tumor Recurrence:** - **ESD:** Associated with lower recurrence rates for rectal polyps and early-stage rectal cancer. This is likely due to its precise dissection technique, which minimizes residual tumor tissue. - **TEM:** Recurrence rates are slightly higher compared to ESD, particularly for larger lesions. #### 3. **Complication Rates:** - **ESD:** Demonstrates a lower overall complication rate compared to TEM. While ESD is technically demanding, its precision reduces risks such as postoperative bleeding and perforation. - **TEM:** Has a higher complication rate, but complications are generally manageable with proper postoperative care. #### 4. **R0 Resection Rates:** - Both ESD and TEM achieve comparable R0 resection rates (complete removal of the tumor with clear margins). This indicates that both techniques are effective in achieving tumor-free margins. #### 5. **Operative Time and Hospital Stay:** - **ESD:** May require longer operative times due to its technical complexity. However, patients often benefit from shorter hospital stays due to fewer complications. - **TEM:** Operative time may be shorter, but hospital stays could be longer if complications occur. #### 6. **Technical Complexity:** - **ESD:** Requires significant expertise and specialized training. It is more technically demanding but offers greater precision in dissecting deeper layers of tissue. - **TEM:** Easier to perform compared to ESD and may be more accessible in clinical settings with limited resources. ### Clinical Considerations: - **ESD:** Recommended for patients with larger, complex polyps or early-stage rectal cancer due to its superior precision, lower recurrence rates, and reduced complications. However, it requires a highly skilled operator and specialized equipment. - **TEM:** Suitable for smaller, less complex polyps or in settings where ESD expertise is unavailable. It remains an effective and safe option. ### Summary: While both ESD and TEM are effective for treating rectal polyps, ESD demonstrates advantages in terms of en-bloc resection rates, lower recurrence, and fewer complications. TEM remains a viable option, particularly in cases where ESD expertise or resources are limited. Treatment selection should be guided by the size and complexity of the polyp, the clinician's expertise, and the availability of specialized equipment.

Rapid trypsinogen-2 test and post ERCP discharge Strategy - EJGH Nov 26

The study "Rapid trypsinogen-2 test and post-ERCP discharge strategy" published in the *European Journal of Gastroenterology & Hepatology* (EJGH) on November 26 explores methods to predict adverse events (AEs) following endoscopic retrograde cholangiopancreatography (ERCP). It examines the effectiveness of two strategies: the urinary trypsinogen-2 (UT-2) dipstick test and a risk-factor-based discharge tool, both individually and in combination, to identify patients at high risk of post-ERCP AEs. ### Background and Problem Statement: ERCP is associated with a significant risk of adverse events, including post-ERCP pancreatitis, infections, bleeding, and perforation, with an approximate 10% incidence rate. Current post-ERCP discharge strategies, such as those recommended by the European Society of Gastrointestinal Endoscopy (ESGE), rely on serum amylase or lipase measurements 2–6 hours after the procedure. However, these strategies have limitations: 1. They do not account for AEs other than pancreatitis. 2. They are logistically burdensome, requiring blood sampling, laboratory testing, and additional hospital resources. 3. Post-ERCP hyperamylasemia is common in asymptomatic patients, leading to potential overestimation of risk. The study aimed to evaluate whether the UT-2 dipstick test, the discharge tool, or their combination could serve as simpler, more efficient alternatives for predicting post-ERCP AEs and guiding discharge decisions. ### Results: The study enrolled 268 patients across multiple hospitals from August 2018 to March 2021. Key findings include: - **Adverse Events (AEs):** 10.5% of patients experienced AEs, with 6.1% developing post-ERCP pancreatitis. - **Combined Strategy Performance:** The combination of the UT-2 dipstick test and the discharge tool outperformed individual strategies for predicting AEs, with a sensitivity of 66.7%, specificity of 78.5%, positive predictive value (PPV) of 26.6%, and negative predictive value (NPV) of 95.3%. - For post-ERCP pancreatitis specifically, the combined strategy had a sensitivity of 64.3%, specificity of 76.2%, PPV of 14.9%, and NPV of 97.0%. ### Conclusion: While the combined approach of the UT-2 dipstick test and the discharge tool showed improved predictive accuracy compared to individual strategies, its overall sensitivity remained suboptimal. As a result, the study does not recommend the implementation of either strategy—individually or combined—as a replacement for current post-ERCP discharge protocols. The findings highlight the need for further research to develop reliable, cost-effective, and logistically feasible tools for predicting post-ERCP adverse events.

EUS, TIPS and Cavernous Transformation of the Portal Vein

EUS (Endoscopic Ultrasound), TIPS (Transjugular Intrahepatic Portosystemic Shunt), and Cavernous Transformation of the Portal Vein (CTPV) are interconnected concepts in the management of portal hypertension and its complications, particularly in patients with liver cirrhosis and CTPV. Here's a detailed explanation of these terms and their relationship: ### 1. **Cavernous Transformation of the Portal Vein (CTPV):** - CTPV refers to a condition where the portal vein becomes blocked or thrombosed (due to conditions such as portal vein thrombosis), leading to the formation of a network of collateral veins around the obstructed portal vein. These collateral veins attempt to bypass the blockage to maintain blood flow to the liver. - This condition often arises in patients with liver cirrhosis, portal hypertension, or hypercoagulable states. - CTPV poses significant clinical challenges, including: - **Recurrent variceal hemorrhage** (bleeding from enlarged veins in the esophagus or stomach). - **Ascites** (accumulation of fluid in the abdominal cavity). - Increased risk of complications due to the altered portal venous anatomy. ### 2. **TIPS (Transjugular Intrahepatic Portosystemic Shunt):** - TIPS is a minimally invasive procedure used to treat complications of portal hypertension, such as variceal bleeding and refractory ascites. - The procedure involves creating a shunt (connection) between the portal vein and a hepatic vein within the liver using a stent. This reduces portal vein pressure by allowing blood to bypass the liver and flow directly into the systemic circulation. - **Challenges in CTPV:** - In patients with CTPV, the portal vein is thrombosed or replaced by a network of collateral veins, making it technically difficult to perform TIPS. - The success rate of TIPS in patients with a patent portal vein is high (over 95%), but it drops to 60-70% in patients with CTPV due to the altered anatomy and difficulty in locating the portal vein. ### 3. **EUS (Endoscopic Ultrasound):** - EUS is a diagnostic and therapeutic tool that uses ultrasound imaging via an endoscope inserted into the gastrointestinal tract. It provides high-resolution images of structures adjacent to the GI tract, including the portal vein. - **Role in TIPS for CTPV:** - EUS can be used to guide the localization of the portal vein in patients with CTPV. This is particularly important because traditional TIPS relies on indirect navigation and blind needle puncture, which carries a high risk of complications like intra-abdominal hemorrhage. - In the study mentioned, EUS was used to locate the portal vein and mark it with a metallic coil. This coil served as a direct target for TIPS puncture, significantly improving the accuracy and safety of the procedure. ### 4. **EUS-TIPS Hybrid Approach:** - The integration of EUS-guided portal vein localization with TIPS represents a novel and innovative approach to managing CTPV. - **Key Findings from the Study:** - The study demonstrated the technical success and safety of combining EUS with TIPS in a cohort of 10 patients with liver cirrhosis and CTPV. - All patients successfully underwent the procedure without EUS-related adverse events. - During follow-up, no patients experienced recurrent variceal hemorrhage or ascites, although 30% of patients developed overt hepatic encephalopathy (a known complication of TIPS). - This hybrid approach addresses the limitations of traditional TIPS in CTPV and offers a safer and more effective alternative for these high-risk patients. ### 5. **Conclusion:** - The combination of EUS and TIPS represents a paradigm shift in the management of CTPV, providing a more precise and safer method for treating complications of portal hypertension in patients with altered portal venous anatomy. - This novel approach has the potential to improve clinical outcomes and expand the applicability of TIPS in challenging cases like CTPV.

REACT for colorectal ESD

REACT, which stands for Repositionable Elastic Adaptive Customizable Traction, is an innovative traction method designed to assist in Endoscopic Submucosal Dissection (ESD) for colorectal lesions. ESD is a minimally invasive procedure used to remove complex gastrointestinal lesions, including those in the colon and rectum, while preserving surrounding healthy tissue. However, conventional ESD can be challenging due to issues like poor visibility of the submucosal layer, difficulty in maneuvering instruments, and the need for precise dissection. ### What is REACT-Assisted ESD? REACT-assisted ESD employs orthodontic elastic bands to provide traction during the procedure. These elastic bands are customizable, repositionable, and adaptable, making them highly versatile for different lesion morphologies and locations. The REACT method allows the operator to create multipoint traction, which improves visualization of the submucosal layer and facilitates dissection. ### How REACT Works: 1. **Elastic Bands**: Orthodontic elastic bands are attached to the lesion and the endoscope to create tension. This tension lifts the lesion and exposes the submucosal layer for easier access. 2. **Customizable Setup**: The traction setup can be adjusted and repositioned during the procedure to adapt to the changing needs of the dissection process. 3. **Multipoint Traction**: Multiple bands can be used to provide traction from various angles, enhancing visibility and precision. ### Advantages of REACT-Assisted ESD Compared to Conventional ESD: 1. **Improved Submucosal Access**: REACT provides better exposure of the submucosal layer, which is crucial for safe and efficient dissection. This reduces the risk of incomplete resection or damage to surrounding tissues. 2. **Adaptability**: Unlike conventional methods, REACT can be repositioned during the procedure, allowing the operator to adapt to the lesion's morphology and location as dissection progresses. 3. **Cost-Effective**: The use of orthodontic elastic bands makes REACT a low-cost solution compared to other traction methods or advanced equipment. 4. **Reduced Technical Challenges**: By improving visibility and access, REACT minimizes the technical challenges associated with conventional ESD, which often relies solely on the operator's skill without additional traction assistance. 5. **Enhanced Precision**: Multipoint traction allows for more precise dissection, reducing the likelihood of complications such as perforation or incomplete resection. 6. **Feasibility Across Lesion Types**: REACT's customizable nature makes it applicable to a wide range of colorectal lesions, regardless of their size, shape, or location. ### Summary: REACT-assisted ESD represents a significant advancement in endoscopic techniques for colorectal lesions. By addressing the limitations of conventional ESD, such as poor visibility and difficulty in maneuvering, REACT improves the safety, efficiency, and outcomes of the procedure. Its adaptability and cost-effectiveness make it a promising option for widespread clinical use, pending further validation in multicenter studies.

ESD for upper esophageal cancer

Endoscopic submucosal dissection (ESD) is increasingly recognized as an effective and minimally invasive treatment option for superficial esophageal squamous neoplasms (ESN), including early-stage esophageal cancer. This technique is particularly suitable for treating superficial lesions confined to the mucosal or submucosal layers of the esophagus, as it allows for precise removal of the tumor while preserving the surrounding esophageal tissue. The procedure involves the use of specialized endoscopic tools to dissect and remove the cancerous lesion en bloc (in one piece), which ensures complete removal and allows for accurate pathological assessment. ESD is recommended as the standard of care for early esophageal squamous cell carcinoma (ESCC) when the lesion meets specific criteria for curative resection, such as limited depth of invasion, absence of lymphovascular invasion, and no evidence of lymph node metastasis. Key benefits of ESD for upper esophageal cancer include high rates of complete tumor removal (en bloc and R0 resection), low recurrence rates in curative resections, and the ability to preserve the esophagus, thereby avoiding more invasive surgical procedures like esophagectomy. However, patient selection is critical to ensure optimal outcomes, as deeper or more advanced lesions may require additional treatments such as surgery or chemoradiotherapy. The safety profile of ESD is generally favorable, with a low risk of complications such as bleeding or perforation, though these risks increase with larger or more complex lesions. In the Western world, data on ESD for esophageal cancer is still emerging, but studies indicate that it is a viable and effective treatment option, with outcomes comparable to those reported in Asian countries where the procedure is more established. In summary, ESD represents a safe and effective approach for the treatment of upper esophageal cancer, particularly for superficial lesions. It offers the advantages of organ preservation, accurate pathological assessment, and low recurrence rates, making it a preferred option for carefully selected patients with early-stage esophageal cancer. However, long-term follow-up and multidisciplinary care are essential to monitor for recurrence or progression, especially in cases where curative resection criteria are not met.

Endoscopic Gastroplasty and weight loss

Endoscopic Gastroplasty (EG) is a minimally invasive procedure designed to help manage obesity by reducing the size of the stomach without requiring traditional surgical methods. It is classified as an Endoscopic Bariatric Therapy (EBT), which serves as an alternative to more invasive bariatric surgeries like gastric bypass or sleeve gastrectomy. EG is performed using advanced endoscopic tools that allow the reshaping and suturing of the stomach from within, thereby limiting its capacity and promoting early satiety. ### Techniques of Endoscopic Gastroplasty There are three primary techniques for performing Endoscopic Gastroplasty: 1. **Endoscopic Sleeve Gastroplasty (ESG):** This technique uses the Apollo Overstitch Sx device (Boston Scientific) to place sutures along the stomach, creating a sleeve-like structure that reduces its volume. 2. **Endoluminal Vertical Gastroplasty (EVG):** This method employs the Endomina system (EndoTools Therapeutics) to perform vertical suturing inside the stomach for size reduction. 3. **Primary Obesity Surgery Endoluminal-2 (POSE-2):** Using the Incisionless Operating Platform (USGI Medical), this technique involves placing anchors or sutures to reduce stomach volume and alter its shape. ### Effectiveness of Endoscopic Gastroplasty A clinical study conducted between April 2021 and May 2023 evaluated the outcomes of these three techniques on weight loss among 184 obese patients. The results demonstrated that all three methods were equally effective in achieving weight loss, with no statistically significant differences among the techniques. The primary findings include: - **Total Body Weight Loss (TBWL):** Patients achieved an average of 15.5% at 6 months, 14.5% at 12 months, and 17.1% at 18 months. - **Excess Weight Loss (EWL):** Patients experienced an average EWL of 39.3% at 6 months, 36.7% at 12 months, and 43.0% at 18 months. ### Safety and Feasibility Endoscopic Gastroplasty was found to be a safe and feasible procedure with a 100% technical success rate and a low serious adverse event rate of 1.1%. The minimally invasive nature of the procedure contributes to quicker recovery times and reduced risks compared to traditional bariatric surgery. ### Additional Benefits Beyond weight loss, EG showed significant improvements in: - **Anthropometric Measurements:** Reduction in waist circumference and overall body fat percentage. - **Body Composition:** Improved muscle-to-fat ratio. - **Fatty Liver Disease and Hyperlipidemia:** Marked improvements in liver health and lipid profiles. - **Quality of Life:** Enhanced scores on the Bariatric Analysis and Reporting Outcome System (BAROS) and the Total Self-Development Obesity Control (TSD-OC) test, indicating better physical, emotional, and social well-being. ### Limitations The study had incomplete follow-up rates, with only 56% of patients followed at 6 months, 32% at 12 months, and 15% at 18 months. This limitation may have impacted the robustness of the long-term data, although the researchers assumed missing data were random. ### Conclusion Endoscopic Gastroplasty through ESG, EVG, and POSE-2 is a promising intervention for managing obesity. It provides effective weight loss, improves metabolic health, and enhances quality of life in the medium-term follow-up. Its minimally invasive nature makes it a safer and more feasible option for patients seeking alternatives to surgical bariatric procedures.

ESD, Esophageal Stricture and steroid

**ESD (Endoscopic Submucosal Dissection):** Endoscopic Submucosal Dissection (ESD) is a minimally invasive endoscopic procedure used to treat superficial esophageal cancer. It allows for the precise removal of cancerous lesions while preserving the surrounding healthy tissue. ESD has become the standard treatment for early-stage esophageal cancer due to its favorable outcomes, such as reduced complications and improved prognosis when compared to more invasive surgical options. However, despite its advantages, one of the major challenges following ESD is the development of **esophageal strictures**, particularly after extensive or circumferential ESD (cESD). --- **Esophageal Stricture After ESD:** An esophageal stricture refers to a narrowing of the esophagus, which can lead to difficulty swallowing (dysphagia). This complication is most common after large or circumferential resections during ESD, as the wound healing process often leads to fibrotic scar tissue formation and contraction of the esophageal wall. Patients with esophageal strictures can experience significant discomfort, reduced quality of life, and may require multiple interventions, such as endoscopic balloon dilations, to manage the condition. Preventing esophageal strictures is a critical concern in patients undergoing cESD, as it directly impacts their recovery and long-term outcomes. Various strategies have been explored to reduce the risk of stricture formation, with steroid therapy being one of the most effective approaches. --- **Role of Steroids in Preventing Esophageal Stricture:** Steroids, such as **triamcinolone acetonide (TA)** and **oral prednisone**, are used to prevent esophageal stricture formation by reducing inflammation and inhibiting the excessive production of fibrotic tissue during the healing process. Steroids help modulate the immune response and minimize the risk of scar tissue formation that leads to esophageal narrowing. Two main steroid-based approaches are commonly used: 1. **Combined Steroid Therapy (CST):** This approach involves injecting triamcinolone acetonide (TA) directly into the esophageal wall immediately after cESD, followed by a prolonged course of oral prednisone. CST has shown effectiveness in reducing stricture rates, but it is not always sufficient, especially in cases of extensive resections. 2. **Submucosal Steroid Preinjection Strategy (SSPS):** SSPS is a novel approach where triamcinolone acetonide is pre-injected into the submucosal layer of the esophagus before cESD, creating a "steroid water cushion" to reduce trauma during the procedure. Additional steroid injections are administered postoperatively to further suppress inflammation and fibrosis. SSPS has demonstrated promising clinical outcomes, with better prevention of esophageal strictures compared to CST. --- **Key Clinical Outcomes of Steroid Use:** Steroid therapy, whether CST or SSPS, aims to achieve the following outcomes: - **Reduced stricture rates:** Lower incidence of esophageal narrowing and dysphagia. - **Improved swallowing ability:** Patients experience fewer difficulties in eating and drinking post-procedure. - **Fewer endoscopic interventions:** Stricture prevention reduces the need for repeated balloon dilation sessions. - **Shorter hospitalization and recovery time:** Effective prevention strategies minimize complications and improve overall recovery. - **Cost-effectiveness:** Fewer complications lead to reduced medical expenses and unscheduled visits. --- **Conclusion:** Steroid therapy plays a crucial role in managing esophageal strictures after ESD, particularly circumferential ESD. While CST has been widely used, the novel SSPS approach shows promising results in further improving outcomes by integrating pre-procedural steroid injections. Both strategies aim to enhance patient recovery, reduce complications, and improve quality of life following treatment for superficial esophageal cancer.

Endoscopic Billary Drainage in surgically altered anatomy

Endoscopic biliary drainage (BD) in patients with surgically altered anatomy (SAA) is a complex and challenging medical procedure. SAA refers to patients who have undergone surgeries that change the normal anatomy of the gastrointestinal tract, such as Billroth-II gastrectomy, Roux-en-Y reconstruction, or other similar procedures. These anatomical changes make it difficult to access the bile ducts endoscopically, which is necessary for drainage in cases of biliary obstruction caused by conditions like stones, strictures, or malignancies. ### Why Endoscopic Biliary Drainage is Necessary: Biliary drainage is essential for relieving obstruction in the bile ducts, which can lead to serious complications like infection (cholangitis), jaundice, and liver damage. While BD is a routine procedure in patients with normal anatomy, SAA presents unique challenges due to altered pathways that make the bile ducts harder to reach. Traditional endoscopic retrograde cholangiopancreatography (ERCP), the standard approach for BD, is often not feasible in these patients. Therefore, alternative techniques and specialized approaches are required. ### Techniques for Biliary Drainage in SAA: Several approaches are used for BD in patients with SAA, depending on the type of surgical reconstruction and the expertise available at the medical center. These include: 1. **Device-Assisted Enteroscopy ERCP**: This involves the use of specialized enteroscopes, such as balloon-assisted or spiral-assisted enteroscopes, to navigate the altered anatomy and reach the bile ducts. 2. **Interventional Endoscopic Ultrasound (EUS)**: This technique uses ultrasound guidance to access the bile ducts through the stomach or intestines. It has gained popularity in recent years due to its high success rate and lower need for repeat interventions. 3. **Percutaneous or Surgical Drainage**: In cases where endoscopic techniques fail, percutaneous or surgical approaches may be used as a last resort. ### Findings from Recent Studies: A recent multicenter study involving 432 patients with SAA evaluated the outcomes of different BD techniques. The study found that: - The overall technical success rate of endoscopic BD was 80.3%, and clinical success was 79.9%. - Outcomes were similar across different types of surgical reconstructions, but patients with Billroth-II reconstruction experienced a higher rate of adverse events (14.4%). - Roux-en-Y reconstruction required more advanced techniques, such as device-assisted enteroscopy ERCP and interventional EUS. - Interventional EUS has become increasingly popular in the last two years, showing significantly better clinical outcomes compared to other techniques. It also reduced the need for repeat interventions during follow-up. ### Conclusion: Endoscopic biliary drainage in patients with surgically altered anatomy remains a challenging procedure with suboptimal success rates. However, advancements in interventional EUS techniques have significantly improved outcomes, making it a promising approach for managing these complex cases. The choice of technique depends on the type of surgical reconstruction, the clinical scenario, and the expertise available at the treating center.

EUS-guided gallbladder drainage in acute cholecystitis

EUS-guided gallbladder drainage (EUS-GBD) has emerged as a valuable and reliable treatment option for patients with acute cholecystitis who are considered high-risk for surgical intervention. Acute cholecystitis, an inflammation of the gallbladder typically caused by gallstones, can lead to serious complications if untreated. While surgery remains the standard treatment, certain patients, such as those with significant comorbidities or poor overall health, may not be suitable candidates for surgical procedures. In these cases, EUS-GBD provides an effective alternative. EUS-GBD involves the use of endoscopic ultrasound to place a stent, creating a drainage pathway from the gallbladder to the gastrointestinal tract. This approach eliminates the need for external drainage, as seen in percutaneous transhepatic gallbladder drainage, and offers a minimally invasive solution with fewer complications. Guidelines now recommend EUS-GBD over percutaneous drainage due to its safety and efficacy. Studies have shown that EUS-GBD achieves high rates of technical and clinical success, with durable outcomes over long-term follow-up. It is associated with low rates of adverse events, such as stent obstruction or infection, and provides effective symptom relief while reducing the need for repeat interventions or hospital readmissions. Overall, EUS-GBD represents a transformative option for managing acute cholecystitis in high-risk surgical patients.

EUS-guided Gallbladder drainage in malignant biliary obstruction

EUS-guided gallbladder drainage (EUS-GBD) is an emerging endoscopic technique used in the management of malignant biliary obstruction (MBO), particularly in cases where conventional approaches like endoscopic retrograde cholangiopancreatography (ERCP) are not feasible or have failed. Malignant biliary obstruction commonly occurs due to cancers such as pancreatic cancer, cholangiocarcinoma, or other malignancies that block the bile ducts, leading to complications like jaundice, cholangitis, and liver dysfunction. Effective biliary drainage is critical to relieve symptoms, improve quality of life, and prepare patients for further treatments like chemotherapy or surgery. ### Why EUS-GBD is Important: EUS-GBD has gained attention as a minimally invasive alternative to traditional methods for biliary drainage. It is particularly valuable in cases where the bile ducts are inaccessible or when patients have anatomical or technical challenges that make other approaches difficult. EUS-GBD involves using endoscopic ultrasound to access the gallbladder and place a lumen-apposing metal stent (LAMS) to establish drainage. This approach can be especially beneficial in patients who have not undergone a prior cholecystectomy and have a patent cystic duct, allowing for effective drainage through the gallbladder. ### Key Findings from the recent literature: 1. **Clinical Success**: EUS-GBD was shown to have a high rate of clinical success, meaning it effectively relieved symptoms and resolved biliary obstruction in the majority of patients. Its efficacy was found to be comparable to EUS-guided choledochoduodenostomy (EUS-CDS), another advanced technique for biliary drainage. 2. **Technical Success**: The technical success rate of EUS-GBD was also high, indicating that the procedure could be performed successfully in most cases without significant technical challenges. 3. **Safety**: EUS-GBD demonstrated a favorable safety profile, with a similar rate of adverse events compared to EUS-CDS. Serious complications were relatively rare in both groups. 4. **Patient Selection**: EUS-GBD may be particularly suitable for patients with distal malignant biliary obstruction who have not undergone a cholecystectomy and have a clearly patent cystic duct. This makes it a viable first-line option in carefully selected patients. ### Advantages of EUS-GBD: - Minimally invasive and can be performed endoscopically without the need for surgery. - Provides effective biliary drainage, relieving symptoms such as jaundice and cholangitis. - Avoids the need for percutaneous drainage, which can be associated with higher morbidity and discomfort. - Can be an alternative to EUS-CDS in certain clinical scenarios. ### Limitations: - EUS-GBD requires specialized expertise and equipment, which may not be available in all centers. - It is not suitable for patients who have undergone a cholecystectomy or those with an obstructed cystic duct. - Long-term outcomes and durability of the stent placement require further study. ### Conclusion: EUS-guided gallbladder drainage represents a promising and effective option for managing malignant biliary obstruction, particularly in patients who are not candidates for traditional approaches like ERCP. The study demonstrated that EUS-GBD is comparable to EUS-CDS in terms of efficacy and safety, making it a valuable addition to the therapeutic arsenal for biliary drainage in patients with distal malignant biliary obstruction. Careful patient selection and expertise in advanced endoscopic techniques are critical to achieving optimal outcomes.

EUS - Performance matrix by ESGE

Key takeaways from the European Society of Gastrointestinal Endoscopy (ESGE) guidelines for the performance matrix in endoscopic ultrasound (EUS): 1. **Informed Patient Consent**: ESGE mandates that informed patient consent must be obtained for 100% of EUS procedures to ensure ethical and legal compliance. 2. **Adequate Documentation of Landmarks**: At least 90% of EUS procedures should include detailed documentation of anatomical landmarks to maintain high-quality diagnostic standards. 3. **Structured Training and Supervision**: ESGE recommends structured training programs for EUS trainees, with at least 20% of procedures involving supervised training using assessment tools to ensure competency development. 4. **Standardized Description of Pancreatic Cystic Lesions**: A standardized description of pancreatic cystic lesions should be provided in at least 85% of cases to ensure uniform reporting and clinical decision-making. 5. **Diagnostic Tissue Acquisition**: ESGE emphasizes diagnostic tissue acquisition using EUS-guided fine-needle aspiration (FNA) or fine-needle biopsy (FNB) for solid lesions, with a success rate of ≥85% of procedures. 6. **Adverse Events Monitoring**: Adverse events should be kept below 5% for procedures involving cystic lesions and below 3% for solid lesions, ensuring patient safety. 7. **Updated Antibiotic Use for Cystic Lesions**: The previous recommendation to administer antibiotics for EUS-guided puncture of cystic lesions has been omitted in the current guideline due to recent evidence suggesting it may not be necessary. 8. **Quality Assessment at Center Level**: ESGE emphasizes the importance of monitoring and evaluating EUS performance metrics at both the center and individual endoscopist levels to ensure consistent quality. 9. **Landmark Documentation as a Quality Indicator**: Proper documentation of anatomical landmarks serves as a critical quality indicator for the accuracy and reliability of EUS procedures. 10. **Training and Assessment Tools**: ESGE advocates for the use of structured assessment tools during EUS training to objectively evaluate the skills of trainees and improve their proficiency. 11. **Focus on Pancreatic Lesions**: Special attention is given to standardizing the description and management of pancreatic cystic lesions, reflecting the importance of accurate diagnosis in this area. 12. **Diagnostic Yield Optimization**: The guideline underscores the importance of optimizing diagnostic tissue acquisition using EUS-guided fine-needle techniques to improve diagnostic yield for solid lesions. 13. **Minimizing Adverse Events**: ESGE sets clear benchmarks for minimizing adverse events in EUS procedures to prioritize patient safety and procedural efficacy. 14. **Evidence-Based Updates**: The guideline reflects recent evidence in its recommendations, such as omitting the routine use of antibiotics for puncturing cystic lesions, showcasing ESGE's commitment to evidence-based practice. 15. **Continuous Quality Improvement**: ESGE encourages centers to adopt these performance measures as part of their continuous quality improvement initiatives, ensuring better outcomes for patients undergoing EUS procedures. These takeaways highlight ESGE's commitment to improving the quality, safety, and effectiveness of endoscopic ultrasound practices across Europe.

Endoscopic papillectomy for laterally spreading lesions of the papilla

Endoscopic papillectomy is a recognized treatment for ampullary lesions, including the rare subtype of laterally spreading lesions (LSLs) of the papilla of Vater. LSLs are characterized by their extensive involvement of the duodenal mucosa, making them distinct and more challenging to treat compared to non-LSL ampullary lesions. A recent study compared the outcomes of endoscopic papillectomy for LSLs versus non-LSLs in matched patient cohorts. The study included 1422 endoscopic papillectomies, with a subset of 232 matched patients (116 LSLs and 116 non-LSLs) based on factors such as age, sex, co-morbidities, and histologic subtype. The primary outcome, complete resection (R0) after the first intervention, was significantly lower in the LSL group (54.3%) compared to the non-LSL group (69.0%). However, after repeated endoscopic interventions, technical success rates were similar for both groups (82.8%). Despite achieving comparable technical success, LSLs exhibited a significantly higher recurrence rate (41.3%) compared to non-LSLs (15.0%) during a median follow-up of 22 months. Additionally, disease-free survival rates at 1 and 3 years were notably lower in the LSL group (61.1% and 44.0%, respectively) compared to the non-LSL group (86.1% and 81.6%, respectively). Complication rates, however, were not significantly different between the two groups (32.8% for LSLs vs. 26.7% for non-LSLs). In conclusion, endoscopic papillectomy is a safe and viable option for treating LSLs of the papilla of Vater, but it often requires multiple interventions to achieve complete resection. The higher recurrence rates associated with LSLs highlight the need for vigilant post-procedure surveillance and follow-up care.

Cyanoacrylate Glue for Gastric Varices

Cyanoacrylate glue is a medical adhesive commonly used in the treatment of gastric varices, particularly in patients with cirrhosis who are experiencing variceal bleeding. Gastric varices are dilated veins in the stomach, which can rupture and lead to life-threatening bleeding. Cyanoacrylate glue is injected endoscopically into the varices to achieve hemostasis by rapidly solidifying upon contact with blood, thereby sealing the bleeding vessels. A randomized controlled trial compared two strategies for cyanoacrylate therapy in patients with cirrhosis and large gastric varices experiencing their first variceal bleed: aggressive and conservative approaches. In the aggressive approach, all visible gastric varices were obliterated with cyanoacrylate glue, while in the conservative approach, only varices with high-risk features or signs of recent bleeding were treated. The study found that both approaches had similar outcomes in terms of 1-year variceal rebleeding rates (18.2% for aggressive vs. 15.0% for conservative) and all-cause mortality (22.2% vs. 32.9%, respectively). Aggressive therapy, however, achieved faster obliteration of varices and required fewer endoscopic sessions. Adverse event rates were comparable between the two groups. In conclusion, while aggressive cyanoacrylate therapy may expedite variceal obliteration, its clinical outcomes are similar to those of conservative therapy, making both approaches viable options depending on patient needs.

EPOC trial

The EPOC trial (Prophylactic clip closure after ESD of large flat and sessile polyps) is a multicenter randomized controlled trial conducted to evaluate the effectiveness of prophylactic clip closure in reducing delayed bleeding rates following colorectal endoscopic submucosal dissection (ESD) of flat and sessile polyps measuring 20–50 mm. The trial was conducted across four institutions in Japan and aimed to address the lack of evidence regarding the efficacy of clip closure in colorectal ESD, as opposed to endoscopic mucosal resection (EMR), where its benefits are better established. ### Key Details of the EPOC Trial: #### **Objective:** To compare the clinically significant delayed bleeding rates between a prophylactic clip closure group and a control group following ESD for colorectal polyps. #### **Design:** - Multicenter randomized controlled trial. - Patients were randomly assigned to two groups: - **Closure group:** Underwent prophylactic clip closure after ESD. - **Control group:** Did not receive clip closure after ESD. - The trial included both intention-to-treat (ITT) and per-protocol (PP) analyses. #### **Primary Endpoint:** The delayed bleeding rate after colorectal ESD. #### **Secondary Endpoints:** - Severe delayed bleeding rates. - Delayed perforation rates. - Post-ESD coagulation syndrome rates. #### **Results:** 1. **Delayed Bleeding Rates:** - ITT analysis showed delayed bleeding rates of **6.7%** in the closure group and **20.1%** in the control group. - The absolute risk difference (ARD) for delayed bleeding was **13.5%** (95% CI: 5.6% to 20.9%), with an odds ratio (OR) of **0.28** (95% CI: 0.13 to 0.60; p<0.001). 2. **Severe Delayed Bleeding Rates:** - Severe delayed bleeding rates were **1.3%** in the closure group and **8.7%** in the control group. - ARD was **7.4%** (95% CI: 2.2% to 12.4%), with an OR of **0.14** (95% CI: 0.03 to 0.64; p=0.003). 3. **Multivariate Analysis:** - Prophylactic clip closure was identified as a significant independent preventive factor for both delayed bleeding (OR: **0.22**; 95% CI: 0.08 to 0.50; p<0.001) and severe delayed bleeding (OR: **0.22**; 95% CI: 0.05 to 0.76; p=0.015). 4. **Other Findings:** - No cases of delayed perforation were observed. - Post-ESD coagulation syndrome rates were not significantly different between the closure and control groups. - Clip closure was successfully achieved in approximately **90% of cases**. #### **Conclusion:** Prophylactic clip closure significantly reduced delayed bleeding rates following colorectal ESD for polyps measuring 20–50 mm. It was recommended as a preventive measure to improve safety outcomes in colorectal ESD procedures. #### **Implications for Practice and Policy:** The study supports the adoption of prophylactic clip closure as a standard practice after colorectal ESD to mitigate the risk of delayed bleeding, which is a common and serious complication.

Laterally spreading tumors

Laterally spreading tumors (LSTs) are a distinct category of colorectal lesions characterized by their nonpolypoid, flat appearance and their lateral growth pattern rather than vertical growth. These lesions are defined as being at least 1 cm in size and are considered precancerous or potentially cancerous. LSTs are important to identify and classify due to their unique growth behavior and varying risks of malignancy. They are generally detected during colonoscopy and are often more challenging to identify compared to polypoid lesions due to their flat morphology. Early detection and removal of LSTs are critical to prevent progression to colorectal cancer. ### Categories of LSTs: LSTs are broadly divided into two main categories: granular (LST-G) and non-granular (LST-NG). These subtypes are differentiated based on their surface appearance and histological features, and each has distinct clinical implications. 1. **Granular (LST-G):** LST-G lesions are characterized by a granular surface, often appearing as a collection of small nodules or granules. These lesions are more common and generally have a lower risk of malignant transformation, with approximately 10% containing cancer. LST-Gs are further subcategorized into homogeneous and nodular mixed types. Homogeneous LST-Gs have a uniform granular appearance, while nodular mixed types have areas of larger nodules. Although the overall risk of malignancy is low, larger lesions or those with mixed nodular patterns may carry a slightly higher risk. 2. **Non-Granular (LST-NG):** LST-NG lesions have a smooth or flat surface without granularity. They are less common but are associated with a significantly higher risk of malignancy, with up to 33% of these lesions containing cancer. LST-NGs are further classified into flat-elevated and pseudo-depressed types. The pseudo-depressed subtype, in particular, is highly suspicious for malignancy and requires careful evaluation and management. Due to their higher cancer risk, LST-NG lesions are often prioritized for removal and histopathological examination. ### Clinical Significance: The distinction between LST-G and LST-NG is essential for determining the appropriate management strategy. LST-G lesions, especially smaller ones, may be managed conservatively or with endoscopic resection, while LST-NG lesions often warrant more aggressive intervention due to their higher potential for malignancy. Advanced endoscopic techniques, such as endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR), are commonly used for the complete removal of these lesions. Regular surveillance and follow-up are also critical for preventing recurrence or progression to colorectal cancer.

Endoscopic Submucosal Dissection for Early Gastric Cancer Using a Novel Bending Attachment

Endoscopic submucosal dissection (ESD) is a minimally invasive technique used for the removal of early-stage gastrointestinal cancers, including early gastric cancer. This procedure allows for precise en bloc resection of lesions while preserving healthy tissue. However, ESD can be technically challenging, particularly in areas where access and visualization are limited, such as the lesser curvature of the upper gastric body. In this context, a novel single-use bending attachment, called the AttachBend, has been successfully utilized to enhance the ESD procedure for a patient with early gastric cancer. The AttachBend is a lightweight accessory designed to provide an additional bending function to a standard thin therapeutic endoscope, addressing the limitations of conventional multibending endoscopes. Traditional multibending endoscopes, while effective, can be expensive, heavier, and may increase operator burden, making them less practical for routine use. ### Case Description The patient presented with early gastric cancer located in the lesser curvature of the upper gastric body. During the ESD procedure, the operator faced technical difficulties due to the orientation of the muscle layer, which was directly facing the endoscope. This positioning made it challenging to maintain a clear view of the submucosal layer and perform safe dissection. To overcome these challenges, the AttachBend was mounted onto the endoscope. This attachment allowed the operator to manually adjust the bending angle of the endoscope, enabling a parallel approach to the muscle layer. This adjustment significantly improved visualization of the submucosal space and facilitated effective countertraction using the endoscopic hood. ### Advantages of the AttachBend 1. **Enhanced Visualization**: The added bending capability provided a better view of the submucosal layer, which is critical for safe and precise dissection. 2. **Improved Maneuverability**: The attachment allowed for more precise positioning of the dissection knife, enabling controlled and smooth dissection of the lesion. 3. **Safety**: The improved access and visualization reduced the risk of complications, such as perforation or incomplete resection. 4. **Cost-Effectiveness**: Unlike multibending endoscopes, the AttachBend is a single-use accessory, offering a more affordable and lightweight alternative without requiring specialized equipment. ### Outcome The use of the AttachBend resulted in successful en bloc resection of the lesion without any adverse events. Pathological examination confirmed complete removal of the cancerous tissue with negative margins, indicating no residual disease. This outcome highlights the practical advantages of the AttachBend in overcoming technical difficulties during gastric ESD. ### Conclusion The AttachBend represents a promising innovation for enhancing the safety, efficiency, and accessibility of gastric ESD in routine clinical practice. By improving access, visualization, and maneuverability, this novel attachment addresses common challenges associated with conventional techniques, offering a cost-effective and operator-friendly solution. Its successful application in this case suggests that it may be a valuable tool for managing early gastric cancer and potentially other gastrointestinal lesions requiring ESD.

Local Recurrence Risk After Horizontal Margin–Positive En Bloc Colorectal ESD

The systematic review and meta-analysis you are referencing provides an in-depth evaluation of the local recurrence risk after en bloc colorectal endoscopic submucosal dissection (ESD) with positive or indeterminate horizontal margins (HM1/x). Here is a detailed breakdown of the findings: ### Key Findings: 1. **Pooled Recurrence Rate**: - Across 11 studies and 441 cases of HM1/x en bloc colorectal ESD, the pooled recurrence rate was found to be **4.3%**. - This indicates that while the recurrence risk is elevated compared to cases with negative horizontal margins (HM0), the absolute risk remains relatively low. 2. **Nature of Recurrences**: - Recurrence typically occurred at a **median of 14 months** post-procedure. - Among the histologically characterized recurrences, the majority (13 out of 16) were **benign (dysplasia)** rather than invasive cancer. - Invasive recurrences were associated with lesions initially classified as having invasive or high-grade dysplasia. 3. **Management of Recurrences**: - Most benign recurrences were successfully treated with **repeat endoscopic procedures**. - Invasive recurrences, however, required **surgical intervention**. 4. **Comparative Risk**: - The recurrence risk was significantly higher in HM1/x cases compared to HM0 cases, with a pooled odds ratio of **8.04**. - Despite this, the recurrence risk for noninvasive lesions was still relatively low, suggesting that the presence of HM1/x margins does not universally indicate a high recurrence risk. 5. **Implications for Surveillance**: - The findings suggest that current surveillance recommendations, which are largely based on data from piecemeal endoscopic mucosal resection, may be overly cautious for en bloc ESD cases with HM1/x margins. - Surveillance strategies could potentially be refined to balance early detection of recurrences with the avoidance of unnecessary interventions, especially for cases with low-risk pathology. ### Contextual Significance: - The study highlights the importance of distinguishing between benign and invasive recurrences when managing patients with HM1/x margins after en bloc ESD. - It also underscores the need for individualized surveillance protocols that take into account the specific pathology and recurrence risk of the lesion. ### Conclusion: The local recurrence risk after en bloc colorectal ESD with positive or indeterminate horizontal margins (HM1/x) is low, at 4.3%, and is predominantly associated with benign dysplasia. Surveillance strategies may need to be adjusted to reflect this low absolute risk, especially for noninvasive lesions, while still ensuring the timely detection and management of any invasive recurrences.

EUS-Guided Gallbladder vs Bile Duct Drainage for Malignant Biliary Obstruction: Multicenter Trial

The study you are referring to is an international multicenter trial that compared two endoscopic ultrasound (EUS)-guided procedures for managing distal malignant biliary obstruction (MBO): EUS-guided gallbladder drainage (EUS-GBD) and EUS-guided choledochoduodenostomy (EUS-CDS). Traditionally, such conditions are managed using endoscopic retrograde cholangiopancreatography (ERCP), but this study explored alternative primary drainage strategies using EUS-guided techniques with lumen-apposing metal stents. ### Key Details of the Study: 1. **Study Design**: - Retrospective observational trial conducted across 28 tertiary care centers. - Timeframe: April 2017 to August 2024. 2. **Participants**: - A total of 291 patients with distal malignant biliary obstruction were included. - The majority of cases (84%) were due to pancreatic cancer. - 82 patients underwent EUS-GBD, while 209 underwent EUS-CDS. 3. **Methodology**: - To minimize selection bias, the study employed 1-to-1 propensity score matching, resulting in 154 matched patients (77 in each group). - Both procedures utilized lumen-apposing metal stents. 4. **Outcomes Compared**: - **Primary Outcome**: Clinical success (defined as effective biliary drainage and resolution of symptoms). - **Secondary Outcomes**: Technical success, adverse events, and overall survival. ### Results: 1. **Technical Success**: - EUS-GBD: 96%. - EUS-CDS: 99%. - Both procedures showed high and comparable rates of technical success. 2. **Clinical Success**: - Clinical success rates were similar between the two groups. 3. **Adverse Events**: - Both procedures had comparable adverse event profiles, indicating similar levels of safety. 4. **Overall Survival**: - No significant difference in overall survival was observed between the two groups. ### Conclusion: The study concluded that EUS-GBD is a viable and effective alternative to EUS-CDS as a first-line therapy for distal malignant biliary obstruction. Both approaches demonstrated high technical and clinical success rates, comparable safety profiles, and similar survival outcomes. This suggests that the choice between EUS-GBD and EUS-CDS can be guided by factors such as anatomical considerations, operator expertise, and patient-specific characteristics. ### Implications: This trial supports the use of EUS-guided procedures as effective alternatives to ERCP in managing distal MBO. The findings reinforce the flexibility in choosing between EUS-GBD and EUS-CDS, allowing clinicians to tailor their approach to the individual needs of the patient.

Prophylactic Rectal ESD Defect Closure and Post-ESD Outcomes

The study explored the impact of prophylactic closure of rectal ESD (endoscopic submucosal dissection) defects on post-ESD outcomes, focusing on delayed adverse events (DAEs) and post-procedure hospitalization. Here are the key findings: ### Study Details: - **Objective**: To determine whether closing rectal ESD defects prophylactically improves short-term clinical outcomes, particularly reducing delayed bleeding, perforation, and hospitalization. - **Population**: 385 patients who underwent rectal ESD between 2016 and 2023 across 12 centers in North America and Europe. Patients with intraprocedural perforation were excluded. - **Intervention**: Defect closure was achieved in 166 patients (43%) using techniques like endoscopic suturing, clips, or other closure devices. - **Outcome Measures**: Delayed adverse events (DAEs) — defined as bleeding or perforation within two weeks — and post-procedure hospitalization rates were analyzed. ### Key Findings: 1. **Delayed Adverse Events (DAEs)**: - Overall, DAEs occurred in **5.5%** of patients. - Risk factors for DAEs included chronic anticoagulant use, NICE 3 lesions (high-risk features), and incomplete resections. - Prophylactic defect closure did not significantly reduce the overall rate of DAEs compared to leaving defects open. - **Delayed perforations** were observed exclusively in the open-defect group, while no perforations occurred in patients with closed defects. 2. **Hospitalization and Recovery**: - Patients with defect closure had significantly lower rates of overnight hospital admission or observation following ESD. - This suggests that defect closure may improve post-procedure recovery and reduce healthcare resource utilization. 3. **High-Risk Subgroups**: - In patients with higher risk factors (e.g., anticoagulant use or challenging lesions), defect closure showed a numerical reduction in DAEs, though the difference was not statistically significant. ### Clinical Implications: - **Routine Closure**: The study indicates that prophylactic closure may not be necessary for all rectal ESD cases. - **Selective Closure**: Closure is recommended for high-risk patients (e.g., those on anticoagulants or with high-risk lesions) to reduce complications like delayed perforation and hospitalization. ### Conclusion: Prophylactic closure of rectal ESD defects has nuanced benefits. While it may not universally reduce delayed adverse events, it prevents delayed perforation and improves post-procedure recovery, particularly in high-risk patients. The findings suggest a tailored approach, focusing on selective closure for patients with elevated risk profiles to optimize outcomes and resource utilization.

Efficacy of PEG–Ascorbic Acid Plus Linaclotide vs Senna for Bowel Preparation (APPLE Trial)

The APPLE trial (Efficacy of PEG–Ascorbic Acid Plus Linaclotide vs Senna for Bowel Preparation) was a multicenter, endoscopist-blinded, randomized controlled trial conducted across five centers in Japan. The study aimed to evaluate whether adding linaclotide to a low-volume bowel preparation regimen (polyethylene glycol plus ascorbic acid, 1L-PEG) improves bowel cleansing efficacy compared to senna. ### Study Design: - **Participants**: A total of 1,464 outpatients scheduled for colonoscopy. - **Intervention Groups**: 1. **1L-PEG/AL**: 1 L polyethylene glycol plus ascorbic acid with 0.5 mg linaclotide. 2. **1L-PEG/AS**: The same regimen with 24 mg senna. - **Primary Endpoint**: Adequate bowel preparation assessed using the Boston Bowel Preparation Scale (BBPS). ### Key Findings: 1. **Efficacy**: - The linaclotide regimen (1L-PEG/AL) achieved significantly higher rates of adequate bowel preparation compared to the senna regimen (1L-PEG/AS): **92% vs 86%**. - Linaclotide showed superior overall and segmental BBPS scores. - The benefit of linaclotide was most pronounced in **high-risk patients** for inadequate bowel preparation, where adequacy reached **94%** with linaclotide compared to **86%** with senna. - In **low-risk patients**, both regimens performed equally well. 2. **Tolerability and Safety**: - Both regimens had similar tolerability, with comparable rates of side effects such as nausea, abdominal pain, sleep disturbances, and willingness to repeat the preparation. - Linaclotide led to an earlier onset of bowel movements and increased defecation before the intake of PEG, without increasing adverse events. 3. **Colonoscopy Outcomes**: - Colonoscopy completion rates, procedure times, and lesion detection rates were comparable between the two regimens. ### Conclusion: The APPLE trial demonstrated that the linaclotide-enhanced low-volume bowel preparation regimen (1L-PEG/AL) provides **superior cleansing efficacy** compared to the senna regimen (1L-PEG/AS), particularly in high-risk patients, while maintaining similar safety and patient acceptability. Linaclotide represents a promising option for improving bowel preparation, especially in patients at high risk of inadequate cleansing.

Spray vs Forced Coagulation in ESD for Early Gastric Neoplasms

The comparison between Spray Coagulation Mode (SCM) and Forced Coagulation Mode (FCM) in Endoscopic Submucosal Dissection (ESD) for early gastric neoplasms has been thoroughly investigated in a multicenter randomized controlled trial conducted across five Japanese institutions. Below is a detailed summary of the findings: ### 1. **Primary Challenge in ESD** - Intraoperative bleeding is a major technical challenge during ESD for early gastric neoplasms, often requiring the use of hemostatic forceps. ### 2. **Study Objective** - The trial aimed to compare the hemostatic effectiveness of SCM-ESD and FCM-ESD in controlling bleeding during ESD. ### 3. **Study Design** - The study was a prospective, multicenter, randomized controlled trial with balanced randomization (1:1). Stratification was based on tumor location, size, and antithrombotic use to ensure validity and generalizability. ### 4. **Key Findings** #### a. **Knife-Only Completion Rate** - SCM-ESD achieved a significantly higher rate of successful ESD completion using only the knife without the need for hemostatic forceps compared to FCM-ESD. #### b. **Reduced Dependence on Hemostatic Forceps** - SCM-ESD markedly decreased both the number and duration of hemostatic forceps use, streamlining the procedure and reducing interruptions. #### c. **Improved Hemostasis** - Spray coagulation provided broader and more stable coagulation, which enhanced bleeding control during submucosal dissection. #### d. **Procedure Time and Dissection Speed** - Despite better bleeding control, the total procedure time and submucosal dissection speed were similar between SCM-ESD and FCM-ESD groups. #### e. **Oncologic Outcomes** - Both groups achieved high rates of en-bloc resection (removal of the tumor in a single piece) and complete (R0) resection, with no significant differences observed. - Curative resection rates were also comparable, indicating that SCM-ESD did not compromise oncologic efficacy. #### f. **Injection Volume** - SCM-ESD required significantly less submucosal injection volume compared to FCM-ESD, which may contribute to procedural efficiency and cost reduction. #### g. **Safety Profile** - Adverse event rates, including intraoperative bleeding and perforation, were low and comparable between the two groups. - SCM-ESD did not increase thermal damage, ensuring that pathological margin assessments were not impaired. #### h. **Benefit for Nonexperts** - SCM-ESD demonstrated improved hemostasis outcomes even when performed by less experienced endoscopists, highlighting its potential to benefit a wider range of practitioners. #### i. **Antithrombotic Use** - The benefits of SCM-ESD were less pronounced in patients receiving antithrombotic agents, suggesting that caution is needed in this subgroup. #### j. **Workflow Efficiency** - SCM-ESD simplified the workflow by reducing the need for device exchanges, thereby minimizing procedural interruptions and enhancing efficiency. ### 5. **Clinical Implications** - SCM-ESD is a promising technique for ESD in early gastric neoplasms, offering several advantages: - Improved bleeding control. - Reduced dependence on hemostatic forceps. - Streamlined workflow and reduced procedural costs. - Preservation of safety and oncologic efficacy. - These benefits make SCM-ESD particularly appealing for less experienced endoscopists and in settings where procedural efficiency is a priority. ### 6. **Limitations** - The benefits of SCM-ESD were less pronounced in patients on antithrombotic therapy, which may require additional strategies for optimal bleeding control in this subgroup. ### 7. **Conclusion** - Spray coagulation mode (SCM) represents a significant advancement in ESD for early gastric neoplasms, addressing the challenge of intraoperative bleeding while maintaining safety, efficacy, and efficiency. It is a valuable technique for improving outcomes and simplifying the procedure for both expert and nonexpert endoscopists.

Impact of the S–O Clip on Endoscopic Submucosal Dissection Outcomes: A Meta-Analysis

The meta-analysis on the impact of the S–O clip on Endoscopic Submucosal Dissection (ESD) outcomes provides compelling evidence supporting the clinical benefits of this traction device. Below is a detailed summary of the findings: ### **Background and Challenges in ESD** Endoscopic submucosal dissection (ESD) is a highly effective technique for removing early gastrointestinal (GI) neoplasms with en-bloc resection. However, it is technically demanding and associated with challenges such as: 1. **Poor submucosal visibility** during dissection. 2. **Long procedure times**, increasing operator fatigue and potential complications. 3. **Risk of complications** such as bleeding and perforation. To address these limitations, traction devices like the S–O clip have been developed to improve procedural efficiency and safety. ### **Role and Mechanism of the S–O Clip** The S–O clip is a specialized traction device designed to enhance submucosal exposure during ESD. Its **spring-and-loop mechanism** provides stable counter-traction, enabling better visibility of submucosal layers and facilitating precise dissection. Importantly, the design minimizes obstruction of the endoscopic field, allowing for uninterrupted visualization and manipulation. ### **Meta-Analysis Design** This meta-analysis followed the **PRISMA guidelines** and synthesized evidence from 17 studies involving 1,449 patients. The included studies compared ESD outcomes with and without S–O clip assistance, focusing on procedure efficiency, safety, and resection quality. ### **Key Findings** #### **1. Procedure Time Reduction** The use of the S–O clip significantly shortened ESD procedure times compared to conventional techniques. This is attributed to improved submucosal exposure, which allows for faster and more precise dissection. The reduction in procedure time may also decrease operator fatigue, enhancing technical precision and overall safety. #### **2. Improved Dissection Speed** Dissection speed was consistently higher with S–O clip assistance across studies. This reflects the device's ability to provide stable traction and optimize the efficiency of submucosal dissection. #### **3. Higher En-bloc Resection Rates** The S–O clip modestly but significantly increased **en-bloc resection rates**, which is critical for achieving complete removal of neoplastic tissue and minimizing recurrence risk. This advantage was particularly evident in colorectal ESD. #### **4. Comparable Complete Resection (R0) Rates** Complete resection rates (R0) were similar between S–O clip-assisted and conventional ESD groups, indicating that the device does not compromise the quality of resection. #### **5. Maintained Safety Profile** No significant increase in intraoperative perforation rates was observed with S–O clip use, demonstrating its safety during ESD. Additionally, post-ESD bleeding rates were comparable between S–O clip-assisted and conventional techniques. #### **6. Lesion-Specific Benefits** - **Gastric Lesions**: The S–O clip significantly reduced procedure time and improved dissection speed for gastric neoplasms. - **Colorectal Lesions**: In colorectal ESD, the device resulted in higher en-bloc resection rates and faster dissection. - **Duodenal Lesions**: Evidence for duodenal lesions was limited, though procedure time appeared reduced with S–O clip use. ### **Additional Advantages** #### **1. Reduced Operator Fatigue** Shorter procedure times with the S–O clip may alleviate operator fatigue, which is particularly important for lengthy and complex ESD cases. Reduced fatigue can improve technical precision and minimize the risk of errors. #### **2. Training Implications** The S–O clip may facilitate safer and more efficient ESD performance by less experienced endoscopists. Its ability to enhance submucosal exposure and simplify dissection may serve as a valuable training tool. #### **3. Cost-Effectiveness** While the S–O clip adds to procedural costs, its ability to reduce procedure time and complications may offset device expenses, particularly in high-volume centers. ### **Evidence Quality** The majority of included studies were assessed as **low risk of bias**, with moderate-to-high certainty of evidence for key outcomes such as procedure time, dissection speed, and en-bloc resection rates. ### **Clinical Recommendations** Based on the meta-analysis findings, the S–O clip is a valuable adjunct for ESD, particularly for gastric and colorectal lesions. It improves procedural efficiency without compromising safety or resection quality. While evidence for duodenal lesions is limited, preliminary data suggest potential benefits. The device is recommended for routine use in ESD, especially in high-volume centers and training programs. ### **Conclusion** The S–O clip significantly enhances ESD outcomes by improving submucosal visibility, reducing procedure time, increasing dissection speed, and modestly improving en-bloc resection rates. Its safety profile is comparable to conventional techniques, with no increased risk of perforation or bleeding. These findings support the widespread adoption of the S–O clip as a valuable tool for optimizing ESD performance.

Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in IBD

The comparative efficacy and safety of endoscopic modalities for colorectal cancer (CRC) screening in patients with inflammatory bowel disease (IBD) have been thoroughly investigated in the modern high-definition (HD) endoscopy era. Below is a detailed analysis based on current evidence: --- ### **1. Background: Elevated CRC Risk in IBD** - Patients with long-standing ulcerative colitis and colonic Crohn’s disease are at significantly increased risk for colorectal cancer. - Regular surveillance is critical to detect dysplasia (precancerous lesions) early and improve outcomes. --- ### **2. Study Overview: High-Definition Endoscopy Era** - A network meta-analysis of 26 randomized controlled trials (RCTs) involving 4,159 patients with IBD was conducted. - The primary outcome was the detection of at least one dysplastic lesion per patient. - The analysis compared multiple HD endoscopic modalities, with HD white light endoscopy (HD-WLE) serving as the reference standard. --- ### **3. Findings: Efficacy of Endoscopic Modalities** #### **a. High-Definition White Light Endoscopy (HD-WLE):** - Used as the reference standard for comparison. - Found to be effective but not the most sensitive modality for dysplasia detection. #### **b. High-Definition Dye-Based Chromoendoscopy (HD-CE):** - Demonstrated a **small but measurable improvement** in dysplasia detection compared to HD-WLE. - The magnitude of benefit ranged from trivial to moderate, with low-certainty evidence based on GRADE criteria. - This technique involves applying dyes (e.g., methylene blue or indigo carmine) to enhance mucosal visualization. #### **c. Virtual Chromoendoscopy (e.g., Narrow Band Imaging):** - Did not show significant improvement in dysplasia detection over HD-WLE. - The evidence suggests that virtual chromoendoscopy may not be superior for surveillance in IBD patients. #### **d. Full-Spectrum Endoscopy:** - No clear difference in dysplasia detection compared with HD-WLE due to imprecise estimates. - Further studies are needed to clarify its effectiveness. #### **e. Autofluorescence Imaging:** - Showed very low-certainty evidence and no reliable advantage in dysplasia detection. - This technique remains investigational in the context of IBD surveillance. #### **f. HD-WLE with Segmental Reinspection:** - Inconclusive benefit due to very low-certainty evidence. - This approach involves re-examining specific segments of the colon for missed lesions. #### **g. Targeted Biopsies:** - No modality demonstrated high-certainty superiority for dysplasia detection from targeted biopsies. - Targeted biopsies remain a cornerstone of surveillance but are dependent on the quality of visualization. #### **h. Random Biopsies:** - Dysplasia detection from random biopsies was rare, limiting their utility in meaningful comparisons. - This finding aligns with the growing preference for targeted biopsies over random sampling. --- ### **4. Safety Profile Across Modalities** - Serious adverse events were **rare** across all endoscopic modalities, indicating an acceptable safety profile for CRC surveillance in IBD patients. --- ### **5. Key Takeaways:** - **HD Dye-Based Chromoendoscopy (HD-CE)** offers a modest improvement in dysplasia detection over HD-WLE but with low-certainty evidence. - Other advanced techniques (e.g., virtual chromoendoscopy, full-spectrum endoscopy, autofluorescence imaging) did not demonstrate consistent superiority over HD-WLE. - Dysplasia detection from random biopsies was infrequent, reinforcing the importance of high-quality mucosal visualization and targeted biopsies. - The choice of modality should balance efficacy, availability, cost, endoscopist expertise, and practical feasibility. --- ### **6. Implications for Guidelines and Clinical Practice** - These findings directly inform guidelines for CRC surveillance in IBD patients. - While HD dye-based chromoendoscopy may be preferred for its slight advantage in dysplasia detection, HD-WLE remains a widely used and effective option. - No single modality demonstrated clear, consistent superiority, emphasizing the need for individualized decision-making in clinical practice. --- ### **7. Recommendations for Clinical Decision-Making** - **Patient Factors:** Consider disease duration, severity, and prior dysplasia history. - **Endoscopist Expertise:** Techniques like HD dye-based chromoendoscopy require training and experience. - **Resource Availability:** Not all centers may have access to advanced modalities like virtual chromoendoscopy or autofluorescence imaging. - **Cost and Feasibility:** HD-WLE is cost-effective and widely available, making it a practical choice in many settings. --- ### **Conclusion** While HD dye-based chromoendoscopy offers a slight improvement in dysplasia detection, the overall differences between modalities are modest. HD-WLE remains a reliable and accessible option for CRC surveillance in IBD patients. Future research is needed to clarify the role of emerging technologies and optimize surveillance strategies.

Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis

Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis (LCH) provides critical insights into the rare and under-recognized gastrointestinal (GI) manifestations of this disease. Below is a detailed overview of the findings and implications: ### 1. **Rarity and Multisystem Nature of LCH:** - Adult-onset LCH is uncommon, and gastrointestinal involvement is particularly rare. - LCH is a multisystem disease that can affect various organs simultaneously, including the oral cavity, lungs, and GI tract. ### 2. **Endoscopic Findings Across the GI Tract:** - **Esophageal Involvement:** - Lesions in the esophagus were characterized by distinct patterns, including: - Raised plaques with central depressions. - Radial telangiectasia. - Barnacle-like satellite nodules. - These findings are unique and contribute to the recognition of esophageal LCH. - **Gastric Involvement:** - Gastric lesions presented with a diverse range of appearances, such as: - Ulcerative defects. - Firm submucosal protrusions with surface erosion. - These findings highlight the variability of gastric LCH manifestations. - **Colorectal Involvement:** - Colonic lesions appeared as clustered submucosal masses, with a predilection for the ileocecal and sigmoid regions. - The submucosal nature of these lesions often made them difficult to detect on superficial examination. ### 3. **Submucosal Predominance and Diagnostic Challenges:** - Many LCH lesions were predominantly subepithelial, with intact overlying mucosa. - This submucosal location complicates the ability to diagnose the disease through superficial biopsies. - A novel endoscopic observation, termed the "mucosal fragmentation sign," was identified during resection. This sign refers to fragile mucosa overlying tumor tissue, likely caused by pressure from expanding submucosal infiltration. ### 4. **Histologic and Molecular Confirmation:** - Diagnosis of LCH relies on histological confirmation of Langerhans cells, which are positive for markers such as: - CD1a. - S100. - Langerin. - Additionally, the presence of the BRAF V600E mutation supports the neoplastic nature of adult LCH. ### 5. **Importance of Deep Biopsies:** - Given the submucosal predominance of LCH lesions, deep biopsies are essential to obtain diagnostic tissue. - Superficial biopsies may fail to capture the underlying pathology, leading to missed or delayed diagnosis. ### 6. **Imaging Limitations:** - Conventional imaging methods, including PET scans, often fail to detect mucosal or submucosal GI LCH lesions. - Endoscopic evaluation is therefore critical for identifying these lesions. ### 7. **Differential Diagnosis and Misdiagnosis Risk:** - GI LCH may mimic other conditions such as carcinoma, lymphoma, or inflammatory diseases. - This overlap increases the risk of misdiagnosis, emphasizing the need for heightened clinical awareness. ### 8. **Clinical Implications and Recommendations:** - **Proactive Endoscopy:** - Patients with confirmed LCH, even in the absence of digestive symptoms, should undergo systematic gastrointestinal endoscopy to detect potential GI involvement. - **Recognition of Endoscopic Patterns:** - Awareness of the characteristic endoscopic findings (e.g., raised plaques, submucosal masses, mucosal fragmentation) can facilitate earlier diagnosis in atypical cases. - **Multidisciplinary Approach:** - Collaboration between gastroenterologists, pathologists, and oncologists is crucial for accurate diagnosis and management. ### 9. **Significance of the Case:** - This case uniquely documents concurrent involvement of the esophagus, stomach, and colon in an adult patient with LCH. - It underscores the value of systematic endoscopic characterization in identifying widespread GI lesions that may not be apparent on imaging or present with overt symptoms. ### 10. **Conclusion:** - Systematic endoscopic evaluation is a vital diagnostic tool in detecting synchronous GI involvement in multisystem LCH. - Early recognition and deep biopsy of characteristic lesions can lead to timely diagnosis and appropriate management, improving outcomes for patients with this rare disease.

Endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis

The endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis (LCH) involves identifying specific patterns and features across the gastrointestinal (GI) tract. This is particularly important as GI involvement in adult-onset LCH is rare and often under-recognized. Below is a detailed description of the endoscopic findings and their implications: ### 1. **Esophageal Involvement** - **Appearance of Lesions**: The esophageal lesions in LCH typically present as raised plaques with central depressions. These plaques may also exhibit: - Radial telangiectasia (dilated blood vessels radiating outward). - Barnacle-like satellite nodules surrounding the primary lesion. - **Endoscopic Recognition**: These findings are distinct and can serve as a clue to the diagnosis, especially when combined with systemic manifestations of LCH. - **Challenges**: Superficial biopsies may not always capture diagnostic tissue due to the subepithelial nature of the lesions. ### 2. **Gastric Involvement** - **Lesion Diversity**: Gastric lesions in LCH can show a variety of morphologies, including: - Ulcerative defects with visible surface erosion. - Firm submucosal protrusions that may appear as masses beneath the mucosa. - **Diagnostic Difficulty**: The submucosal predominance of gastric lesions often complicates diagnosis, as the overlying mucosa may remain intact or only superficially eroded. - **Novel Endoscopic Sign**: The “mucosal fragmentation sign” has been described during endoscopic resection. This sign indicates fragile mucosa overlying tumor tissue, which fragments easily due to outward pressure from the submucosal tumor. ### 3. **Colorectal Involvement** - **Distribution and Morphology**: In the colon, LCH lesions often appear as clustered submucosal masses. These are particularly prominent in: - The ileocecal region. - The sigmoid colon. - **Endoscopic Features**: The lesions are primarily subepithelial, with intact or minimally altered mucosa, which can obscure their detection during routine endoscopy. - **Clinical Implications**: Colorectal lesions may mimic other conditions like carcinoma or lymphoma, increasing the risk of misdiagnosis. ### 4. **Submucosal Predominance** - Across the esophagus, stomach, and colon, a key feature of GI LCH lesions is their submucosal location. This makes superficial biopsies less effective, and deep biopsies are often required to retrieve diagnostic tissue. - **Histologic Confirmation**: Once tissue is obtained, the diagnosis is confirmed by identifying Langerhans cells that are positive for markers such as CD1a, S100, and Langerin. ### 5. **Endoscopic Challenges and Diagnostic Strategies** - **Imaging Limitations**: Conventional imaging and even PET scans may fail to detect these mucosal or submucosal lesions, emphasizing the critical role of endoscopy. - **Biopsy Technique**: Deep biopsies are essential for accurate diagnosis. The “mucosal fragmentation sign” can guide endoscopists in identifying areas for targeted sampling. - **Differential Diagnosis**: GI LCH lesions may mimic other diseases, including carcinoma, lymphoma, or inflammatory bowel disease. Recognizing the characteristic endoscopic patterns is key to avoiding misdiagnosis. ### 6. **Asymptomatic Involvement** - Extensive GI involvement can occur even in patients without digestive symptoms. This underscores the importance of proactive endoscopic evaluation in patients with confirmed LCH, regardless of symptomatology. ### 7. **Clinical Recommendations** - Patients with multisystem LCH should undergo a systematic and comprehensive endoscopic evaluation of the GI tract, even if they are asymptomatic. - Awareness of the specific endoscopic patterns associated with LCH can facilitate earlier and more accurate diagnosis, improving patient outcomes. ### Summary Endoscopic findings in synchronous esophageal, gastric, and colorectal involvement in LCH are distinct and can include raised plaques, submucosal protrusions, ulcerations, and clustered masses. The submucosal predominance of these lesions often necessitates deep biopsies for diagnosis. Recognizing characteristic endoscopic patterns, such as radial telangiectasia, barnacle-like nodules, and the mucosal fragmentation sign, is crucial for identifying GI LCH. Proactive endoscopic evaluation is recommended in all patients with confirmed LCH to detect potential GI involvement, even in the absence of symptoms.

ER-STER for cervical esophageal submucosal tumors via PEG

ER-STER (Endoscopic Retrograde Submucosal Tunnel Resection) represents an innovative approach to address the challenges of resecting cervical esophageal submucosal tumors (SMTs), which are difficult to access and treat using conventional endoscopic techniques due to the limited maneuvering space and proximity to the upper esophageal sphincter (UES). This method utilizes a retrograde approach via a percutaneous endoscopic gastrostomy (PEG) to overcome these limitations. ### Key Features of ER-STER: 1. **Concept and Purpose**: - ER-STER proposes accessing cervical esophageal SMTs retrogradely through a PEG tract, rather than the conventional oral route. - This approach aims to enlarge the working space and reduce manipulation near the sensitive UES region, minimizing discomfort for the patient. 2. **Procedure Overview**: - A submucosal tunnel is created from the anal side of the esophagus (via the PEG tract) to the tumor site. This tunnel allows en bloc resection of the SMTs in the cervical esophagus. - The retrograde access improves visualization and maneuverability, which are often compromised in oral-side tunneling due to space constraints. 3. **Steps Involved**: The ER-STER procedure consists of six key stages: - **Preoperative Evaluation**: Imaging and planning to determine tumor location and feasibility of PEG placement. - **PEG Creation**: A PEG is inserted in the left upper quadrant under imaging guidance, avoiding major vessels and the gastric antrum. - **Scope Insertion**: A gastroscope (slim or therapeutic) is introduced retrogradely through the PEG tract. - **Lesion Localization**: The tumor is identified using pre-marked clips or tattooing for orientation. - **Retrograde Tunnel Resection**: Submucosal injection creates a stable tunnel from the anal side, enabling precise tumor removal. - **Closure of Access Sites**: Both the PEG site and the submucosal tunnel are closed to prevent complications. 4. **Technical Considerations**: - **Submucosal Injection**: Performed 3–5 cm beyond the lesion on the anal side to ensure a stable tunnel. - **Orientation Control**: Clips or tattooing placed orally before the procedure prevent disorientation during retrograde tunneling. - **Insufflation Management**: Low-pressure carbon dioxide insufflation minimizes leakage and ensures safe lumen distension. - **Navigating Tight Spaces**: Techniques like gentle torque control, patient head elevation, and using slimmer scopes help overcome the narrow thoracic inlet. 5. **Advantages**: - Enlarged working space and improved visualization compared to oral-side STER. - Reduced manipulation near the UES, which decreases patient discomfort. - Preservation of overlying mucosa, minimizing the risk of postoperative strictures. - Better orientation during tumor resection, enhancing procedural accuracy. 6. **Safety Measures**: - Peri-procedural antibiotics to prevent stoma infection or mediastinal contamination. - Careful handling of the PEG tract and use of CO₂ insufflation to reduce perforation and leakage risks. - Expert endoscopic technique to avoid retrograde perforation. 7. **Potential Risks**: - PEG-related complications such as stoma infection, retrograde perforation, or mediastinal contamination. - Stricture formation, though less likely due to mucosal preservation. - Theoretical risks of procedural failure due to anatomical or technical challenges. ### Current Status and Future Directions: - **Validation Phases**: - ER-STER is still a theoretical concept and has not yet undergone preclinical or clinical testing. - Structured feasibility studies, including cadaveric testing, animal studies, and pilot human trials, are needed to assess its safety and efficacy. - Evaluation metrics will focus on en bloc resection rate, perforation risk, infection incidence, stricture formation, and procedural time. - **Limitations**: - The technique lacks preclinical or clinical data to confirm its effectiveness and safety. - Requires specialized training and expertise in retrograde tunneling and PEG-related procedures. - **Future Potential**: - ER-STER holds promise as a novel solution for difficult-to-access cervical esophageal SMTs. - If validated through rigorous studies, it could become a standard approach for these challenging cases, offering significant advantages over conventional methods. In summary, ER-STER via PEG introduces a groundbreaking retrograde technique for cervical esophageal SMTs, addressing the limitations of conventional oral-side endoscopic resection methods. While promising, it remains theoretical and warrants thorough preclinical and clinical validation to establish its feasibility and safety.

Robotic endoscopic resection

Robotic endoscopic resection refers to the use of robotic systems to perform advanced endoscopic procedures, particularly for the removal of large or complex lesions in the gastrointestinal (GI) tract. One of the most promising applications of robotic technology in this field is robotic endoscopic submucosal dissection (ESD), which aims to address the limitations of traditional ESD techniques. ### Background on Endoscopic Submucosal Dissection (ESD) ESD is a minimally invasive procedure used to remove large, superficial lesions (e.g., early-stage tumors or precancerous growths) from the GI tract, such as the esophagus, stomach, or colon. The goal of ESD is to achieve "en bloc" resection, meaning the lesion is removed in one piece. This provides several advantages: - **Better oncologic outcomes:** Complete removal reduces the risk of recurrence and allows for more accurate pathological analysis. - **Simplified follow-up:** Patients may require fewer follow-up procedures, such as colonoscopies. - **Environmental benefits:** Fewer follow-up procedures reduce the overall resource use and waste. Despite its benefits, traditional ESD is highly challenging. It requires advanced technical skills, has a steep learning curve, and is often performed without true triangulation (the ability to use multiple instruments independently in a coordinated way). This makes the procedure functionally "one-armed," limiting its precision and efficiency. ### Robotic Endoscopic Resection: A Solution to Current Limitations Robotic endoscopy, specifically robotic ESD, aims to overcome the technical barriers of traditional ESD. One example of a robotic system designed for this purpose is the **EndoMaster EASE system**, which was introduced in a phase II study led by Professor Chiu. This system incorporates: - **Two independently controlled robotic arms:** These arms allow for both cutting and traction, enabling true triangulation. - **A standard working channel:** This accommodates additional tools for the procedure. ### Key Findings from the EndoMaster EASE Study The study evaluated the performance of the EndoMaster EASE system in 45 cases involving colorectal lesions. The results were promising: - **Technical success rate:** 86% of cases were successfully completed using the robotic system. - **R0 resection rate:** Among successful cases, 83.8% achieved R0 resection, meaning no cancerous cells were left at the margins of the removed tissue. - **Dissection speed:** The median speed was 20.6 mm²/min for lesions with an average size of 34.5 mm. While these results do not yet surpass the performance of expert-level ESD or advanced traction techniques, the robotic system shows significant potential, particularly for less experienced endoscopists. The improved visualization and ability to perform triangulation could also shorten the learning curve for ESD. ### Advantages of Robotic ESD 1. **Improved precision:** The robotic arms allow for better control, cutting, and traction, which are critical for successful en bloc resection. 2. **Enhanced visualization:** High-definition imaging and better control of instruments improve the surgeon's ability to identify and remove lesions accurately. 3. **Shortened learning curve:** The intuitive design of robotic systems may make it easier for less experienced endoscopists to perform complex procedures. 4. **Potential for advanced procedures:** Robotic systems could enable new techniques, such as advanced suturing and closure of complex defects, which are difficult or impossible with traditional ESD. ### Challenges of Robotic Endoscopic Resection Despite its promise, robotic ESD faces several challenges: 1. **High cost:** Robotic systems are expensive to acquire and maintain, which may limit their adoption. 2. **Need for general anesthesia:** Unlike traditional ESD, which can sometimes be performed under sedation, robotic ESD often requires general anesthesia, increasing procedural complexity. 3. **Additional staffing requirements:** A robotic procedure may require a larger team, including specialized operators for the robotic system. 4. **Limited data for certain lesions:** Most studies, including the EndoMaster EASE study, have focused on lesions in the rectosigmoid region. Data on other areas of the GI tract are still limited. 5. **Environmental impact:** While fewer follow-up procedures may reduce waste, the environmental impact of the robotic systems themselves (e.g., energy use, disposable components) remains uncertain. ### Future Implications Robotic endoscopic resection represents a significant advancement in therapeutic endoscopy. As the technology continues to evolve, it has the potential to: - Make complex endoscopic procedures safer, more efficient, and more accessible. - Expand the range of lesions and conditions that can be treated endoscopically. - Reduce the dependence on highly experienced endoscopists, democratizing access to advanced care. However, widespread adoption will depend on addressing the current challenges, particularly the high cost and logistical demands. If these hurdles can be overcome, robotic endoscopic resection could revolutionize the field of therapeutic endoscopy, offering new possibilities for minimally invasive treatment of GI diseases.

The Boškoski–Costamagna ERCP Trainer

The Boškoski–Costamagna ERCP Trainer is an advanced simulation tool designed to aid novice trainees in developing their skills in Endoscopic Retrograde Cholangiopancreatography (ERCP), a complex endoscopic procedure used to diagnose and treat conditions affecting the bile ducts, pancreatic ducts, and gallbladder. This trainer provides a structured and controlled environment for hands-on practice, allowing learners to gain technical proficiency before performing procedures on actual patients. The use of the Boškoski–Costamagna ERCP Trainer offers significant advantages in the training pathway for ERCP. By incorporating simulation-based training early in the learning process, trainees can achieve enhanced outcomes, including: 1. **Improved Biliary Cannulation Success**: Practicing on the simulator allows trainees to refine their techniques for accessing the bile duct, a critical and challenging component of ERCP. 2. **Faster Procedure Times**: Simulation training helps users develop efficiency in performing ERCP, translating into reduced procedure times in real clinical settings. 3. **Accelerated Skill Development**: The hands-on experience provided by the trainer facilitates quicker mastery of essential ERCP skills, enabling trainees to progress toward competence more rapidly. The integration of the Boškoski–Costamagna ERCP Trainer into ERCP education programs is supported by evidence that it enhances trainee performance. By simulating real-life scenarios, it allows learners to practice and refine their skills repeatedly without risk to patients. This structured training approach not only boosts confidence but also has the potential to shorten the time required for trainees to become proficient in ERCP procedures. In summary, the Boškoski–Costamagna ERCP Trainer is a critical innovation in medical education, offering a safe, effective, and efficient way to prepare novice endoscopists for the challenges of ERCP. Its adoption in training programs can lead to better patient outcomes and improved procedural success rates.

EUS guided tissue sampling - ESGE statement

The European Society of Gastrointestinal Endoscopy (ESGE) has issued updated statements and recommendations regarding endoscopic ultrasound (EUS)-guided tissue sampling, emphasizing advancements in needle technology, sampling techniques, and specimen handling to optimize diagnostic accuracy. The key points of the ESGE statement are outlined below: ### 1. **Needle Design and Selection**: - **End-cutting Fine-Needle Biopsy (FNB) Needles**: ESGE recommends end-cutting FNB needles over reverse-bevel FNB or standard fine-needle aspiration (FNA) needles for sampling solid pancreatic lesions. This recommendation is based on evidence showing that end-cutting FNB needles provide superior tissue yield and histologic quality. - **Fine-Needle Aspiration (FNA)**: FNA remains a valuable option when rapid on-site evaluation (ROSE) is available. ROSE allows real-time assessment of sample adequacy, ensuring diagnostic accuracy during the procedure. ### 2. **Subepithelial Lesions (SELs)**: - For SELs measuring **≥20 mm**, ESGE considers both EUS-FNB and mucosal incision–assisted biopsy (MIAB) as equally effective sampling methods. - For SELs measuring **<20 mm**, MIAB may be preferred when the operator has sufficient expertise. MIAB is advantageous for smaller lesions as it allows more precise tissue acquisition. ### 3. **Infection Prevention**: - ESGE no longer recommends routine antibiotic prophylaxis before EUS-guided sampling of solid masses or during EUS-FNA of pancreatic cystic lesions. This change reflects evidence indicating a low risk of infection and the need to avoid unnecessary antibiotic use. ### 4. **Specimen Handling and Diagnostic Accuracy**: - ESGE emphasizes the importance of precision-driven sampling strategies and efficient specimen handling to improve diagnostic outcomes. Proper handling of tissue samples is critical for achieving high histologic quality and accurate diagnoses. ### 5. **Advancements in EUS Technology**: - The updated ESGE review highlights advancements in needle technology and sampling techniques, which have significantly improved the diagnostic yield and quality of EUS-guided tissue acquisition. ### Summary: The ESGE statement underscores the importance of selecting the appropriate needle type, tailoring sampling techniques to the lesion type and size, and adopting evidence-based approaches to specimen handling. These updates are aimed at improving diagnostic outcomes and minimizing unnecessary interventions, such as routine antibiotic prophylaxis, in EUS-guided tissue sampling.

Single-use therapeutic gastroscope

The single-use therapeutic gastroscope is a newly approved disposable device designed for complex therapeutic interventions in gastrointestinal endoscopy. This pilot feasibility study assessed its clinical performance during 19 therapeutic procedures, including gastrointestinal bleeding management, pancreatic necrosectomies, foreign body removals, stent placements, and cryo-balloon ablations. The device demonstrated an 84% intraprocedural technical success rate, with clinical success achieved universally when technical success was attained. However, in 16% of cases, clinicians had to switch to reusable gastroscopes due to limitations like poor visibility, suction occlusion, or inadequate scope angulation. User experience rated the device at 3.2 out of 5, reflecting moderate satisfaction. No adverse events were reported, indicating short-term safety. While the single-use gastroscope shows promise for therapeutic applications, its performance limitations and moderate usability suggest the need for further refinement. Broader studies are required to assess its long-term therapeutic reliability, visual performance, and environmental sustainability compared to reusable endoscopes.

MAPS III guideline updates

The MAPS III guideline updates, set for 2025, provide comprehensive, pragmatic, and risk-stratified recommendations for the detection, staging, treatment, and surveillance of gastric precancerous conditions and early gastric neoplasia. Below is a detailed summary of the updates: --- ### **1. Screening Recommendations:** - **Population-Level Screening:** - Endoscopic screening is suggested every **2–3 years** in high-risk regions (age-standardized incidence rate [ASR] >20 per 100,000). - In **intermediate-risk regions**, screening every **5 years** may be considered if it is cost-effective. - Screening is **not recommended** in low-risk regions. - **Individual Risk Assessment:** - Regardless of geographic origin, **individual gastric cancer risk assessment** is recommended at the time of the **first gastroscopy**. - Screening or surveillance beyond the age of **80 years** is generally discouraged, although patient-specific comorbidities should be considered when planning treatment. --- ### **2. Endoscopy and Biopsy Techniques:** - **High-Quality Endoscopy:** - Use of **virtual chromoendoscopy** (with appropriate training) is recommended for: - Detection of gastric lesions. - Targeted biopsies. - Staging of atrophic gastritis and intestinal metaplasia. - Post-therapy surveillance. - **Biopsy Strategy:** - Random biopsies are only recommended when no visible endoscopic abnormalities are detected. - Suggested biopsy sampling involves: - Two vials with **2 biopsies each** from the **antrum/incisura** and the **corpus**. - **Advanced Imaging:** - Routine advanced imaging (e.g., **EUS, CT, MRI, or PET-CT**) before endoscopic resection is **not recommended** unless: - Deep invasion is suspected. - The suitability of endoscopic resection is uncertain. --- ### **3. Treatment Recommendations:** - **Endoscopic Resection:** - **Endoscopic submucosal dissection (ESD)** is recommended for most differentiated dysplastic or intramucosal cancers, based on size and ulceration criteria. - **Endoscopic mucosal resection (EMR)** may be an option for small, low-risk lesions. - **Post-Resection Management:** - Clear histology-based pathways are outlined: - **Curative/Very Low-Risk Lesions:** Typically require no further treatment. - **Curative/Low-Risk Lesions:** May need further staging or multidisciplinary discussion. - **Local-Risk Lesions:** Favor endoscopic surveillance or re-treatment. - **High-Risk Lesions** (e.g., deep invasion, lymphovascular invasion [LVI], positive vertical margins, large/ulcerated or poorly differentiated tumors): Require staging and multidisciplinary evaluation for additional therapy. --- ### **4. Staging Systems:** - Validated endoscopic grading systems are endorsed for staging gastric precancerous conditions and neoplasia: - **Kimura–Takemoto classification.** - **EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia).** - **OLGA (Operative Link on Gastritis Assessment).** - **OLGIM (Operative Link on Gastric Intestinal Metaplasia Assessment).** --- ### **5. H. pylori Management:** - **H. pylori Eradication:** - Strongly recommended for: - Patients with precancerous conditions (e.g., atrophic gastritis or intestinal metaplasia). - Patients who have undergone therapy for gastric precancerous lesions or early gastric cancer. --- ### **6. Lifestyle and Preventive Measures:** - Patients should be advised to **stop smoking**, as it is a risk factor for gastric cancer. - **Low-dose aspirin** may be considered for cancer prevention in selected individuals who are at high cardiovascular risk. --- ### **Key Considerations:** - The guidelines emphasize **personalized risk assessment** and evidence-based approaches for surveillance and treatment. - Screening and surveillance should be **tailored to the patient's age, risk factors, and comorbidities**, with a focus on avoiding unnecessary procedures in low-risk groups or elderly patients. - The use of advanced endoscopic techniques and validated staging systems ensures the accurate detection and management of gastric precancerous conditions. --- In summary, the 2025 MAPS III guidelines aim to optimize the early detection and management of gastric precancerous conditions and early cancer through risk stratification, high-quality endoscopic techniques, and individualized care plans. These updates reflect the latest evidence and advancements in gastric cancer prevention and treatment.

Water-aided colonoscopy

Water-aided colonoscopy refers to a set of advanced techniques where water is used instead of, or in combination with, gas (such as air or carbon dioxide) during a colonoscopy procedure. These techniques aim to improve the process of colonoscope insertion, enhance visualization of the colon and its lesions, and assist in the resection (removal) of abnormal tissue like polyps or larger lesions. The three main methods under water-aided colonoscopy are **water immersion**, **water exchange**, and **underwater resection**. ### Techniques: 1. **Water Immersion**: - During insertion of the colonoscope, water is infused into the colon and left in place. - This reduces colonic distension (stretching) and prevents the formation of loops in the colon, making the procedure smoother and less uncomfortable for the patient. 2. **Water Exchange**: - Water is infused into the colon during insertion, but it is actively suctioned out along with debris and other material. - This improves the cleanliness of the colon and enhances the visibility of the mucosal (inner) surface during withdrawal, which is critical for detecting abnormalities. 3. **Underwater Resection**: - Lesions, such as polyps, are submerged in water during their removal. - This technique aids in polypectomy (removal of polyps) and advanced resections, such as UEMR (underwater endoscopic mucosal resection) or UESD (underwater endoscopic submucosal dissection). ### Utility of Water-Aided Colonoscopy: - **Improved Adenoma Detection Rates (ADR)**: Water exchange has been shown to increase the detection of adenomas (precancerous polyps), as the enhanced cleanliness and visibility of the colon's surface make it easier to identify abnormalities. - **Better Bowel Cleanliness**: Water exchange removes debris and residual stool during the procedure, resulting in a cleaner colon for examination and resection. - **Enhanced Resection Outcomes**: Underwater resection methods, such as UEMR, are associated with higher rates of en bloc resection (removing the lesion in one piece) and lower recurrence rates compared to conventional methods. - **Reduced Thermal Injury**: The water acts as a "heat sink" during procedures that use electrocautery (heat-based cutting), dissipating thermal energy and potentially reducing the risk of deep tissue injury. - **Comfort and Efficiency**: Water immersion reduces colonic stretching and loop formation, which can make the procedure more comfortable for patients and easier for the endoscopist to navigate the colon. ### Challenges: Despite its benefits, water-aided colonoscopy has barriers to widespread adoption, including longer learning curves for practitioners, additional training time, and reimbursement models that often prioritize procedural volume over outcomes. In summary, water-aided colonoscopy is an innovative approach that enhances the safety, efficiency, and diagnostic accuracy of colonoscopy procedures, particularly for detecting and removing abnormal growths in the colon.

Conventional and underwater ESD for superficial colorectal neoplasms

The study compared conventional endoscopic submucosal dissection (CESD) and underwater endoscopic submucosal dissection (UESD) for removing superficial colorectal neoplasms (SCNs). UESD was hypothesized to offer procedural advantages by utilizing buoyancy to lift lesions, potentially reducing dependence on gravity and improving visualization. The primary endpoint was dissection speed, calculated as the specimen area divided by total procedure time. The trial randomized 139 patients, with 69 undergoing CESD and 70 undergoing UESD. Results showed no significant difference in median dissection speed between the two techniques (CESD: 17.4 mm²/min vs. UESD: 19.9 mm²/min; P=0.19). However, multivariate analysis revealed that the lesion’s position relative to gravity influenced dissection speed. CESD was more effective for lesions on the nongravity side, while UESD performed better for lesions on the gravity side. Both techniques achieved high safety outcomes, with en bloc resection and no perforations. In conclusion, neither technique universally outperformed the other, but tailoring the method to lesion orientation could improve procedural efficiency.

Origami method for duodenal ESD

The Origami Method (OGM) is a modified double-layered suturing technique developed specifically for closing large mucosal defects following duodenal endoscopic submucosal dissection (ESD). Duodenal ESD is a minimally invasive procedure used to remove lesions or tumors from the duodenum but often results in sizeable defects. These defects pose significant risks, including perforation and bleeding, making effective closure techniques critical. ### Key Features of the Origami Method: 1. **Double-Layered Closure**: - The technique involves folding the muscle layer inward and securing it with through-the-scope clips. This creates a double-layered closure that enhances stability and promotes better healing of the defect. 2. **Improved Stability**: - The inward folding of the muscle layer ensures that the closure is robust and durable, minimizing the risk of postoperative complications. 3. **Efficient Procedure**: - The median closure time for OGM is reported to be only 16 minutes, demonstrating its practicality and efficiency in clinical settings. 4. **Safety and Durability**: - In a study of 28 patients, OGM achieved complete closure in 96% of cases (27 out of 28), including the largest lesion with a defect size of 110 mm. - Follow-up endoscopy conducted in 21 patients within 3–5 days post-procedure confirmed that the folded muscle layer remained intact in all cases. - No complications related to clipping were observed, including zero cases of clip-induced perforations, delayed perforations, or delayed bleeding. ### Study Details: - **Patient Pool**: - The study included 28 patients treated between June 2022 and April 2023 at a tertiary hospital. - Lesions in the duodenal bulb or involving the major papilla were excluded from the analysis. - **Defect Size**: - The median defect size was 38 mm, ranging from 26 to 110 mm, indicating the method's capability to handle large defects effectively. ### Advantages of the Origami Method: 1. **High Success Rate**: - Achieved a near-perfect closure rate of 96%. 2. **Safety**: - No complications related to the closure technique were reported. 3. **Durability**: - The folded muscle layer remained intact during follow-up, demonstrating reliable postoperative healing. 4. **Efficiency**: - The median closure time was relatively short, at 16 minutes. ### Clinical Implications: The Origami Method offers a promising alternative to conventional closure techniques for managing large duodenal defects caused by ESD. Its ability to provide reliable, safe, and durable closures makes it highly feasible for clinical use, especially in challenging cases involving large mucosal defects. In summary, OGM represents a significant advancement in duodenal ESD defect management, combining practicality, safety, and effectiveness to reduce postoperative risks and improve patient outcomes.

POEM training in Europe- ESGE Statement

The European Society of Gastrointestinal Endoscopy (ESGE) has issued a comprehensive Position Statement regarding the training curriculum for performing peroral endoscopic myotomy (POEM) in Europe. POEM is an advanced endoscopic procedure that is now recognized as a first-line treatment for achalasia and other spastic esophageal motility disorders. Given the high level of technical expertise required and the potential risks of significant adverse events, ESGE stresses the importance of a structured, standardized training program to ensure safe and effective practice. ### Key Highlights of the ESGE POEM Training Curriculum: #### 1. **Training Foundations** - Trainees must develop a strong theoretical foundation before performing POEM. This includes: - Understanding the pathophysiology of achalasia and other spastic esophageal motility disorders. - Being proficient in diagnostic techniques, such as high-resolution manometry, which is critical for diagnosing and managing these conditions. - Familiarity with expected treatment outcomes and strategies for managing complications. #### 2. **Prerequisites for Training** - Trainees should already have advanced endoscopic skills, particularly in techniques such as Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD). These skills are directly transferable to the submucosal dissection required for POEM. - For those without prior ESD experience, training should include at least **20 simulated POEM procedures** on ex vivo or animal models before progressing to human cases. #### 3. **Observational Training** - Trainees are advised to observe at least **20 live POEM procedures** at expert centers. This allows them to gain insight into the technical nuances, procedural steps, and decision-making processes involved in POEM. #### 4. **Hands-On Clinical Training** - Trainees should perform a minimum of **10 supervised human POEM cases** under the guidance of experienced mentors. - It is recommended to begin with straightforward cases, avoiding complex or high-risk cases during the early stages of training. - The goal is for trainees to be able to independently complete all steps of the POEM procedure by the end of their training. #### 5. **Competency Evaluation** - Competency is assessed based on: - Procedural success. - Clinical outcomes (e.g., improvement in symptoms and quality of life). - Low rates of adverse events. - The evaluation should ensure that the trainee can perform the procedure safely and effectively. #### 6. **Quality Assurance and Continuous Improvement** - Centers offering POEM training are encouraged to maintain prospective registries of their procedures. These registries will help monitor the quality of training, track clinical outcomes, and ensure continuous improvement in the field. #### 7. **Consensus-Based Development** - The recommendations in the ESGE Position Statement were developed through a systematic review of the literature and a Delphi consensus process. This involved collaboration with expert POEM endoscopists from across Europe to ensure the curriculum is both evidence-based and practical. ### Conclusion: The ESGE emphasizes that the structured training program outlined in this Position Statement is crucial for maintaining high standards of care and patient safety in the practice of POEM. By adhering to these recommendations, trainees can develop the necessary skills and knowledge to perform POEM with precision and confidence, ultimately improving patient outcomes.

Biliary drainage prior to pancreatoduodenectomy with EUS-guided choledochoduodenostomy versus conventional ERCP

The study compared two methods of preoperative biliary drainage for patients undergoing pancreatoduodenectomy: endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) and conventional endoscopic retrograde cholangiopancreatography (ERCP). Preoperative biliary drainage is often necessary but can lead to complications that complicate surgery. EUS-CDS has been proposed as a safer alternative to ERCP, but its impact on surgical outcomes and complexity was unclear. The study analyzed 937 patients across eight Dutch centers, with 42 undergoing EUS-CDS and 895 undergoing ERCP before surgery. Major postoperative complications occurred in 19% of EUS-CDS patients compared to 33% of ERCP patients, suggesting a trend toward fewer major complications with EUS-CDS (relative risk 0.50), although this difference was not statistically significant. Secondary outcomes, such as overall complications, bile leaks, and pancreatic fistulas, were similar between the two groups. Propensity score-matched analysis confirmed these findings, indicating no significant difference in postoperative risk between the techniques. Surgeons reported that prior EUS-CDS rarely made surgery more challenging, with most finding it not (45%) or only slightly (31%) more difficult. Only 24% found it clearly or severely more complex. Overall, EUS-CDS appears to be a safe and effective preoperative biliary drainage method, with no significant impact on postoperative complications or surgical complexity.

Radical Endoscopic Resection of high risk T1 esophageal adenocarcinoma

Radical Endoscopic Resection (ER) is a minimally invasive procedure that is used to treat early-stage esophageal adenocarcinoma (EAC), specifically high-risk T1 EAC. T1 esophageal adenocarcinoma refers to a cancer that is confined to the innermost layers of the esophagus. The "T1" designation is part of the tumor-node-metastasis (TNM) cancer staging system and indicates that the tumor has invaded the lamina propria, muscularis mucosae, or submucosa of the esophagus but has not spread to deeper layers, lymph nodes, or distant organs. High-risk T1 EAC refers to cases where there are specific features that increase the likelihood of lymph node metastasis (LNM) or recurrence. These risk factors may include: 1. **Invasion into the submucosa (T1b tumors)**: Tumors that extend deeper into the submucosal layer are associated with a higher risk of lymph node involvement compared to tumors confined to the mucosa (T1a). 2. **Poor tumor differentiation**: Poorly differentiated tumors are more aggressive and have a greater potential to spread. 3. **Lymphovascular invasion (LVI)**: The presence of cancer cells in lymphatic or blood vessels increases the risk of metastasis. 4. **Tumor size and other pathological features**: Larger tumors or those with specific histological features may also be considered higher risk. ### Role of Radical Endoscopic Resection (ER) in High-Risk T1 EAC Radical Endoscopic Resection involves the complete removal of the tumor from the esophageal wall with negative deep margins (no cancer cells at the edges of the removed tissue). This procedure is considered an organ-preserving alternative to esophagectomy, a more invasive surgical procedure that involves removing part or all of the esophagus. The role of Radical ER in high-risk T1 EAC is as follows: 1. **Curative Intent**: For carefully selected patients, Radical ER can serve as a curative treatment by completely removing the cancerous lesion, provided there is no evidence of lymph node involvement or distant metastasis. 2. **Pathological Staging**: After the tumor is removed, the excised tissue is analyzed to assess the depth of invasion, tumor differentiation, and presence of lymphovascular invasion. This information helps determine the risk of lymph node metastasis and guides further management. 3. **Minimally Invasive Approach**: Compared to esophagectomy, Radical ER is less invasive, has fewer complications, and allows patients to preserve their esophagus, which improves quality of life. 4. **Alternative to Surgery**: For patients who are not good candidates for surgery due to age, comorbidities, or personal preference, Radical ER followed by close endoscopic surveillance is a viable and safe alternative. ### Study Findings on Long-Term Outcomes The study you referenced evaluated the long-term outcomes of patients with high-risk T1 EAC who underwent Radical ER. The key findings were: 1. **Surgery After ER**: - Among 26 patients who underwent additional esophagectomy after Radical ER, 19% had residual T1 cancer in the surgical specimen. - 8% were found to have lymph node metastases. - This indicates that a small proportion of patients may still have residual disease or undetected lymph node involvement even after Radical ER. 2. **Endoscopic Surveillance**: - 80 patients were followed with endoscopic surveillance after Radical ER without undergoing additional surgery. - Over a median follow-up of 47 months, 6% developed metastases, and 5% died due to EAC. 3. **Risk of Metastasis and Mortality**: - The combined metastasis rate across all patients was 7%, with 6% experiencing lymph node metastasis and 5% succumbing to EAC-related mortality. - These findings suggest that the risk of hidden lymph node spread is relatively low after complete endoscopic removal of the tumor. ### Implications of the Study The study highlights that Radical ER followed by endoscopic surveillance is a reasonable and safe management strategy for selected high-risk T1 EAC patients. However, careful patient selection is crucial to ensure that those with higher risks of lymph node metastasis are appropriately identified and managed. For some patients, additional surgery (esophagectomy) may still be necessary to address the risk of residual cancer or lymph node involvement. ### Considerations for Future Research The study emphasizes the need for further prospective research to refine patient selection criteria and optimize management strategies. This includes identifying which patients are most likely to benefit from endoscopic surveillance versus additional surgery after Radical ER. In summary, Radical Endoscopic Resection plays a critical role in the management of high-risk T1 esophageal adenocarcinoma by offering a less invasive, organ-preserving treatment option with curative potential for carefully selected patients. However, long-term outcomes depend on accurate staging, risk stratification, and close follow-up.

Gloucester Comfort Scale scores

The Gloucester Comfort Scale (GCS) is a clinician-assessed scoring system used to evaluate patient comfort during procedures such as colonoscopy. It is a 1–5 scale, with higher scores indicating greater discomfort or pain experienced by the patient. The GCS is widely used by clinicians to rate patient comfort based on their observations during the procedure. However, the study you referenced highlights significant limitations in the accuracy of GCS scores when compared to patient-reported experiences. Key findings regarding GCS scores from the study: 1. **Discrepancies Between Clinician and Patient Scores**: Clinicians often underestimated or overestimated patient discomfort and pain levels when using the GCS. Specifically: - Discomfort was underestimated in 30% of patients and overestimated in 21%. - Pain was underestimated in 29% of patients and overestimated in 16%. 2. **Underestimation in Moderate-to-Severe Cases**: The mismatch was particularly pronounced in patients with moderate-to-severe symptoms (scores ≥3). Among these patients: - Clinicians underestimated discomfort in 92% of cases. - Clinicians underestimated pain in 90% of cases. 3. **Low Agreement Between Clinician and Patient Scores**: Statistical analysis showed weak alignment between clinician-reported GCS scores and patient-reported measures: - Cohen’s kappa values indicated minimal agreement for discomfort (κ = 0.34) and weak agreement for pain (κ = 0.47). 4. **Recommendation for Improvement**: The study suggests that the GCS alone may not accurately reflect patients' true experiences of discomfort and pain during colonoscopy. To improve patient-centered care, it recommends incorporating patient-reported experience measures (PREMs), such as the Newcastle ENDOPREM, which directly capture patients' perceptions on a similar 1–5 scale. In summary, while the Gloucester Comfort Scale is a commonly used tool, its reliability is limited when it comes to accurately assessing discomfort and pain from the patient's perspective. Integrating patient-reported measures alongside clinician assessments is strongly advised to ensure a more accurate and holistic evaluation of patient comfort during medical procedures.

Optical assessment of scars after EMR - STAR-LNPCP Trial

The STAR-LNPCP trial conducted a multicenter study to assess the reliability of optical assessment as a follow-up method for scars after piecemeal endoscopic mucosal resection (EMR) of large colorectal polyps (≥20 mm). The study aimed to determine whether routine biopsy is still necessary during the 6-month follow-up, especially in community hospital settings where evidence has been limited. Traditionally, follow-up included tattoo placement and routine biopsies to detect recurrence, but expert centers have suggested that careful optical assessment may suffice, potentially avoiding unnecessary biopsies. ### Key Details of the STAR-LNPCP Trial: 1. **Study Design**: - Post-hoc analysis of the STAR-LNPCP trial. - Conducted across 30 Dutch community hospitals between 2019 and 2022. - Included 1277 scar assessments after piecemeal EMR. 2. **Scar Identification**: - Scar identification was highly successful, achieved in 95% of cases (1215 out of 1277). - Tattoo placement did not impact the ability to locate scars. 3. **Routine Biopsy**: - Routine biopsies were performed in 86% of cases (1050 out of 1215 scars). - Recurrence was detected in 19% of biopsied scars. 4. **Optical Assessment Findings**: - Optical diagnosis showed a **negative predictive value (NPV)** of 98%, meaning if the scar appeared normal to the endoscopist, there was a 98% chance that no recurrence was present. - Diagnostic accuracy was high at 93%, with a **Cohen's kappa** of 0.78, indicating substantial agreement between optical assessment and histological biopsy results. - Positive predictive value was 74%, but false positives were more common when clips had been used during the initial procedure (11% vs. 5%). 5. **Performance of Dedicated Endoscopists**: - Dedicated endoscopists performed better than non-specialized endoscopists: - Higher scar identification rate (96% vs. 88%). - Fewer missed recurrences. 6. **Implications**: - The study supports that routine biopsies and tattoo placement can be safely omitted during follow-up when scars are evaluated by well-trained, dedicated endoscopists. - Optical assessment alone is highly reliable for ruling out recurrence, simplifying follow-up and reducing unnecessary procedures. ### Conclusion: The STAR-LNPCP trial demonstrated that optical assessment is a robust and effective method for follow-up of scars after piecemeal EMR of large colorectal polyps. With a high negative predictive value and diagnostic accuracy, routine biopsy may no longer be necessary, particularly when performed by skilled endoscopists. This approach can streamline follow-up in community hospital settings, reduce patient burden, and minimize unnecessary interventions.

EUS-guided gallbladder drainage in patients with cirrhosis

Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) is a minimally invasive procedure that has proven to be safe and effective for treating symptomatic gallbladder disease in patients with cirrhosis. Cirrhotic patients are traditionally considered high-risk for surgical procedures due to their compromised liver function, increased bleeding risk, and susceptibility to complications. EUS-GBD provides an alternative to surgery, offering relief from gallbladder-related symptoms and inflammation without the need for more invasive interventions. A multicenter study compared outcomes of EUS-GBD in cirrhotic (47 patients) and non-cirrhotic (123 patients) individuals. Both groups showed similar rates of technical success (97.9% vs. 95.1%) and clinical success (93.6% vs. 94.9%), with rare adverse events and comparable survival rates. Acute cholecystitis was more prevalent in cirrhotic patients, reflecting their higher disease burden. Overall, EUS-GBD demonstrated equivalent safety and effectiveness in cirrhotic and non-cirrhotic patients, establishing it as a viable option for gallbladder drainage in cirrhosis.

Hemostatic powder TC-325 in Maliganant upper GI bleeding

Hemostatic powder TC-325 has emerged as a promising treatment option for malignant upper gastrointestinal bleeding (MUGIB), which is one of the most difficult types of GI bleeding to manage. MUGIB often results from cancer-related lesions that bleed heavily and are resistant to control using standard endoscopic therapy (SET). TC-325 has demonstrated clinical superiority over SET in terms of quicker and more reliable control of bleeding, and recent research has explored its cost-effectiveness as a first-line treatment in the United Kingdom. ### Clinical Effectiveness of TC-325: 1. **Immediate Hemostasis**: TC-325 showed higher rates of immediate bleeding control compared to SET. This means that patients treated with TC-325 experienced faster stabilization of their bleeding, reducing the risk of complications. 2. **Lower Rebleeding Rates**: Patients who received TC-325 had fewer instances of rebleeding within a 30-day period compared to those treated with SET. This reduces the need for repeat interventions. 3. **Reduced Need for Additional Procedures**: Because TC-325 is more effective in controlling bleeding, it minimizes the need for further treatments such as additional endoscopic procedures, radiotherapy, surgery, or transcatheter arterial embolization. These additional interventions are often costly and carry higher risks for patients. ### Cost-Effectiveness of TC-325: 1. **Financial Savings**: The use of TC-325 resulted in an average cost savings of £245.88 per patient compared to SET. This is due to fewer repeat procedures, hospital readmissions, and shorter hospital stays. 2. **Quality-Adjusted Life Years (QALY)**: TC-325 provided a small but meaningful improvement in QALY (0.001), reflecting enhanced patient outcomes and quality of life. 3. **Consistency Across Scenarios**: Sensitivity analyses showed that TC-325 remained cost-saving and effective in 80.1% of simulated scenarios, reinforcing its reliability and robustness across varying conditions. ### Advantages of TC-325: - **Reduced Rebleeding**: By effectively controlling bleeding, TC-325 helps avoid the complications associated with recurrent bleeding episodes. - **Lower Overall Costs**: Fewer interventions and shorter hospital stays lead to significant cost savings for healthcare systems. - **Improved Patient Outcomes**: Faster bleeding control and fewer complications improve the overall quality of care and patient experience. ### Implications for the UK Healthcare System: The study used official 2023–2024 NHS cost data to ensure realistic estimates of the financial impact. With its dual benefits of clinical effectiveness and cost savings, TC-325 is recommended as a cost-effective, reliable first-line treatment for MUGIB in the UK. Its adoption could improve patient outcomes while reducing the financial burden on healthcare systems. ### Conclusion: TC-325 hemostatic powder is a groundbreaking advancement in the management of malignant upper GI bleeding. By offering superior bleeding control, fewer repeat interventions, and cost savings, TC-325 is both clinically and economically advantageous compared to standard endoscopic therapy. Its strong performance across various scenarios makes it an ideal first-line treatment for MUGIB in the UK healthcare setting.

Bariatric and metabolic endoscopy: ESGE Technical Review

The "Bariatric and Metabolic Endoscopy: ESGE Technical Review" provides a detailed and comprehensive overview of endoscopic bariatric and metabolic therapies (EBMTs), which are minimally invasive treatment options for obesity and related metabolic diseases. The review focuses on the latest advancements in this field, offering clinicians practical guidance on the use, safety, and effectiveness of these therapies. ### Key Highlights of the Review: #### 1. **Types of Endoscopic Bariatric and Metabolic Therapies (EBMTs):** - **Stomach-Based Therapies:** - **Intragastric Balloons (IGBs):** These devices occupy space in the stomach, causing a feeling of fullness and reducing food intake. - **Endoscopic Sleeve Gastroplasty (ESG):** A procedure that uses sutures to reduce stomach volume and mimic the effects of surgical sleeve gastrectomy. - **Aspiration Therapy:** A reversible technique that involves placing a device to aspirate ingested food from the stomach, reducing calorie absorption. - **Small-Bowel–Based Therapies:** - **Duodenal Mucosal Resurfacing (DMR):** A procedure that modifies the duodenal lining, potentially improving glucose metabolism and insulin sensitivity. - **Bypass Sleeves (Endoluminal Sleeves):** Devices that act as a barrier to prevent contact between food and the proximal small intestine, mimicking the effects of surgical bypass. #### 2. **Mechanisms of Action:** - The review explains how each therapy works to promote weight loss and improve metabolic health. These mechanisms include: - Restriction of food intake. - Alteration of gut hormones. - Changes in nutrient absorption and metabolism. #### 3. **Indications and Patient Selection:** - EBMTs are recommended for patients with obesity (BMI ≥ 30 kg/m²) who have not achieved sufficient results with lifestyle modifications or pharmacotherapy. They may also be suitable for patients who are not candidates for bariatric surgery or prefer less invasive options. - Patient selection is critical, and the review emphasizes the importance of multidisciplinary care, including dietitians, psychologists, and medical professionals. #### 4. **Effectiveness and Safety:** - EBMTs demonstrate promising outcomes for weight loss and metabolic improvements, particularly in controlling type 2 diabetes and other obesity-related conditions. - While they carry a lower risk compared to surgical interventions, common adverse events include nausea, vomiting, abdominal pain, and, in rare cases, more serious complications. - The review discusses strategies to manage complications and prevent weight regain, which remains a challenge in some patients. #### 5. **Evidence and Research Gaps:** - The review highlights the need for more high-quality, randomized controlled trials and long-term follow-up studies to better understand the durability of outcomes and to establish the precise role of EBMTs in clinical practice. - There is a call for standardized protocols and guidelines to optimize the use of these therapies. #### 6. **Practical Guidance for Clinicians:** - The review serves as a technical guide for healthcare providers, detailing the proper techniques for performing EBMTs and offering recommendations for their safe and effective application. - It underscores the importance of individualized treatment plans and the integration of EBMTs into a comprehensive obesity management strategy. ### Conclusion: The ESGE Technical Review positions EBMTs as an emerging and valuable tool in the fight against obesity and metabolic diseases. While these therapies show significant potential due to their minimally invasive nature and favorable safety profile, their long-term efficacy and role in the broader treatment pathway require further investigation. This review provides clinicians with the knowledge and framework necessary to incorporate EBMTs into modern obesity care, ensuring patient safety and optimal outcomes.

Endoscopic vacuum therapy for nonvariceal UGI bleeding

Endoscopic vacuum therapy (EVT), traditionally used for gastrointestinal perforations and leaks, has shown promising results as a treatment for nonvariceal upper gastrointestinal bleeding (NVUGIB), including cases resistant to standard hemostatic therapies. The following provides detailed insights into its application and effectiveness based on the study: ### Background and Context: - **NVUGIB** refers to upper gastrointestinal bleeding not caused by esophageal or gastric varices. It can arise from conditions such as peptic ulcers, gastric erosions, or duodenal ulcers. - EVT's use for bleeding gained interest during the COVID-19 pandemic when case reports highlighted its success in controlling diffuse duodenal bleeding in COVID-19 patients. This success suggested that EVT might have broader applications beyond its traditional role in managing perforations and leaks. ### Study Overview: - Researchers analyzed **19 patients** treated with EVT for NVUGIB, using data from a prospectively collected database. - A significant portion of these patients (**57.9%**) had already failed conventional treatments, such as endoscopic, radiologic, or pharmacologic interventions, making them a high-risk, difficult-to-manage group. ### Bleeding Sites and Challenges: - The **duodenum** was the most common site of bleeding in the study, particularly areas with fibrosis or diffuse bleeding. These sites are notoriously challenging to manage using traditional endoscopic techniques due to anatomical complexities and the nature of the bleeding. ### Effectiveness of EVT: 1. **Technical Success**: - EVT achieved technical success in **100% of patients**, meaning the vacuum device was successfully placed and functioned as intended. 2. **Clinical Success**: - Stable hemostasis, without the need for further interventions, was achieved in **89.5% of patients**. - Outcomes were similar for COVID-related bleeding and non-COVID-related bleeding patients (**88% vs. 91%**), demonstrating EVT's consistent effectiveness regardless of underlying inflammation or coagulopathy associated with COVID-19. 3. **Safety**: - No procedure-related adverse events were reported, indicating EVT is both effective and safe. - The rebleeding rate was only **11%**, which is favorable compared to standard therapies in challenging NVUGIB cases. ### Advantages of EVT for NVUGIB: - **Effective in difficult cases**: Particularly useful for large fibrotic ulcers or diffuse duodenal bleeding where conventional endoscopic methods often fail. - **Safe**: The absence of procedure-related complications highlights its safety profile. - **Consistent performance**: EVT works reliably across different patient populations, including those with COVID-related coagulopathies. ### Limitations and Future Directions: - While the results are promising, the study involved a small sample size (19 patients). Larger studies are necessary to confirm these findings. - Further research is needed to define optimal patient selection criteria and refine EVT protocols for NVUGIB. ### Conclusion: Endoscopic vacuum therapy (EVT) is emerging as a valuable option for managing difficult cases of nonvariceal upper gastrointestinal bleeding (NVUGIB). Its high technical and clinical success rates, combined with a favorable safety profile, make it a promising alternative to standard treatments, especially for complex cases involving fibrotic ulcers or diffuse duodenal bleeding. However, larger-scale studies are required to validate these findings and optimize its use in clinical practice.

POEM for symptomatic blown-out myotomy

Blown-out myotomy (BOM) is a structural complication that can occur after a previous myotomy for achalasia, a condition where the esophagus has difficulty moving food into the stomach. In BOM, the original myotomy (a surgical cut in the esophageal muscles to improve swallowing) fails or disrupts, leading to poor esophageal emptying and a recurrence of symptoms like difficulty swallowing, chest pain, or regurgitation. When these symptoms significantly impact a patient’s quality of life, it is referred to as symptomatic blown-out myotomy. Peroral Endoscopic Myotomy (POEM) is a minimally invasive endoscopic procedure that is used as a salvage treatment for symptomatic BOM. During POEM, a flexible endoscope is inserted through the mouth to access the esophagus. The surgeon creates a tunnel in the esophageal lining and cuts the problematic muscle layers to restore proper esophageal function. The study found that POEM is both safe and effective for treating symptomatic BOM. It had a low rate of complications, even in anatomically altered cases like BOM. Clinical success was high (85.7% at 2 years), meaning most patients experienced significant symptom relief. This makes POEM a reliable option for patients with recurrent achalasia symptoms due to BOM, helping them regain better swallowing and quality of life.

In-hospital mortality in patients with lower GI bleeding

In-hospital mortality in patients with lower gastrointestinal bleeding (LGIB) can be significant, depending on various factors. A new tool, the ALIBI score, was developed to predict the risk of death in patients hospitalized with LGIB. This scoring system helps doctors identify high-risk patients and improve their management. The ALIBI score is based on five key factors that increase the risk of death: older age, higher Charlson co-morbidity index (indicating more severe underlying health conditions), bleeding that starts during hospitalization, hemodynamic instability (e.g., low blood pressure or shock), and elevated serum creatinine (a marker of kidney function). These factors are combined into a 0–13 point scale. In a study of 1,198 patients, the ALIBI score was tested and then validated on 752 more patients from multiple countries. It showed strong accuracy in predicting mortality, with higher scores indicating greater risk. Patients were categorized into three risk groups: low risk (0–4 points, 1% mortality), intermediate risk (5–9 points, 4.6% mortality), and high risk (10–13 points, 19.1% mortality). The ALIBI score outperformed previous tools and can guide doctors in prioritizing care, planning interventions, and improving outcomes for patients with LGIB.

Effects of PPI on LAMS occlusion rate following pancreatic necrosectomies

This study explored the impact of proton pump inhibitors (PPIs) on lumen-apposing metal stent (LAMS) occlusion rates in patients undergoing pancreatic necrosectomy for walled-off necrosis (WON). LAMS are used to drain infected or necrotic fluid collections in the pancreas, offering a minimally invasive alternative to surgical approaches. However, complications like stent blockage can occur, requiring additional procedures such as endoscopic necrosectomy to remove debris. The study analyzed data from 893 patients and 967 LAMS placements across multiple European centers. After excluding intermittent PPI users and incomplete records, 768 stents were evaluated. Among these, 577 patients were on continuous PPIs, while 191 did not use PPIs. Results showed that PPI use significantly increased LAMS occlusion rates (30% in PPI users vs. 23% in non-users) and the need for endoscopic necrosectomies. Statistical models confirmed that continuous PPI use heightened the risk of stent blockage (OR 0.61, P = 0.04 for non-PPI users) and necrosectomy (IRR 0.8, P = 0.006). A dose-dependent and compound-specific effect of PPIs was also observed. PPIs may contribute to stent occlusion by altering gastric pH, which can affect the composition of pancreatic fluid and promote debris accumulation. Importantly, avoiding PPIs did not increase bleeding risks or other complications, suggesting routine PPI use during LAMS placement should be reconsidered to improve outcomes.

Endoscopic surveillance recommendations for Barrett's Esophagus - AGA View

The American Gastroenterological Association (AGA) provides detailed recommendations for endoscopic surveillance in patients with Barrett’s Esophagus (BE). Below is a comprehensive summary of the AGA's guidelines based on the context provided: ### 1. **Surveillance for Nondysplastic Barrett’s Esophagus (NDBE):** - **Recommended Interval:** Endoscopic surveillance is suggested every **3 years** for patients with NDBE. - **Extended Interval:** Surveillance may be extended to **5 years** for patients at **very low risk**, such as those with **short-segment BE (<3 cm)**. - **Discontinuation of Surveillance:** Surveillance can be stopped in selected patients based on age and comorbidities. Factors to consider include: - **Life expectancy:** Patients with limited life expectancy may not benefit from continued surveillance. - **Frailty:** Frailty and other comorbid conditions should guide the decision to discontinue surveillance. ### 2. **Surveillance for Ultra-Short Segment Barrett's Esophagus (<1 cm):** - **No Surveillance Recommended:** Endoscopic surveillance is **not recommended** for patients with ultra-short segment BE (less than 1 cm) with intestinal metaplasia. ### 3. **Endoscopy Techniques for Surveillance:** - **Preferred Approach:** High-definition white light endoscopy (HD-WLE) combined with chromoendoscopy (CE) is preferred over HD-WLE alone. - **Recommendation Strength:** Strong recommendation based on moderate-quality evidence. - **Type of Chromoendoscopy:** Either virtual chromoendoscopy or dye-based chromoendoscopy is acceptable, depending on: - **Expertise of the endoscopist** and - **Availability of equipment**. - **Biopsy Protocol:** Use chromoendoscopy-directed biopsies in addition to a structured biopsy protocol, such as the **Seattle protocol**: - **Seattle Protocol Guidelines:** - **4-quadrant biopsies every 2 cm** for patients with no dysplasia. - **4-quadrant biopsies every 1 cm** for patients with a history of dysplasia. ### 4. **Quality Standards for Barrett’s Exams:** - Barrett’s examinations must meet **high-quality endoscopy standards**, including: - Optimal mucosal visualization. - Adequate inspection time. - Proper technique for mucosal evaluation. ### 5. **Confirmation of Dysplasia Diagnosis:** - Any diagnosis of dysplasia must be confirmed by an **expert pathologist**. - This is especially important for cases of **indefinite for dysplasia (IND)**, **low-grade dysplasia (LGD)**, and **early neoplasia**. ### 6. **Management of New Diagnoses:** - For new diagnoses of Barrett’s Esophagus (BE), IND, or LGD: - **Repeat Endoscopy:** Perform repeat endoscopy within **6 months**. - **Medication:** Patients should be on **high-dose proton pump inhibitors (PPI)** during this period to exclude prevalent high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). ### 7. **Surveillance Intervals for Dysplasia:** - **Low-Grade Dysplasia (LGD):** - If ablation therapy is **not chosen**, perform surveillance endoscopy **every 6 months for 1 year**, then annually thereafter. - **Indefinite for Dysplasia (IND):** - Annual surveillance endoscopy is recommended until the grade changes. - **No Endoscopic Eradication Therapy (EET):** EET is **not recommended** for IND after expert review. ### Key Points to Remember: - Surveillance intervals depend on the presence and grade of dysplasia. - High-quality endoscopic techniques and biopsy protocols are essential for accurate surveillance and diagnosis. - Decisions regarding surveillance discontinuation should be individualized based on patient factors such as age, frailty, and life expectancy. These recommendations aim to optimize the early detection and management of dysplasia and prevent progression to esophageal adenocarcinoma in patients with Barrett’s Esophagus.

Endoscopic Nasobiliary Drainage for Type 1 Autoimmune Pancreatitis

Endoscopic Nasobiliary Drainage (ENBD) is a minimally invasive procedure used to drain bile from the biliary system to relieve jaundice or other complications caused by bile duct obstruction. A small catheter is placed through the nose into the bile duct to allow bile to flow externally or internally. Type 1 autoimmune pancreatitis (AIP) is a form of chronic pancreatitis often associated with IgG4-related disease. It is characterized by pancreatic inflammation, swelling, and narrowing of the bile duct, which can lead to obstructive jaundice. Differentiating AIP from malignancies and managing bile duct obstruction are crucial in treatment. Biliary drainage in type 1 AIP is necessary to relieve jaundice and assess bile duct abnormalities. It helps in distinguishing AIP from malignancies and evaluating the patient’s response to steroid therapy while minimizing invasive procedures. In a study of 83 patients with type 1 AIP and jaundice, ENBD effectively improved liver function and provided clear bile duct visualization. It was safe, with only 2% experiencing mild complications. ENBD also helped avoid repeated ERCP procedures and confirmed steroid responsiveness. This study highlights ENBD as a useful and safe option for managing jaundice in type 1 AIP, depending on the patient’s condition and pancreatic structure.

Endocytoscopy

Endocytoscopy is an advanced, high-resolution imaging technique used in medical diagnostics, particularly in the field of gastroenterology and oncology. It is a form of ultra-high magnification endoscopy that allows clinicians to visualize cellular and subcellular structures of tissues in real time during endoscopic procedures. This technique bridges the gap between conventional endoscopy and histopathology, enabling "virtual biopsy" without the need for tissue excision. ### Key Features of Endocytoscopy: 1. **Magnification Power**: Endocytoscopy offers magnification levels up to 500-1,000 times, allowing the visualization of cellular details such as nuclei, cytoplasm, and intracellular structures. 2. **Real-Time Imaging**: Unlike traditional biopsy methods that require tissue collection and laboratory processing, endocytoscopy provides immediate cellular imaging during the procedure. 3. **Special Staining**: To enhance visualization of cellular structures, specific stains such as methylene blue, toluidine blue, or acetic acid may be applied to the tissue during the procedure. ### Procedure: Endocytoscopy is typically performed using specialized endoscopes equipped with ultra-high magnification lenses. After the application of contrast agents or stains, the clinician examines the target tissue at the cellular level. This technique is often used in conjunction with conventional endoscopy to provide additional diagnostic information. ### Role and Applications: Endocytoscopy plays a critical role in diagnosing and managing various diseases, particularly in areas where cellular-level analysis is crucial. Its applications include: 1. **Cancer Detection and Diagnosis**: - **Colorectal Cancer**: Endocytoscopy is used to identify precancerous lesions and early-stage cancers by observing cellular abnormalities. - **Esophageal Cancer**: It aids in detecting dysplasia and early malignancies in Barrett's esophagus. - **Gastric Cancer**: Helps in distinguishing between benign and malignant lesions. 2. **Evaluation of Inflammatory Diseases**: - In conditions such as inflammatory bowel disease (IBD), endocytoscopy can help assess mucosal inflammation and cellular changes. 3. **Differentiation of Lesions**: - Endocytoscopy allows clinicians to differentiate between benign, pre-malignant, and malignant lesions without the need for excisional biopsy. 4. **Monitoring Treatment Response**: - It can be used to monitor cellular changes in response to therapeutic interventions, such as chemotherapy or radiation therapy. 5. **Minimally Invasive Diagnosis**: - By reducing the need for tissue biopsies, endocytoscopy minimizes patient discomfort and speeds up the diagnostic process. ### Advantages: - Provides histological-level detail without tissue removal. - Reduces the need for invasive biopsies. - Offers real-time diagnostic insights. - Improves the accuracy of lesion characterization. - Enhances the ability to detect early-stage cancers and subtle cellular abnormalities. ### Limitations: - Requires specialized equipment and expertise. - Interpretation of cellular images may be challenging and requires significant training. - The technique may not be suitable for all types of tissues or lesions. - Limited availability in some healthcare settings due to cost and technical requirements. ### Future Directions: As technology advances, endocytoscopy is expected to become more widely available and integrated into routine clinical practice. Improvements in image resolution, automated analysis using artificial intelligence (AI), and broader applications in other medical fields (e.g., pulmonology, urology) are anticipated. Additionally, combining endocytoscopy with other diagnostic modalities, such as confocal laser endomicroscopy, may further enhance diagnostic accuracy. In summary, endocytoscopy represents a significant innovation in the field of medical imaging and diagnostics, offering unparalleled insights into cellular structures in real time. Its ability to provide "virtual biopsies" has the potential to revolutionize the way clinicians detect, diagnose, and manage diseases.

Confocal Laser Endoscopy

Confocal Laser Endoscopy is an advanced imaging technique that combines the principles of confocal microscopy and endoscopy to provide high-resolution, real-time visualization of tissues at the cellular and subcellular levels. It is particularly useful in clinical settings for diagnosing and monitoring various diseases, including gastrointestinal disorders, cancer, and other pathological conditions. Below is a detailed explanation of the topic tailored for postgraduate (PG) students: --- ### **Principle of Confocal Laser Endoscopy** The technique is based on the principle of confocal microscopy, where a laser beam is focused on a specific point in the tissue, and only the light reflected or emitted from that focal point is collected. This minimizes the scattering of light and improves image resolution and contrast. By scanning multiple points in the tissue, a detailed image of the tissue structure can be reconstructed. Confocal laser endoscopy uses an endoscope equipped with confocal optics to access internal organs and tissues. The system typically employs fluorescence imaging, where a fluorescent dye or contrast agent is used to enhance the visualization of cellular structures. --- ### **Components of Confocal Laser Endoscopy** 1. **Confocal Microscope**: - The core technology that allows for high-resolution imaging by rejecting out-of-focus light. - Uses pinholes to ensure that only light from the focal plane is detected. 2. **Laser Source**: - Provides a monochromatic and coherent light beam for precise imaging. - Commonly used lasers include diode lasers or solid-state lasers. 3. **Endoscope**: - A flexible or rigid tube equipped with confocal optics. - The endoscope is inserted into the body to visualize internal tissues. 4. **Fluorescent Contrast Agents**: - Substances such as fluorescein or indocyanine green (ICG) are injected or applied to enhance tissue contrast. - These agents bind to specific cellular components, enabling the differentiation of normal and abnormal tissues. 5. **Image Processing System**: - Software and hardware for real-time image acquisition, processing, and display. - Allows clinicians to visualize and interpret findings immediately. --- ### **Applications of Confocal Laser Endoscopy** 1. **Gastroenterology**: - Used to examine the gastrointestinal tract, including the esophagus, stomach, and colon. - Helps identify early signs of cancer, such as Barrett's esophagus or colorectal cancer. - Detects microscopic changes in mucosal structures, aiding in the diagnosis of inflammatory bowel disease (IBD) and celiac disease. 2. **Oncology**: - Provides detailed visualization of tumor margins and cellular architecture. - Helps differentiate between benign and malignant lesions. 3. **Dermatology**: - Confocal laser endoscopy is used to examine skin lesions and diagnose skin cancers like melanoma without the need for invasive biopsies. 4. **Pulmonology**: - Enables imaging of the respiratory tract, including the bronchial mucosa, for detecting lung cancer or other pulmonary disorders. 5. **Urology**: - Used to visualize the bladder and urethra for conditions like bladder cancer. --- ### **Advantages of Confocal Laser Endoscopy** 1. **High Resolution**: - Provides microscopic-level visualization of tissues, enabling the identification of cellular and subcellular changes. 2. **Real-Time Imaging**: - Allows clinicians to observe tissue structures and dynamics instantly during the procedure. 3. **Minimally Invasive**: - Reduces the need for biopsies and surgical interventions, minimizing patient discomfort. 4. **Targeted Diagnosis**: - With the use of fluorescent dyes, specific tissue components can be highlighted, improving diagnostic accuracy. 5. **Dynamic Observations**: - Enables the study of physiological processes, such as blood flow or cellular interactions, in live tissues. --- ### **Limitations of Confocal Laser Endoscopy** 1. **Cost**: - The equipment is expensive, which may limit its availability in resource-constrained settings. 2. **Operator Expertise**: - Requires specialized training for proper use and interpretation of images. 3. **Depth Limitation**: - Confocal imaging is effective for superficial layers of tissue but may not penetrate deeply into thicker tissues. 4. **Need for Contrast Agents**: - The use of fluorescent dyes may pose risks such as allergic reactions in some patients. 5. **Field of View**: - The imaging area is relatively small, which may require multiple scans to cover larger tissue areas. --- ### **Future Directions** Confocal Laser Endoscopy is a rapidly evolving field with ongoing advancements aimed at improving its capabilities. Some key areas of development include: 1. **Integration with Artificial Intelligence (AI)**: - AI algorithms are being developed to assist in image analysis and enhance diagnostic accuracy. 2. **Development of Novel Contrast Agents**: - Research is focused on creating safer and more specific fluorescent dyes for targeted imaging. 3. **Miniaturization**: - Efforts are being made to develop smaller, more portable devices for widespread clinical use. 4. **Multiphoton Imaging**: - Combining confocal laser endoscopy with multiphoton techniques to achieve deeper tissue penetration and better imaging quality. --- ### **Conclusion** Confocal Laser Endoscopy represents a significant advancement in medical imaging, offering unparalleled resolution and real-time visualization of tissues. Its applications span multiple fields, including gastroenterology, oncology, dermatology, pulmonology, and urology. While it has certain limitations, ongoing research and technological innovations are expected to overcome these challenges, making it an indispensable tool in modern medicine. PG students should focus on understanding the underlying principles, clinical applications, and future trends to leverage this technology effectively in their practice and research.

EUS and EUS Elastography

Endoscopic Ultrasound (EUS) and EUS Elastography are advanced diagnostic techniques used primarily in gastroenterology to evaluate and characterize lesions in the gastrointestinal tract and surrounding structures. While they are related, they differ significantly in their principles, applications, and diagnostic capabilities. Below is a detailed contrast between EUS and EUS Elastography: --- ### **1. Definition and Principle** **EUS (Endoscopic Ultrasound):** - EUS combines endoscopy and ultrasound to provide detailed imaging of the gastrointestinal tract and adjacent organs (e.g., pancreas, liver, bile ducts, lymph nodes). - It uses high-frequency sound waves to generate real-time images of tissue structures, allowing for visualization of both mucosal layers and deeper structures. **EUS Elastography:** - EUS Elastography is an advanced extension of EUS that assesses the stiffness or elasticity of tissues. - It works by measuring tissue deformation in response to applied pressure or vibration, providing a color-coded map (strain map) that reflects tissue stiffness. This helps differentiate benign from malignant lesions, as malignant tissues are typically stiffer. --- ### **2. Purpose and Diagnostic Focus** **EUS:** - Primary purpose is to visualize anatomical structures and detect abnormalities such as cysts, tumors, inflammation, or fibrosis. - It allows for detailed imaging of the layers of the gastrointestinal wall and surrounding organs. - EUS is commonly used for staging cancers, guiding fine-needle aspiration (FNA), and evaluating subepithelial lesions. **EUS Elastography:** - Focuses on characterizing tissue stiffness to differentiate between benign and malignant lesions. - It enhances diagnostic accuracy by providing additional information about the mechanical properties of tissues, which is particularly useful in assessing pancreatic masses, lymph nodes, and other suspicious lesions. - Helps in non-invasive risk stratification of lesions before biopsy. --- ### **3. Imaging Output** **EUS:** - Produces grayscale, high-resolution, real-time images of the anatomical structures. - The images primarily depict the size, shape, and echogenicity of lesions or organs. **EUS Elastography:** - Produces a color-coded map superimposed on the grayscale EUS image. - The color map represents tissue stiffness: - **Blue:** Hard/stiff tissue (often indicative of malignancy). - **Green:** Intermediate stiffness. - **Red:** Soft tissue (often indicative of benign lesions). --- ### **4. Diagnostic Applications** **EUS:** - Commonly used for: - Staging of cancers (e.g., pancreatic, esophageal, rectal cancer). - Identifying and sampling submucosal lesions. - Evaluating biliary obstruction or pancreatitis. - Guiding therapeutic interventions like drainage or celiac plexus neurolysis. **EUS Elastography:** - Used as a complementary tool to EUS for: - Differentiating between benign and malignant lesions based on tissue stiffness. - Assessing pancreatic masses, submucosal tumors, and lymph nodes. - Providing additional diagnostic confidence before performing a biopsy. --- ### **5. Advantages** **EUS:** - Provides detailed anatomical imaging with high spatial resolution. - Allows direct visualization and real-time guidance for procedures like FNA. - Useful in staging malignancies and assessing tumor invasion into adjacent structures. **EUS Elastography:** - Non-invasive and provides functional information about tissue stiffness. - Helps improve diagnostic accuracy in distinguishing benign from malignant lesions. - Reduces unnecessary biopsies by identifying low-risk lesions based on stiffness. --- ### **6. Limitations** **EUS:** - Limited in differentiating benign from malignant lesions based solely on imaging. - Operator-dependent technique requiring significant expertise. - Cannot provide functional information about tissue stiffness. **EUS Elastography:** - May be less accurate in certain clinical scenarios, such as lesions with mixed stiffness or when surrounding tissue affects the strain map. - Requires high-quality EUS images as a basis for elastography analysis. - Interpretation of color maps can be subjective and operator-dependent. --- ### **7. Clinical Example** - **EUS:** A pancreatic lesion is visualized as hypoechoic and irregularly shaped. EUS can help guide FNA for histopathological evaluation. - **EUS Elastography:** The same pancreatic lesion appears blue on the strain map, indicating high stiffness and increasing suspicion for malignancy. This information can guide the clinician to prioritize biopsy and further management. --- ### **8. Integration in Practice** EUS and EUS Elastography are often used together in clinical practice: - EUS provides structural imaging and guides interventions like FNA. - EUS Elastography adds functional information about tissue stiffness, improving diagnostic accuracy and reducing unnecessary procedures. --- ### **Conclusion** While EUS is a powerful tool for imaging and guiding interventions, EUS Elastography enhances the diagnostic capabilities of EUS by assessing tissue stiffness, aiding in the differentiation of benign and malignant lesions. Together, these techniques complement each other and provide a comprehensive evaluation of gastrointestinal and surrounding lesions, especially in oncology and advanced gastroenterology.

EMR-L versus ESD in treating small gastric stromal tumors

Endoscopic ligator-assisted mucosal resection (EMR-L) and endoscopic submucosal dissection (ESD) are two techniques used to treat small gastric stromal tumors (GSTs). Here's a detailed comparison based on the context provided: --- ### **What are Small Gastric Stromal Tumors (GSTs)?** Small gastric stromal tumors are a type of gastrointestinal stromal tumor (GIST) that originate in the connective tissue of the stomach. These tumors are typically less than 1.0 cm in diameter and are often detected incidentally during endoscopic examinations. While small GSTs are usually benign, complete removal is essential to prevent potential malignant transformation or complications. --- ### **What is ESD?** **Endoscopic Submucosal Dissection (ESD)** is a highly advanced endoscopic technique designed for the complete removal of gastrointestinal tumors, including GSTs. It involves precise dissection of the submucosal layer to excise the tumor in one piece. #### **Advantages of ESD:** 1. **Complete Resection:** ESD allows for en bloc removal, ensuring complete tumor excision with clear margins. 2. **Effective for Larger Tumors:** It is particularly effective for tumors larger than 1 cm or those located in challenging areas. 3. **High Precision:** The technique provides excellent control, minimizing damage to surrounding tissues. #### **Limitations of ESD:** 1. **Complex Procedure:** ESD requires advanced technical skills and significant training, making it challenging for less experienced endoscopists. 2. **Longer Operation Time:** The procedure is time-intensive due to the meticulous dissection required. 3. **Higher Costs:** ESD is associated with higher hospital costs due to the complexity of the procedure and equipment used. 4. **Steep Learning Curve:** It demands significant expertise, which limits its widespread use in clinical practice. --- ### **What is EMR-L?** **Endoscopic Ligator-Assisted Mucosal Resection (EMR-L)** is a simpler and less invasive alternative to ESD. It involves using a ligator device to trap the tumor in a loop followed by resection. This technique is particularly suitable for smaller tumors under 1.0 cm in diameter. #### **Advantages of EMR-L:** 1. **Simpler Procedure:** EMR-L is easier to perform and requires less technical expertise compared to ESD. 2. **Shorter Operation Time:** On average, EMR-L takes significantly less time (16.92 ± 4.76 minutes) compared to ESD (46.46 ± 12.27 minutes). 3. **Lower Costs:** The procedure is more cost-effective, with an average cost of 17,136.87 ± 2959.80 yuan versus 22,760.24 ± 5199.45 yuan for ESD. 4. **Shorter Hospital Stay:** Patients undergoing EMR-L have shorter recovery times, with an average hospital stay of 6.12 ± 1.55 days compared to 7.53 ± 2.24 days for ESD. #### **Limitations of EMR-L:** 1. **Size Restriction:** EMR-L is primarily effective for smaller tumors (less than 1.0 cm). It may not be suitable for larger or more complex lesions. 2. **Less Precision:** While effective, EMR-L may not provide the same level of precision as ESD, especially for tumors in difficult locations. --- ### **Comparison of EMR-L and ESD:** #### **Effectiveness:** Both EMR-L and ESD achieved a **100% complete resection rate** in the pilot study, demonstrating equal effectiveness in removing small GSTs. #### **Practical Advantages of EMR-L:** - **Shorter Operation Time:** EMR-L is quicker, making it more suitable for routine clinical practice. - **Lower Costs:** EMR-L is more affordable, reducing the financial burden on patients and healthcare systems. - **Shorter Hospital Stay:** Patients recover faster, which enhances overall patient satisfaction. #### **Advantages of ESD:** - ESD remains the gold standard for larger or more complex GSTs due to its precision and ability to remove tumors en bloc. --- ### **Clinical Implications:** The findings from the pilot study suggest that **EMR-L** is as safe and effective as **ESD** for treating **GSTs smaller than 1.0 cm**, while offering significant advantages in terms of simplicity, cost, and recovery time. These benefits make EMR-L a promising minimally invasive option for small GSTs in clinical practice. However, **ESD** remains the preferred choice for cases requiring higher precision or involving larger tumors. --- ### **Conclusion:** For small gastric stromal tumors (less than 1.0 cm), EMR-L is emerging as a simpler, quicker, and more cost-effective alternative to ESD. While ESD offers unmatched precision for larger or complex tumors, EMR-L provides a practical solution for routine clinical management of small GSTs, potentially replacing ESD in these cases.

Predicting endoscopic hemostasis failure in esophageal variceal bleeding

The study aimed to develop and validate a predictive nomogram for assessing the risk of endoscopic hemostasis failure in cirrhotic patients presenting with acute esophagogastric variceal bleeding (EGVB). EGVB is a severe complication of portal hypertension, with a high mortality rate, especially if endoscopic hemostasis fails. Conducted as a retrospective single-center study, 296 patients treated between January 2020 and February 2025 were analyzed. Patients were divided into successful (n=273) and failed (n=23) endoscopic hemostasis groups, with failure defined as rebleeding within five days or inability to control hemorrhage per Baveno VII criteria. Four independent predictors of failure were identified: Shock Index (SI > 1.2), Red Color (RC) sign, active bleeding during endoscopy, and Child-Turcotte-Pugh (CTP) score. Using LASSO regression and multivariate logistic regression, a nomogram was developed with the formula: Logit (P) = −3.548 + 1.695×SI + 2.303×RC sign + 1.785×Active bleeding + 0.46×CTP score. The nomogram demonstrated excellent predictive performance with an AUC of 0.890, outperforming traditional scoring systems like CTP, MELD, and Rockall. Risk stratification classified patients into low, medium, and high-risk categories, with failure rates of 0%, 5.7%, and 19.2%, respectively. High-risk patients require ICU-level monitoring and immediate interventions such as secondary endoscopy, balloon tamponade, or TIPS in case of rebleeding. The study highlights the importance of hemodynamic stability (SI), endoscopic findings (RC sign and active bleeding), and liver function (CTP score) in predicting failure. While the nomogram showed promising results, the study’s single-center retrospective design limits external validation. Future research should incorporate imaging modalities and AI-driven analysis for enhanced precision.

Purastat and its role Upper GI bleeding

Purastat is an innovative and promising hemostatic agent specifically designed for the management of upper gastrointestinal bleeding (UGIB), particularly non-variceal UGIB. It is a synthetic peptide-based gel that belongs to the class of self-assembling peptide hydrogels. Its novel mechanism of action and clinical applications make it a valuable tool for addressing bleeding in challenging scenarios where conventional methods may fail. ### **Role of Purastat in Upper GI Bleeding:** #### **Mechanism of Action:** Purastat works by forming a nanofiber hydrogel when exposed to physiological conditions. This hydrogel provides multiple benefits at the bleeding site: 1. **Physical Hemostasis:** The hydrogel forms a physical barrier over the bleeding site, effectively preventing further blood loss and promoting clot formation. 2. **Platelet Aggregation:** It acts as a scaffold to facilitate platelet aggregation and stabilize clots. 3. **Mucosal Protection:** By covering the bleeding site, it protects the underlying tissue from further damage caused by gastric acid or mechanical forces, which aids in healing. #### **Clinical Applications in UGIB:** Purastat is primarily used in endoscopic procedures to manage **non-variceal upper gastrointestinal bleeding (NVUGIB)**. It has demonstrated efficacy in controlling bleeding from various causes, including: 1. **Peptic Ulcers:** - Active bleeding from gastric or duodenal ulcers. - Bleeding associated with adherent clots or visible blood vessels in ulcers. 2. **Post-Endoscopic Procedures:** - Used as an adjunct to prevent rebleeding after interventions such as thermal coagulation or hemoclip application. 3. **Other Causes of UGIB:** - Bleeding from malignancies, radiation-induced ulcers, or post-surgical sites. #### **Advantages of Purastat in UGIB:** 1. **Ease of Application:** - Purastat is delivered through an endoscope using a catheter, making it minimally invasive and easy to apply directly to the bleeding site. 2. **Rapid Hemostasis:** - It has shown to quickly stop bleeding in challenging cases, even when conventional methods fail. 3. **Safety Profile:** - Purastat is biocompatible and biodegradable, meaning it is well-tolerated without significant adverse effects. It has minimal systemic absorption, reducing the risk of systemic side effects. 4. **Potential for Prophylaxis:** - Purastat has been explored for use in preventing bleeding in high-risk patients, such as those undergoing endoscopic procedures or with recurrent bleeding risks. #### **Limitations:** 1. **Cost:** - Purastat is relatively expensive compared to conventional hemostatic methods, which may limit its accessibility, especially in resource-limited settings. 2. **Limited Evidence Base:** - While initial studies and trials have shown promising results, long-term data and large-scale randomized controlled trials are needed to fully establish its efficacy and cost-effectiveness. 3. **Restricted Indications:** - Currently, Purastat is primarily used for non-variceal UGIB. Its role in managing **variceal bleeding** is not established. ### **Clinical Evidence:** 1. **Randomized Controlled Trials:** Studies have shown Purastat's effectiveness in achieving hemostasis in cases of non-variceal UGIB, particularly in peptic ulcers with active bleeding or stigmata of hemorrhage. 2. **Meta-Analyses:** Systematic reviews suggest that Purastat reduces the need for additional endoscopic interventions and lowers rebleeding rates when used as an adjunctive therapy. 3. **Real-World Applications:** Case reports and series highlight its successful use in refractory bleeding cases, such as bleeding from malignancies or other challenging lesions. ### **Clinical Guidelines:** While Purastat is not yet universally included in major guidelines for UGIB management (e.g., ACG, ESGE, or ASGE), it is recognized as a promising adjunct for cases of refractory bleeding or when conventional methods fail. As more evidence emerges, it may become a standard part of UGIB management protocols. ### **Summary:** Purastat represents a significant advancement in the management of UGIB, offering rapid and effective hemostasis in cases of non-variceal bleeding. Its innovative mechanism of action, ease of application, and favorable safety profile make it a valuable tool, especially for challenging or refractory cases. However, its high cost and limited evidence base remain barriers to widespread adoption. As more clinical trials and real-world studies are conducted, Purastat is likely to play an increasingly important role in UGIB management. ### **Key Takeaways:** - **Indication:** Primarily used for non-variceal UGIB (e.g., peptic ulcer bleeding, post-endoscopic procedures). - **Mechanism:** Self-assembling peptide hydrogel creates a physical barrier, facilitates clot stabilization, and protects the mucosa. - **Advantages:** Rapid hemostasis, ease of use, biocompatibility, and low systemic side effects. - **Limitations:** High cost and limited evidence compared to traditional methods. - **Future Potential:** May be incorporated into clinical guidelines as more evidence emerges. Purastat is an exciting development in the field of gastroenterology, offering hope for better outcomes in the management of upper gastrointestinal bleeding.

Traction techniques in endoscopic submucosal dissection (ESD)

Traction techniques in endoscopic submucosal dissection (ESD) play a crucial role in improving procedural outcomes, safety, and feasibility, particularly in Western settings where ESD adoption has faced challenges. These techniques act as a mechanical "third hand" during the procedure, providing consistent countertraction to enhance visualization and facilitate dissection of the submucosal layer. Below is a detailed overview of traction techniques in ESD: ### **Challenges in ESD** - **Longer operating times:** ESD is technically demanding and often requires prolonged procedural time, especially in Western centers where expertise is still developing. - **Higher complication rates:** Without adequate traction, the risk of complications such as perforation increases, particularly in challenging anatomical locations like the esophagus and colon. - **Steep learning curve:** ESD requires advanced skills, and Western practitioners often face difficulties in mastering the technique compared to their Eastern counterparts, where ESD is more widely practiced. ### **Role of Traction Techniques** Traction techniques address these challenges by improving visibility of the submucosal layer and providing better control during dissection. They help reduce procedure time, improve resection rates, and lower complication risks. Key benefits include: 1. **Enhanced visualization:** Traction creates tension on the tissue, exposing the submucosal layer for safer and more precise dissection. 2. **Efficiency:** By facilitating dissection, traction reduces procedure time by approximately 20 minutes, as demonstrated in meta-analyses. 3. **Safety:** Traction techniques lower the risk of perforation, particularly in anatomically difficult areas, by improving operator control. 4. **Improved outcomes:** They increase R0 resection rates, ensuring complete removal of lesions with clear margins. ### **Types of Traction Techniques** Several traction methods have been developed, each with unique advantages. These include: 1. **Clip-with-Line Method:** - A clip is attached to the lesion along with a suture or line, which is externally manipulated to provide traction. - Simple and cost-effective, but requires additional coordination between the operator and assistant. 2. **Clip-and-Snare Technique:** - A snare is used in combination with a clip to pull the tissue and expose the submucosal layer. - Effective in providing dynamic traction but may be more challenging to maneuver. 3. **Internal Elastic Devices:** - Devices like rubber bands or elastic threads are used to provide continuous traction. - These are particularly useful in sites with limited working space. 4. **Double-Scope Systems:** - A second endoscope is introduced to assist with providing traction. - While effective, this method requires additional equipment and personnel, making it less feasible in routine practice. 5. **Single-Operator Traction Tools:** - Newer tools designed for single-operator use provide consistent traction without the need for external assistance. - These innovations are particularly promising for simplifying the procedure and improving efficiency. ### **Evidence Supporting Traction Techniques** - **Meta-analyses:** Studies demonstrate that traction-assisted ESD reduces procedure times, increases R0 resection rates, and lowers perforation risks. - **Western Data:** Although limited, emerging evidence from Western centers shows that selective use of traction techniques yields outcomes comparable to those reported in Eastern studies. - **Technical Challenges:** Traction techniques are especially beneficial in anatomically difficult sites like the esophagus and colon, where visualization and access are more challenging. ### **Importance in Western Practice** In Western settings, the adoption of traction-assisted ESD is particularly valuable due to the barriers mentioned earlier. Expert centers emphasize the need for endoscopists to become proficient with multiple traction techniques to adapt to diverse anatomical and procedural challenges. This versatility helps shorten the learning curve and improve procedural success rates. ### **Conclusion** Traction techniques represent a practical and effective strategy to enhance the safety, efficiency, and outcomes of ESD. By addressing challenges such as visualization, procedural time, and complication risks, these methods support broader adoption of ESD in Western clinical practice. As newer traction tools and devices continue to emerge, their role in refining ESD techniques and expanding accessibility is likely to grow further.

Predicting mortality and readmission in UGIB

This study aimed to assess the accuracy of three pre-endoscopic scoring systems—Glasgow-Blatchford Score (GBS), AIMS65, and pre-endoscopic Rockall Score (pRS)—in predicting 30-day mortality and hospital readmission in patients with upper gastrointestinal bleeding (UGIB) in Iranian tertiary hospitals. Conducted prospectively between April 2024 and April 2025, the study included 290 patients presenting with UGIB symptoms such as hematemesis, melena, syncope, and coffee-ground vomiting. Most patients had severe comorbidities like hepatic failure, malignancy, or heart disease, contributing to a high 30-day mortality rate of 23.4%. Among the scoring systems, the pre-endoscopic Rockall Score (pRS) showed the highest predictive accuracy for mortality (AUROC 0.815) and readmission (AUROC 0.605). AIMS65 also performed well for mortality prediction (AUROC 0.813) but was less effective for readmission (AUROC 0.548). The Glasgow-Blatchford Score (GBS) demonstrated moderate predictive ability for mortality (AUROC 0.762) and was primarily useful for identifying low-risk patients needing early discharge. Low-risk thresholds for the scoring systems—pRS < 1, GBS < 2, and AIMS65 < 1—achieved high sensitivity and negative predictive value (NPV), with pRS showing the best balance (sensitivity 95.4%, NPV 87.5%). This highlights its utility in safely identifying patients for early discharge. Laboratory findings such as low hemoglobin and albumin levels and high blood urea nitrogen (BUN) and INR values were strongly associated with mortality, emphasizing the importance of biochemical and hemodynamic parameters. The study concluded that pRS is the most effective tool for predicting mortality and readmission, supporting its use for risk stratification and resource optimization in emergency settings. However, results may not generalize to non-tertiary care settings, and newer risk models were not evaluated due to resource constraints.

Efficacy of 200 mg vs 1200 mg Simethicone with 3 L PEG for Afternoon Colonoscopy.

This study compared the effectiveness of 200 mg versus 1200 mg simethicone (SIM) added to 3 L polyethylene glycol electrolyte solution (PEG-ELS) for afternoon colonoscopy preparation. Conducted at Shenzhen People’s Hospital between February and July 2024, the randomized, endoscopist-blinded trial included 668 participants. Both groups consumed their bowel preparation between 9:00–11:00 AM for colonoscopies performed 4–6 hours later. The primary outcome was bowel preparation adequacy, measured by the Boston Bowel Preparation Scale (BBPS). Both doses achieved comparable results: 95.8% adequate preparation for 200 mg versus 97.6% for 1200 mg. Secondary outcomes, such as mucosal visibility (Bubble Scale score), adenoma detection rate (ADR), and polyp detection, were statistically similar. Subgroup analysis showed slightly higher right-colon adenoma detection with 1200 mg SIM, but this did not affect overall ADR. Adverse effects like nausea and bloating were slightly lower in the 200 mg group, and both doses had high patient acceptability. The 200 mg dose, costing $1 compared to $6 for 1200 mg, offers significant cost savings without compromising efficacy. The study concludes that 200 mg SIM is a safe, effective, and economical choice for afternoon colonoscopy preparation, pending validation in broader populations.

A new horizon of endoscopic anti-reflux therapy

The new horizon of endoscopic anti-reflux therapy is exemplified by the emergence of Anti-Reflux Mucosal (ARM) interventions, which include anti-reflux mucosectomy (ARMS), mucosal ablation (ARMA), and mucoplasty (ARMP). These techniques represent a groundbreaking advancement in the minimally invasive treatment of gastroesophageal reflux disease (GERD), particularly for patients who remain symptomatic despite pharmacologic therapy. ARM therapies aim to bridge the gap between long-term acid suppression with medications and invasive surgical options like Nissen fundoplication. ### Key Features and Innovations in Endoscopic Anti-Reflux Therapy: 1. **Rationale for Development**: - GERD is a prevalent condition, and approximately 30–40% of patients continue to experience symptoms despite the use of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs). - ARM techniques were developed to provide a cost-effective, incisionless, and minimally invasive alternative for patients with drug-refractory GERD who do not have large hiatal hernias or major esophageal motility disorders. 2. **Mechanism of Action**: - ARM procedures rely on mucosal removal or modification to induce ulceration, followed by controlled healing at the gastroesophageal junction (GEJ). This healing process leads to shrinkage and tightening of the GEJ, reconstructing the natural mucosal flap valve and enhancing its anti-reflux barrier function. 3. **Specific Techniques**: - **Anti-Reflux Mucosectomy (ARMS)**: Involves mucosal resection to induce controlled scarring and tightening of the GEJ. Long-term data show symptom improvement in 68–81% of patients and PPI discontinuation in 42%. - **Anti-Reflux Mucosal Ablation (ARMA)**: A simpler variant of ARMS that uses argon plasma coagulation instead of resection. It achieves clinical response rates exceeding 70% with measurable improvements in reflux metrics. - **Anti-Reflux Mucoplasty (ARMP)**: A more advanced technique that closes mucosal defects during the initial session, providing immediate anti-reflux effects and reducing risks of delayed ulcer healing or bleeding. 4. **Technical Innovations**: - Tools such as prong clips, loop-assisted systems, and hand suturing have enabled full-thickness closure, involving mucosa, submucosa, and muscle fibers, to reinforce the anti-reflux flap valve. - The development of the "angle booster" accessory improves endoscopic access and visualization of the cardia, enhancing procedural precision. - The counter-mucosal incision technique prevents dehiscence during mucosal closure, ensuring durable valve tightening. 5. **Clinical Outcomes**: - ARM interventions have demonstrated success rates of 70–82% in terms of symptom relief and PPI discontinuation. - Minor complications, such as transient dysphagia (11%) and bleeding (5%), are typically manageable endoscopically, with no major life-threatening complications reported in meta-analyses. 6. **Comparative Effectiveness**: - ARM techniques show comparable efficacy to radiofrequency ablation and Nissen fundoplication, with the added benefits of shorter recovery times, reduced postoperative discomfort, and lower costs. - ARMP provides controlled tightening and immediate symptom relief, making it a preferred option for patients with naïve anatomy, while ARMA is suited for redo cases or patients with submucosal fibrosis. 7. **Application Beyond GERD**: - The mucoplasty principle is being explored for other gastrointestinal conditions, such as treating multiple Schatzki’s rings. This represents the first functional "endoscopic plastic surgery" approach in gastrointestinal disease. 8. **Future Directions**: - Research is focusing on the long-term durability of ARM techniques, standardization of ulcer dimensions for optimal tightening, incorporation of full-thickness suturing, and cost-effectiveness comparisons with surgical options like Nissen fundoplication and magnetic sphincter augmentation. ### Conclusion: Endoscopic anti-reflux therapy, particularly ARM interventions, has redefined the treatment landscape for GERD. These techniques offer a minimally invasive, anatomy-tailored approach that provides significant symptom relief (70–82%) with minimal complications. By addressing the limitations of pharmacologic therapy and offering an alternative to surgery, ARM therapies represent a promising new horizon in the individualized management of GERD.

ERCP Complications

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a critical therapeutic procedure for managing pancreaticobiliary diseases, but it is associated with significant risks. Below is a detailed overview of ERCP complications, including their incidence, risk factors, prevention strategies, and management: --- ### **1. Post-ERCP Pancreatitis (PEP):** - **Incidence:** - Occurs in ~5% of unselected patients. - Increases to ~15% in high-risk patients. - Severe PEP occurs in <1% of cases but can result in significant morbidity and occasional mortality. - **Risk Factors:** - Repeated cannulation attempts. - Pancreatic duct injection. - Sphincter of Oddi dysfunction. - Female sex, younger age, and history of recurrent pancreatitis. - **Prevention:** - Universal prophylaxis with rectal NSAIDs (indomethacin or diclofenac), reducing the risk by 50%. - Aggressive intravenous hydration with lactated Ringer’s solution due to its anti-inflammatory and microcirculatory benefits. - Prophylactic pancreatic stent placement (PSP) in high-risk patients, particularly when combined with NSAIDs. - Technical measures such as guidewire-assisted cannulation, early transition to precut sphincterotomy, and avoiding aggressive pancreatic duct contrast injection. --- ### **2. Bleeding (Postsphincterotomy Bleeding):** - **Incidence:** - Occurs in 1–2% of ERCP procedures, primarily after sphincterotomy. - **Risk Factors:** - Cholangitis, anticoagulation, thrombocytopenia, and chronic renal disease. - **Prevention and Management:** - Proper management of anticoagulants before and after ERCP. - Intraprocedural bleeding can often be controlled with epinephrine injection or balloon tamponade. - Persistent bleeding may require endoscopic therapy using clips, thermal probes, or fully covered self-expanding metal stents (fcSEMS). --- ### **3. Perforation:** - **Incidence:** - Rare, occurring in 0.1–0.6% of cases. - Can result from sphincterotomy, dilation, or guidewire trauma. - **Management:** - Early recognition during the procedure is critical. - Small or retroperitoneal perforations can often be managed endoscopically using clips, sutures, or stents. - Larger or delayed perforations may require surgical repair or drainage, particularly if associated with peritonitis or systemic infection. --- ### **4. Infection:** - **Types:** - **Cholangitis:** The most common infectious complication, occurring in 0.5–3% of cases. - **Cholecystitis:** Can occur days after ERCP, especially following metallic stent placement. - **Risk Factors:** - Incomplete biliary drainage. - Hilar obstruction. - Contaminated duodenoscopes. - **Prevention:** - Prophylactic antibiotics in high-risk situations (e.g., hilar obstruction or incomplete drainage). - Use of single-use or fully sterilizable duodenoscopes to reduce duodenoscope-associated infections. - **Management:** - Cholangitis: Antibiotics and ensuring adequate biliary drainage. - Cholecystitis: Managed with antibiotics and drainage (endoscopic or percutaneous) depending on patient stability. --- ### **5. Duodenoscope-Associated Infections:** - **Cause:** - Contamination of duodenoscopes despite reprocessing efforts. - **Prevention:** - Transition to single-use or fully sterilizable duodenoscopes. - Enhanced reprocessing protocols. --- ### **6. Other Complications:** - **Aspiration Pneumonia:** Rare but possible if patients aspirate during the procedure. - **Cardiopulmonary Complications:** Related to sedation or underlying patient comorbidities. --- ### **Strategies to Minimize ERCP Complications:** 1. **Proper Patient Selection:** - Avoid diagnostic ERCP when less invasive alternatives like Endoscopic Ultrasound (EUS) or Magnetic Resonance Cholangiopancreatography (MRCP) are available. - Reserve ERCP for therapeutic interventions. 2. **Technical Expertise:** - High-volume endoscopists and centers achieve better outcomes and fewer complications. - Centralization of ERCP to specialized units is recommended. 3. **Training and Quality Assurance:** - Use of simulation training, coaching, and report cards to improve operator skill. - Structured debriefing and mentorship programs to address the psychological impact of complications on endoscopists (second victim syndrome). 4. **Early Recognition and Multidisciplinary Management:** - Prompt identification of complications with early CT imaging when perforation or infection is suspected. - Collaboration between gastroenterology, surgery, and radiology teams for optimal rescue management. 5. **Emerging Technologies:** - AI-assisted quality monitoring and augmented reality simulators to improve procedural safety. - Digital endoscopy reporting platforms to standardize complication prevention protocols. --- ### **Conclusion:** While ERCP carries significant risks, advancements in prophylactic strategies, technical refinement, and endoscopic rescue methods have greatly reduced morbidity and mortality. Prevention, early recognition, and expert management of complications are critical to improving patient outcomes.

Endoscopic management of NVNPUB - A Canadian Guideline

The Canadian Association of Gastroenterology (CAG), in collaboration with international experts, has developed evidence-based guidelines specifically for the endoscopic management of nonvariceal, nonpeptic ulcer upper gastrointestinal bleeding (NVNPUB). This guideline addresses bleeding caused by conditions such as malignant tumors, Mallory-Weiss tears (MWTs), Dieulafoy’s lesions (DLs), and gastric antral vascular ectasia (GAVE). Below is a detailed overview of the guidelines: --- ### **Purpose** The guideline provides recommendations to standardize the management of NVNPUB, which has seen an epidemiologic shift in recent years. NVNPUB now accounts for one-third to two-thirds of upper gastrointestinal (GI) bleeding cases, surpassing peptic ulcer bleeding due to a decline in ulcer incidence and a rise in malignancy and vascular-related causes. --- ### **Development and Methodology** - **Origin**: Developed by the CAG with international collaboration and endorsed by major societies such as the American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE), European Society of Gastrointestinal Endoscopy (ESGE), and World Endoscopy Organization (WEO). - **Framework**: Recommendations were formed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology, which evaluates evidence strength and balances benefits against risks. - **Recommendation Classification**: Recommendations are categorized as either strong ("panel recommends") or conditional ("panel suggests") based on the certainty of evidence and balance of effects. --- ### **Key Recommendations for Endoscopic Management** #### **1. Malignant Upper GI Bleeding** - **Preferred Treatment**: The guidelines suggest using topical hemostatic agents (THAs) over conventional endoscopic therapy or no therapy. THAs are associated with better hemostasis and fewer rebleeding events, though the evidence supporting this is of very low certainty. - **Evidence**: TC-325 powder (a THA) demonstrated a lower further bleeding rate (26%) compared to standard therapy (50%), with immediate hemostasis failure in 5% of cases and a 2% adverse event rate. - **Conventional Therapy**: Mechanical methods (e.g., clips), thermal methods (e.g., argon plasma coagulation [APC], bipolar electrocoagulation), and injection therapies (e.g., epinephrine, sclerosants) remain viable but are less effective for diffusely oozing tumors. - **Oncologic Therapy**: Following endoscopic hemostasis, oncologic treatments such as surgery, chemotherapy, or radiation are recommended when feasible. These interventions improve six-month survival rates despite higher toxicity risks. --- #### **2. Mallory-Weiss Tears (MWTs)** - **Active Bleeding**: For spurting or oozing bleeding, endoscopic therapy using endoscopic band ligation (EBL) or through-the-scope clips (TTSC) is recommended over epinephrine injection or no therapy. - **Nonbleeding Stigmata**: For nonbleeding stigmata, the guidelines suggest against intervention. --- #### **3. Dieulafoy’s Lesions (DLs)** - **Preferred Treatment**: Mechanical methods such as EBL or TTSC, or contact thermal coagulation, are preferred over epinephrine injection alone. - **Discouraged Therapy**: Epinephrine injection alone is strongly discouraged due to high rebleeding rates. --- #### **4. Gastric Antral Vascular Ectasia (GAVE)** - **Preferred Treatment**: EBL is suggested over APC due to better outcomes, including fewer transfusion requirements and greater hemoglobin improvement. --- ### **Adverse Events** Endoscopic therapies generally have low complication rates. For topical hemostatic agents, adverse effects occur in approximately 2% of cases, mostly presenting as mild distension or bleeding. --- ### **Research Gaps** The guideline highlights the need for randomized controlled trials (RCTs) comparing THAs with conventional or combined therapies. Additional research is needed to evaluate patient-reported outcomes, cost-effectiveness, and quality of life in NVNPUB management. --- ### **Outcome Priorities** Critical outcomes considered in the guidelines include: - Further bleeding - Rebleeding rates - Hemostasis success - Transfusion requirements - Mortality within 7–30 days --- ### **Certainty of Evidence** Most recommendations are conditional and based on very low certainty due to limited RCTs and heterogeneity in study designs and populations. --- ### **Equity and Feasibility** The accessibility of THAs may pose challenges in low-resource settings. The guidelines emphasize equitable implementation strategies to ensure widespread applicability. --- ### **Patient-Centered Approach** The guidelines encourage shared decision-making tailored to patient-specific factors, such as: - Comorbidities - Severity of bleeding - Treatment goals (comfort vs. aggressive therapy) --- ### **Implementation Value** This guideline offers a global framework for NVNPUB management, aiming to standardize care, improve patient outcomes, and guide local adaptations by healthcare systems. It serves as a critical tool for clinicians managing upper GI bleeding from nonvariceal, nonpeptic ulcer causes. --- In summary, the Canadian guideline for NVNPUB management emphasizes the use of topical hemostatic agents for malignant bleeding, mechanical methods for MWTs and DLs, and endoscopic band ligation for GAVE. It prioritizes patient-centered care and highlights areas for future research to address evidence gaps.

Endoscopic Balloon Dilation in IBD

Endoscopic balloon dilation (EBD) is a minimally invasive procedure used in the management of intestinal strictures in patients with inflammatory bowel disease (IBD), particularly Crohn’s disease (CD). Strictures are areas of narrowing in the gastrointestinal tract caused by inflammation, fibrosis, or a combination of both, which can lead to obstructive symptoms such as abdominal pain, bloating, and difficulty passing stool. EBD aims to widen these narrowed segments, thereby alleviating symptoms, avoiding surgical intervention, and improving patients' quality of life. ### Key Findings from the Study on EBD in IBD: #### 1. **Definition of Difficult EBD**: - EBD procedures were classified as "difficult" if they required more than three dilations per year without achieving satisfactory outcomes. These cases often involved technical challenges and poorer long-term results compared to easier cases. #### 2. **Prevalence**: - Difficult EBD accounted for **54.5%** of all procedures, whereas easier EBDs comprised **45.5%**. #### 3. **Technical Success**: - Easier EBDs achieved **100% surgery-free survival** beyond 12 months, compared to **97.4%** in difficult cases (P = 0.004). Despite good technical success rates, **17.3%** of patients eventually required surgery due to unsuccessful dilation outcomes. #### 4. **Risk Factors for Difficult EBD**: - **Smoking**: The strongest independent predictor of difficult EBD, with an odds ratio (OR) of **4.75** (95% CI 2.78–8.36; P < 0.001). Smoking cessation could significantly improve outcomes. - **Prestenotic Dilation**: Associated with nearly **3-fold higher odds** of difficult EBD (OR 2.79; 95% CI 1.28–6.59; P = 0.013). - **Balloon Diameter**: Smaller balloon sizes increased difficulty — each 1-mm decrease raised the risk (OR 1.21), while larger final diameters were protective (OR 0.68). - **Medication Impact**: - **Adalimumab (ADA)** and **Ustekinumab (UST)** therapies were linked to more difficult EBDs. - **Vedolizumab (VDZ)** and immunosuppressive co-therapy (azathioprine, 6-MP, methotrexate) were associated with easier EBDs and improved outcomes. - **Radiologic Predictors**: - Presence of **multiple strictures** (35% vs 16.8%) and **prestenotic dilation** (14.3% vs 3.3%) were more frequent in difficult cases (P < 0.001). - **Anatomic Pattern**: - Ileocolonic phenotype (L3) and longer stricture lengths were more common in technically difficult dilations. - **Age**: - Younger age was associated with higher likelihood of difficult EBD (P < 0.001), possibly reflecting more aggressive disease behavior. - **Crohn’s Disease Predominance**: - The vast majority of difficult EBDs occurred in Crohn’s disease patients, confirming its fibrostenotic nature. #### 5. **Protective Factors**: - **Vedolizumab (VDZ)**: Demonstrated therapeutic protection and improved outcomes in EBD. - **Immunosuppressive Co-therapy**: Use of azathioprine, 6-MP, or methotrexate was linked to easier EBDs. - **Total Parenteral Nutrition (TPN)**: Showed a significant protective effect (OR 0.13; 95% CI 0.05–0.34; P < 0.001), likely due to its role in promoting mucosal healing. #### 6. **Clinical Implications**: - **Smoking Cessation**: Addressing smoking as a modifiable risk factor could reduce procedural difficulty and improve outcomes. - **Medication Optimization**: Favoring therapies like Vedolizumab or combination immunosuppression may enhance success rates. - **Improved Dilation Techniques**: Using larger balloon diameters and addressing prestenotic dilation could reduce procedural difficulty. - **Tailored Therapy**: Individualized treatment plans based on patient characteristics (e.g., age, disease phenotype, and medication history) could lower surgical rates and healthcare costs. #### 7. **Conclusion**: - More than half of EBD procedures were classified as difficult, often requiring repeat interventions. Optimizing modifiable risk factors, tailoring therapy, and improving procedural techniques may enhance success, reduce surgical rates, and lower healthcare costs. ### Summary of EBD in IBD: EBD represents an effective, surgery-sparing approach for managing strictures in IBD, especially Crohn’s disease. However, certain factors, such as smoking, smaller balloon diameters, and specific medication regimens, increase the risk of procedural difficulty. Protective strategies, including smoking cessation, Vedolizumab therapy, combination immunosuppression, and nutritional support like TPN, can improve outcomes. Careful patient selection and individualized treatment plans are essential to maximize the benefits of EBD while minimizing complications and the need for surgical intervention.

VS System for diagnosing early gastric cancer

### **VS Classification System for Diagnosing Early Gastric Cancer** The **VS Classification System** is a standardized diagnostic approach designed to detect **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**, a specialized endoscopic imaging technology. This system enhances the visualization of mucosal and vascular changes in the stomach lining, enabling precise and early detection of cancerous lesions. --- ### **Key Components of the VS Classification System** The VS system is based on the evaluation of two critical features: 1. **Vascular Pattern (V)** 2. **Surface Pattern (S)** These features are assessed using **magnifying endoscopy with NBI**, which provides high-resolution images of the stomach's mucosal and submucosal layers. #### **1. Vascular Pattern (V)** - **Irregular Microvascular Architecture**: - Distorted, tortuous, or dilated capillary structures. - Loss of normal vascular symmetry and organization. - **Demarcation Line**: - A clear boundary separating abnormal vascular patterns from surrounding normal mucosa. - **Corkscrew Vessels**: - Abnormal, twisted vessels often seen in early gastric cancer, indicative of neoplastic changes. #### **2. Surface Pattern (S)** - **Irregular Microsurface Structure**: - Loss of normal pit patterns. - Presence of irregular, ridged, or nodular mucosal surface architecture. - **White Zone Changes**: - Areas of abnormal light reflection, suggesting mucosal damage or cancerous transformation. --- ### **Diagnostic Criteria** Early gastric cancer (EGC) is suspected when: 1. **Vascular Pattern**: - Irregular microvascular architecture is observed. - A distinct **demarcation line** separates the lesion from normal mucosa. 2. **Surface Pattern**: - Irregular microsurface structure is present. - **White zone changes** are visible. When **both vascular and surface irregularities** are identified, the likelihood of EGC is significantly increased. --- ### **Clinical Applications** 1. **Targeted Biopsy**: - The VS system helps identify suspicious areas for biopsy, improving diagnostic accuracy and reducing unnecessary biopsies. 2. **Endoscopic Submucosal Dissection (ESD)**: - Lesions diagnosed using the VS system can be resected precisely via ESD, ensuring complete removal with clear margins. 3. **Surveillance**: - High-risk patients (e.g., those with chronic atrophic gastritis or intestinal metaplasia) can be monitored using the VS system to detect EGC at an early stage. --- ### **Advantages of the VS Classification System** 1. **High Sensitivity and Specificity**: - Improves diagnostic accuracy compared to conventional white light endoscopy (WLE). - Sensitivity: ~88%; Specificity: ~75% (depending on study and operator expertise). 2. **Non-Invasive**: - NBI is integrated into standard endoscopy systems, eliminating the need for dyes or additional equipment. 3. **Improved Diagnostic Yield**: - Enhances the detection of subtle mucosal changes indicative of early gastric cancer. --- ### **Limitations** 1. **Operator Dependence**: - Requires expertise in magnifying NBI and familiarity with VS classification patterns. 2. **False Positives**: - Inflammatory lesions or benign changes may mimic irregular vascular and surface patterns, leading to potential overdiagnosis. --- ### **Comparison: VS Classification vs White Light Endoscopy (WLE)** | **Parameter** | **VS Classification (NBI)** | **White Light Endoscopy (WLE)** | |------------------------------|--------------------------------------|-----------------------------------------| | **Vascular Visualization** | Enhanced with high contrast | Limited visualization | | **Surface Architecture** | Detailed microsurface pattern | Poor resolution of surface patterns | | **Diagnostic Accuracy** | Higher sensitivity and specificity | Lower sensitivity for early lesions | | **Targeted Biopsy** | Precise biopsy sampling | Random biopsy sampling | --- ### **Clinical Evidence Supporting VS Classification** 1. **Ezoe et al. (2011)**: - Demonstrated that magnifying NBI with the VS system was more accurate than WLE for diagnosing gastric mucosal cancer. - Sensitivity: 88%; Specificity: 75%. 2. **Zhang et al. (2016)**: - A meta-analysis showed that NBI combined with the VS classification significantly improved diagnostic efficacy for EGC. 3. **Dinis-Ribeiro et al. (2017)**: - Prospective studies confirmed that the VS system reduces unnecessary biopsies while maintaining high diagnostic accuracy. --- ### **Future Directions** 1. **Artificial Intelligence (AI)**: - AI algorithms are being developed to automate the VS classification process, reducing operator dependency and enhancing diagnostic precision. 2. **Training Programs**: - Structured training for endoscopists to improve proficiency in recognizing VS patterns and using NBI technology. 3. **Expansion to Other GI Cancers**: - The VS classification system may be adapted for diagnosing other gastrointestinal cancers, such as esophageal or colorectal neoplasms. --- ### **Summary** The **VS Classification System** is a powerful tool for diagnosing **early gastric cancer (EGC)** using **Narrow Band Imaging (NBI)**. By evaluating **vascular patterns** (irregular microvascular architecture, demarcation line) and **surface patterns** (irregular microsurface structure, white zone changes), the system provides high sensitivity and specificity for early cancer detection. It facilitates **targeted biopsies**, improves diagnostic accuracy, and supports precise therapeutic interventions like **endoscopic submucosal dissection (ESD)**. Despite its operator dependency, the VS system represents a significant advancement in endoscopic imaging, offering the potential for earlier detection and better outcomes in gastric cancer management.

Speed Boat Device - Novel Resection Technique

The Speedboat RS2 device, developed by Creo Medical Ltd, is an advanced bipolar electrosurgical tool designed for minimally invasive endoscopic procedures like Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM). It features a 4.2-mm distal cutting section, proximal insulated areas, an integrated injection needle, and utilizes bipolar radiofrequency for cutting and microwave energy for coagulation. These features ensure precise tissue dissection, effective hemostasis, and minimal thermal damage. The device is ideal for en bloc resection of gastrointestinal lesions, submucosal tumor excision, and treating esophageal motility disorders. Its integrated cutting, coagulation, and injection functionalities streamline workflows, reduce procedural time, and enhance safety. Clinical studies demonstrate its efficacy in reducing bleeding risks, lowering adverse events, and improving recovery outcomes compared to traditional monopolar tools. The Speedboat RS2 is versatile, user-friendly, and particularly effective for lesions in anatomically challenging locations.

EndoFLIP

**EndoFLIP (Endolumenal Functional Lumen Imaging Probe): A Comprehensive Overview** EndoFLIP is an advanced diagnostic tool designed to measure **esophageal distensibility** and **sphincter compliance** in real time. It is a highly specialized instrument that complements high-resolution manometry (HRM) by evaluating the **mechanical properties** (geometry and distensibility) of the esophagogastric junction (EGJ) and other sphincters. Unlike manometry, which primarily measures pressure, EndoFLIP provides detailed insights into how the EGJ or other sphincters expand and respond to pressure changes. --- ### **Principle of EndoFLIP** EndoFLIP is based on the principle of **impedance planimetry**, which measures the cross-sectional area (CSA) and intraluminal pressure within a lumen, such as the esophagus. - **Key Components:** - A catheter-mounted balloon filled with conductive saline solution. - Multiple impedance electrodes and a pressure transducer inside the balloon. - **How It Works:** - The balloon is inflated within the lumen to specific volumes (e.g., 30–60 mL). - The impedance electrodes measure the CSA, while the pressure transducer measures intraluminal pressure. - These measurements are used to calculate the **Distensibility Index (DI)**: \[ DI = \frac{\text{Cross-Sectional Area (CSA)}}{\text{Intraluminal Pressure (mmHg)}} \] - **DI** reflects how easily a sphincter or lumen expands in response to pressure. --- ### **Procedure** 1. **Catheter Placement:** - The EndoFLIP catheter is inserted during a **sedated upper endoscopy** procedure. - The balloon is positioned across the area of interest (e.g., EGJ, pylorus, or anal sphincter). 2. **Balloon Inflation:** - The balloon is inflated to predetermined volumes (typically 30–60 mL) to distend the lumen. 3. **Real-Time Measurements:** - The device provides real-time data on CSA and pressure, displayed as **color-coded topographic maps** that illustrate luminal geometry and compliance. 4. **Data Interpretation:** - The physician analyzes the DI and other parameters to assess the functional properties of the sphincter or lumen. --- ### **Clinical Applications** EndoFLIP is useful in a variety of clinical settings, especially for disorders involving the EGJ and other sphincters. Key applications include: 1. **Achalasia:** - Evaluates EGJ distensibility before and after treatments like **pneumatic dilation**, **POEM (Per-Oral Endoscopic Myotomy)**, or **Heller’s myotomy**. - Helps monitor therapeutic outcomes. 2. **EGJ Outflow Obstruction (EGJOO):** - Differentiates between true mechanical obstruction and functional variants of the condition. 3. **GERD (Gastroesophageal Reflux Disease):** - Identifies a hypotensive or excessively compliant EGJ, which may contribute to reflux. 4. **Post-Surgical Assessment:** - Evaluates the adequacy or overtightening of the wrap after anti-reflux surgery (e.g., **fundoplication**) or myotomy. 5. **Pyloric and Anal Disorders:** - Emerging applications include assessing the pylorus in **gastroparesis** and the anal sphincter in **anorectal disorders**. --- ### **Advantages of EndoFLIP** - **Direct and Dynamic Assessment:** - Provides real-time evaluation of sphincter distensibility and compliance. - **Concurrent with Endoscopy:** - Can be performed during sedated endoscopy, allowing for simultaneous diagnostic and therapeutic procedures. - **Immediate Feedback:** - Offers quick results to guide interventions, such as during POEM or balloon dilation. --- ### **Limitations of EndoFLIP** - **Requires Sedation:** - The procedure necessitates sedation and endoscopy for catheter placement. - **No Peristaltic Assessment:** - Unlike manometry, EndoFLIP does not evaluate esophageal peristalsis or coordination. - **Limited Normative Data:** - Compared to manometry, there is less established normative data for interpreting results. --- ### **Conclusion** EndoFLIP is a cutting-edge diagnostic tool that provides unique insights into the mechanical and functional properties of the esophagogastric junction and other sphincters. Its ability to measure distensibility and compliance in real time makes it invaluable for diagnosing and managing conditions like achalasia, EGJ outflow obstruction, GERD, and post-surgical complications. While it has some limitations, its advantages in dynamic assessment and real-time feedback make it an essential tool in modern gastroenterology.

Efficacy and Safety of ARMS versus Stretta in GERD

The comparison of **Anti-Reflux Mucosectomy (ARMS)** and **Radiofrequency Ablation (Stretta)** for the treatment of **Gastroesophageal Reflux Disease (GERD)** highlights differences in efficacy and safety profiles. Here's a detailed breakdown based on the systematic review and meta-analysis: ### **Efficacy** Both ARMS and Stretta are effective in managing GERD, as evidenced by their ability to: 1. **Reduce GERD Symptoms**: - Both procedures significantly alleviate GERD-related symptoms, improving patients' quality of life. 2. **Improve GERD-Health Related Quality of Life (GERD-HRQL) Scores**: - Patients undergoing either ARMS or Stretta report significant improvements in GERD-HRQL scores, indicating better disease management and symptom control. 3. **Lower DeMeester Scores**: - Both procedures effectively reduce DeMeester scores, which measure acid exposure in the esophagus, reflecting improved acid control. 4. **Reduce Proton Pump Inhibitor (PPI) Dependence**: - Both ARMS and Stretta help reduce or eliminate the need for long-term PPI therapy, which is a common goal in GERD management. ### **Safety** While both procedures are effective, their safety profiles differ significantly: 1. **Adverse Events with ARMS**: - ARMS is associated with a **higher risk of complications** compared to Stretta. The procedure carries risks such as: - **Perforation**: A serious complication involving a tear in the esophagus. - **Bleeding**: Increased risk due to the mucosal resection process. - **Strictures**: Narrowing of the esophagus as a result of scarring. - **Overall Morbidity**: Higher rates of procedure-related complications. 2. **Safety Profile of Stretta**: - Stretta demonstrates a **more favorable safety profile** with fewer adverse events. As a less invasive procedure, it is generally associated with minimal complications, making it a safer option for many patients. ### **Clinical Implications** - **ARMS**: - May be considered in cases where a more aggressive approach is warranted, but the risk of complications must be carefully weighed. - Requires close monitoring and expertise due to the higher likelihood of adverse events. - **Stretta**: - Offers a safer alternative with a lower risk of complications. - Preferred in patients where safety is a primary concern, such as those with comorbidities or higher surgical risks. ### **Conclusion** Both ARMS and Stretta are effective in managing GERD, but **Stretta** is favored in terms of safety. The choice between the two should be individualized, considering the patient's specific condition, risk tolerance, and the expertise of the treating physician.

Endoscopic Sleeve Gastroplasty on Obesity-Related Comorbidities

Endoscopic Sleeve Gastroplasty (ESG) has shown significant promise in managing obesity-related comorbidities, as evidenced by a prospective 5-year study. Here are the key findings related to its impact: ### 1. **Weight Loss** - Patients undergoing ESG achieved an **average weight loss of 11.8%** over a 5-year period. This weight reduction is considered clinically significant and sustainable for long-term health benefits. ### 2. **Improvement in Obesity-Related Comorbidities** ESG demonstrated substantial improvements in several obesity-related conditions: - **Hypertension**: Sustained reductions in systolic blood pressure were observed, indicating better control of high blood pressure. - **Dyslipidemia**: LDL cholesterol levels were significantly reduced, improving lipid profiles and reducing cardiovascular risks. - **Type 2 Diabetes**: HbA1c levels, a marker of long-term blood sugar control, were significantly lowered, indicating better glycemic management. - **Metabolic-Associated Steatotic Liver Disease (MASLD)**: ESG improved liver function markers, suggesting a positive impact on liver health and a reduction in fatty liver disease progression. ### 3. **Reduced Medication Dependence** - Patients experienced a decreased need for medications to manage their comorbidities, highlighting the metabolic benefits of ESG beyond weight loss. ### 4. **Minimally Invasive and Long-Term Efficacy** - ESG is a **minimally invasive procedure**, making it an attractive alternative to more invasive bariatric surgeries. - The 5-year follow-up data supports its **long-term efficacy** for both weight reduction and metabolic improvements. ### Conclusion The study underscores ESG as an effective therapeutic option for addressing both obesity and its associated comorbidities. By improving key metabolic markers, reducing medication reliance, and achieving sustained weight loss, ESG offers a comprehensive and minimally invasive approach to managing obesity and its related health challenges.

Post ERCP-Induced Perforation

Endoscopic retrograde cholangiopancreatography (ERCP)-induced perforation is a rare but serious complication that requires prompt diagnosis and appropriate management to minimize morbidity and mortality. Management strategies are guided by the type and severity of the perforation, the patient's clinical status, and the timing of diagnosis. Below is a detailed discussion of management strategies based on the context provided and general clinical guidelines: --- ### **1. Classification of ERCP-Induced Perforations** ERCP-induced perforations are classified using the **Stapfer classification**, which categorizes perforations into four types: - **Type I**: Perforation of the duodenum or stomach due to guidewire or scope-related injury. - **Type II**: Periampullary perforations often caused by sphincterotomy, the most common type identified in the Japanese cohort study. - **Type III**: Perforation related to a ductal injury (e.g., bile or pancreatic duct). - **Type IV**: Retroperitoneal air without clear evidence of a perforation. Management strategies depend on the type and severity of perforation. --- ### **2. Importance of Early Diagnosis** - **Intraprocedural Recognition**: Early identification during the ERCP procedure is critical for improving outcomes. Signs may include extraluminal air on fluoroscopy, bile leakage, or patient instability. - **Postprocedural Diagnosis**: Delayed diagnosis can occur if symptoms such as abdominal pain, fever, or signs of peritonitis develop after the procedure. A high index of suspicion is needed. --- ### **3. Imaging for Diagnosis** - **CT Scan**: A key tool for confirming the presence of perforation, assessing the extent of injury, and identifying complications such as retroperitoneal air or fluid collections. - **Fluoroscopy**: During the procedure, fluoroscopic findings such as extraluminal contrast can suggest perforation. --- ### **4. Management Strategies** Management is tailored to the type of perforation, clinical presentation, and imaging findings. Broadly, the options include **conservative management**, **endoscopic therapy**, and **surgical intervention**: #### **A. Conservative Management** - Suitable for small, contained perforations without signs of sepsis or peritonitis. - Includes: - Nil per os (NPO) or bowel rest. - Intravenous fluids to maintain hydration. - Broad-spectrum antibiotics to prevent or treat infection. - Pain control. - Serial clinical and radiologic monitoring. - Often used for Type III and Type IV perforations or stable patients with minimal leakage. #### **B. Endoscopic Therapy** - **Primary Strategy for Type II Perforations**: The Japanese cohort study highlights the effectiveness of endoscopic therapy for periampullary perforations (Type II), which are the most common. - Techniques include: - **Endoscopic clipping**: To close the perforation. - **Stent placement**: To divert bile or pancreatic secretions and facilitate healing. - **Fibrin glue or sealants**: To seal the perforation in some cases. - Benefits of Endoscopic Therapy: - Shorter hospital stays. - Faster recovery. - Favorable outcomes compared to surgery. #### **C. Surgical Intervention** - Reserved for cases where conservative or endoscopic management fails, or for large, unstable perforations (e.g., Type I injuries). - Indications include: - Generalized peritonitis. - Hemodynamic instability. - Large or uncontained perforations. - Failure of non-surgical management. - Surgical options may involve primary repair, resection, or drainage of abscesses. --- ### **5. Post-Management Considerations** - **Close Monitoring**: Patients require careful follow-up to detect complications such as abscess formation, sepsis, or delayed healing. - **Nutritional Support**: May be necessary for patients requiring prolonged bowel rest. - **Prevention in Future Procedures**: For patients requiring repeat ERCP, careful technique and risk mitigation strategies should be employed. --- ### **6. Key Takeaways from the Japanese Cohort Study** - **Incidence**: Duodenal perforation occurred in 0.12% of cases, with Type II being the most common. - **Endoscopic Therapy**: Associated with better outcomes, shorter hospital stays, and faster recovery compared to surgery. - **Timely Diagnosis**: Early recognition, particularly intraprocedural, was critical to improving prognosis. - **Surgery**: Should be reserved for selected cases where other strategies are insufficient. --- ### **7. Conclusion** The management of ERCP-induced perforation requires a multidisciplinary approach involving gastroenterologists, surgeons, and radiologists. Early diagnosis and timely intervention are essential. Endoscopic therapy is the preferred strategy for most cases, particularly Type II perforations, while surgery is reserved for severe or refractory cases. Adherence to these principles can optimize outcomes and minimize complications.

pHoenix Score for GERD Using 24-Hour pH Monitoring

The **pHoenix Score (pHx-S)** is a novel diagnostic metric developed to enhance the accuracy of diagnosing **gastroesophageal reflux disease (GERD)** using 24-hour pH monitoring. It addresses limitations of traditional methods like acid exposure time (AET) and the DeMeester score (DMS) by integrating upright and supine acid exposure times, offering a more comprehensive and reliable assessment of GERD. Below are the key aspects of the pHoenix Score: --- ### **1. Novel Metric:** The pHoenix Score combines **upright and supine acid exposure times (AET)** into a single metric. This integration provides a more holistic evaluation of acid reflux patterns across different body positions, improving diagnostic precision compared to AET alone. --- ### **2. Reduced Inconclusive Results:** One of the major advantages of the pHoenix Score is its ability to significantly reduce inconclusive GERD diagnoses. In studies, the pHx-S reduced inconclusive diagnoses to **4.7% of cases**, which is a **57% reduction** compared to using AET alone. This makes the pHoenix Score particularly valuable in clinical scenarios where traditional methods might leave uncertainty. --- ### **3. High Diagnostic Accuracy:** The pHoenix Score demonstrates exceptional diagnostic performance: - **Sensitivity:** Up to 97.6% - **Specificity:** Up to 100% These metrics are comparable to the established DeMeester score (DMS), underscoring the reliability and robustness of the pHoenix Score in identifying GERD. --- ### **4. Meal Independence:** Unlike some traditional diagnostic methods that require strict compliance with meal recording, the pHoenix Score's accuracy is **independent of meal periods**. Whether meal periods are included or excluded during the 24-hour pH monitoring, the pHx-S maintains its diagnostic precision. This feature simplifies the process for both patients and clinicians. --- ### **5. Clinical Advantages:** The pHoenix Score offers several clinical benefits: - **Simplifies GERD diagnosis:** By integrating upright and supine AET, it provides a straightforward and comprehensive measure. - **Reduces ambiguity:** The reduction in inconclusive diagnoses helps clinicians make more confident treatment decisions. - **Avoids reliance on patient compliance:** Since meal recording is not essential, it reduces the burden on patients and minimizes the risk of errors due to non-compliance. --- ### **Conclusion:** The **pHoenix Score (pHx-S)** represents a significant advancement in GERD diagnosis using 24-hour pH monitoring. Its integration of upright and supine AET, high sensitivity and specificity, independence from meal recording, and ability to reduce inconclusive cases make it a valuable tool for clinicians. By addressing the limitations of traditional metrics like AET and DMS, the pHoenix Score simplifies and improves the diagnostic process for GERD.

Nissen fundoplication versus Toupet fundoplication on postoperative manometry findings

When comparing Nissen fundoplication (LNF) and Toupet fundoplication (LTF) based on postoperative manometry findings, the following distinctions emerge: 1. **Improvement in LES Pressure:** - Both Nissen and Toupet fundoplications significantly increase lower esophageal sphincter (LES) pressure after surgery. This confirms that both procedures are effective in controlling gastroesophageal reflux by improving the barrier function of the LES. 2. **Esophageal Motility Outcomes:** - Toupet fundoplication (LTF) demonstrates better outcomes in terms of esophageal motility parameters compared to Nissen fundoplication (LNF). Specifically: - LTF leads to a **larger reduction in break size** (a measure of esophageal peristaltic integrity). - LTF results in a **greater increase in distal contractile integral (DCI)**, which reflects the strength and coordination of esophageal contractions. - These findings suggest that LTF has a more favorable impact on preserving or improving esophageal motility, making it particularly advantageous for patients with pre-existing borderline or impaired esophageal motility. 3. **Clinical Implications:** - While both procedures improve reflux control through increased LES pressure, the superior motility outcomes observed with LTF may explain why it is associated with fewer obstructive side effects, such as dysphagia (difficulty swallowing) or gas-bloat syndrome, compared to LNF. - As a result, Toupet fundoplication is often considered the preferred option for patients with compromised esophageal motility, as it achieves a balance between effective reflux control and preservation of esophageal function. In summary, while both surgeries improve LES pressure, Toupet fundoplication offers better postoperative esophageal motility outcomes, making it a more suitable choice for certain patient populations.

Blown-Out Myotomy (BOM)

**Blown-Out Myotomy (BOM):** Blown-Out Myotomy (BOM) is a relatively rare but significant complication that can occur after undergoing Peroral Endoscopic Myotomy (POEM), a minimally invasive procedure used to treat esophageal motility disorders such as achalasia. Here is a detailed explanation of BOM based on the provided context: --- ### **Incidence of BOM:** - BOM was observed in **4.7% of patients** (28 out of 598) who underwent POEM during the study period. - While the overall incidence is low, it remains a notable complication requiring attention. --- ### **Timeline of BOM Progression:** - The development of BOM typically occurs within **1 to 3 years** after the POEM procedure. - After this initial period, the condition tends to **stabilize**, suggesting that the risk of progression decreases over time. --- ### **Risk Factors for BOM:** Certain factors were found to significantly increase the risk of developing BOM: 1. **Male Sex**: Males were more likely to develop BOM than females. 2. **Thinner Esophageal Muscle Layers**: Patients with thinner esophageal muscle layers at the time of the myotomy were at higher risk. 3. **Presence of Clinical Reflux**: The occurrence of clinical reflux following the POEM procedure was strongly associated with BOM development. These risk factors highlight the importance of careful patient selection and monitoring, as well as tailoring the POEM procedure to individual anatomical and clinical characteristics. --- ### **Severity Classification of BOM:** - BOM is defined by **diverticular-like changes** in the esophagus, which can vary in severity. - Grades 2 and 3 BOM, characterized by **obvious diverticular changes** that may sometimes include **food retention**, are categorized as **endoscopic BOM**. These cases are more severe and are likely to require closer monitoring and management. --- ### **Clinical Implications:** - While BOM is relatively uncommon, it is an **important complication** that can significantly impact a patient's quality of life. - Patients with identified risk factors (e.g., male sex, thin muscle layers, clinical reflux) are at higher risk, emphasizing the need for **personalized treatment plans** and **long-term surveillance** after POEM. --- ### **Key Takeaways:** - BOM is a rare but significant complication of POEM, with a 4.7% incidence rate. - It typically develops within 1-3 years post-POEM and then stabilizes. - Risk factors include male sex, thinner esophageal muscle layers, and post-POEM clinical reflux. - The severity of BOM can range from mild to severe, with Grades 2 and 3 requiring particular attention. - Long-term follow-up is crucial to monitor for BOM and ensure timely intervention if needed. In conclusion, while POEM is an effective treatment for esophageal motility disorders, the potential for BOM underscores the importance of careful patient evaluation, procedural precision, and post-procedure monitoring.